

ASSOCIATE EDITOR: GUNNAR SCHULTE

G α s–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant G α s-PKA Signaling[Ⓢ]

Dana J. Ramms, Francesco Raimondi, Nadia Arang, Friedrich W. Herberg, Susan S. Taylor, and J. Silvio Gutkind

Department of Pharmacology (D.J.R., N.A., J.S.G.), Department of Chemistry and Biochemistry (S.S.T.), and Moores Cancer Center (D.J.R., N.A., J.S.G.), University of California, San Diego, La Jolla, California; Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Pisa, Italy (F.R.); and Department of Biochemistry, University of Kassel, Kassel, Germany (F.W.H.)

Abstract	1327
Significance Statement	1327
I. Introduction	1327
II. G α s–Protein Kinase A Pathway Basics	1328
A. Fine-Tuning cAMP Levels	1328
B. Regulatory Subunits	1329
C. Catalytic Subunits	1331
D. Protein Kinase A Microdomains	1331
E. Transcriptional Regulation	1332
F. Metabolic Regulation	1333
G. Other cAMP Effectors	1334
III. Mutational Landscape of the G α s–Protein Kinase A Pathway Signalopathies	1334
A. Mutations in GNAS	1335
B. Mutations in Protein Kinase A Catalytic Subunits	1336
C. Mutations in Protein Kinase A Regulatory Subunits	1338
D. Fusion Proteins: An Emerging Mutational Theme	1340
E. Expanding the Mutational Themes	1341
IV. Human G α s–Protein Kinase A Pathway Signalopathies	1342
A. Infectious Diseases	1342
1. Cholera	1342
B. Endocrine and Metabolic Diseases	1342
1. Carney Complex	1342
2. Cushing Syndrome and Adrenocortical Adenomas	1344
3. Cardiac Myxoma	1344
4. Fibrous Dysplasia and McCune-Albright Syndrome	1345
5. Acromegaly, Gigantism, and Pituitary Tumors	1345
6. Hyperthyroidism	1346
7. Inactivating Parathyroid Hormone/Parathyroid Hormone–Related Peptide Signaling Disorder	1346

Address correspondence to: Dr. J. Silvio Gutkind, University of California, San Diego 3855 Health Sciences Dr., Room 2344, La Jolla, CA 92093-0803. E-mail: sgutkind@health.ucsd.edu

D.J.R. and this work were supported by the National Institutes of Health National Institute of General Medical Sciences Cellular and Molecular Pharmacology Training Grant [T32-GM007752], the National Science Foundation Graduate Research Fellowship Program, and the National Cancer Institute Cancer Systems Biology Consortium [U54-CA209891]. F.R. was supported by the Italian Ministry of University and Research through the Department of excellence “Faculty of Sciences” of Scuola Normale Superiore. The research leading to these results also received funding from the Italian Association for Cancer Research (AIRC) under My First AIRC Grant (MFAG) 2020 - ID. 24317 project – P.I. Raimondi Francesco. F.W.H. was supported by the Federal Ministry of Education and Research (BMBF) [16GW0270 TargetRD] and the Kassel graduate school “clocks.”

Ⓢ This article has supplemental material available at [pharmrev.aspetjournals.org](https://doi.org/10.1124/pharmrev.120.000269).
<https://doi.org/10.1124/pharmrev.120.000269>

C.	Neoplasms and Carcinomas	1347
1.	GNAS–Protein Kinase A as Oncogenes: Beyond Endocrine Tumors	1347
2.	Mucin Production Drives Clinical Phenotypes	1348
3.	GNAS and Protein Kinase A Link Inflammation to Cancer Initiation	1350
4.	GNAS–Protein Kinase A as Tumor Suppressors	1352
5.	G α s–Protein Kinase A Induced Therapeutic Resistance in Cancer	1354
V.	Targeting the G α s–Protein Kinase A Pathway Signalopathies	1356
A.	Targeting G Protein–Coupled Receptors and G Protein–Coupled Receptor Ligands	1356
B.	Targeting the Protein Kinase A Holoenzyme Directly	1357
1.	ATP Analog Inhibitors of the Catalytic Subunit	1357
2.	Peptide Inhibitors of the Catalytic Subunit	1357
3.	Bisubstrate Inhibitors of the Catalytic Subunit	1357
4.	Targeting the Regulatory Subunits with cAMP Analogs	1357
5.	Inhibitors of A-Kinase Anchoring Protein Binding	1358
6.	Emerging Approaches	1358
C.	Degraders of Pathway Components	1358
D.	Targeting Protein Kinase A Indirectly	1359
E.	Synthetic Lethality Approaches	1359
VI.	Conclusion	1360
	References	1360

Abstract—Many of the fundamental concepts of signal transduction and kinase activity are attributed to the discovery and crystallization of cAMP-dependent protein kinase, or protein kinase A. PKA is one of the best-studied kinases in human biology, with emphasis in biochemistry and biophysics, all the way to metabolism, hormone action, and gene expression regulation. It is surprising, however, that our understanding of PKA's role in disease is largely underappreciated. Although genetic mutations in the PKA holoenzyme are known to cause diseases such as Carney complex, Cushing syndrome, and acrodysostosis, the story largely stops there. With the recent explosion of genomic medicine, we can finally appreciate the broader role of the G α s-PKA pathway in disease, with contributions from aberrant functioning G proteins and G protein–coupled receptors, as well as multiple alterations in other pathway components and negative regulators. Together, these represent a broad family of diseases we term the G α s-PKA pathway signalopathies. The G α s-PKA pathway signalopathies encompass diseases caused by germline, postzygotic, and somatic mutations in the G α s-PKA pathway, with largely endocrine and neoplastic phenotypes.

Here, we present a signaling-centric review of G α s-PKA-driven pathophysiology and integrate computational and structural analysis to identify mutational themes commonly exploited by the G α s-PKA pathway signalopathies. Major mutational themes include hotspot activating mutations in G α s, encoded by *GNAS*, and mutations that destabilize the PKA holoenzyme. With this review, we hope to incite further study and ultimately the development of new therapeutic strategies in the treatment of a wide range of human diseases.

Significance Statement—Little recognition is given to the causative role of G α s-PKA pathway dysregulation in disease, with effects ranging from infectious disease, endocrine syndromes, and many cancers, yet these disparate diseases can all be understood by common genetic themes and biochemical signaling connections. By highlighting these common pathogenic mechanisms and bridging multiple disciplines, important progress can be made toward therapeutic advances in treating G α s-PKA pathway-driven disease.

I. Introduction

cAMP-dependent protein kinase, or protein kinase A, was one of the first kinases to be described as part of a signal transduction cascade and has served as the prototypical example ever since. As a holoenzyme, consisting of a regulatory (R) subunit dimer and two catalytic (C) subunits, PKA orchestrates complex protein phosphorylation networks by integrating upstream second messenger signals with spatial access to substrates; each layer is elegantly regulated to maintain homeostatic signaling across a diverse array of cell types. These signals manifest as a wide spectrum of physiologic functions, ranging from steroidogenesis in the adrenal cortex to stem cell maintenance in the hair follicle (Fig. 1A). Given this

diversity and complex regulation, it is not surprising that mutations and dysregulation of PKA signaling can play a causative role in many human diseases. However, despite the vast amount of information surrounding PKA and its myriad of physiologic functions, the broad role of aberrant PKA signaling in disease is largely underappreciated. The study of signalopathies, or genetic disorders of signaling pathways, has emerged in recent years, including focuses on the Ras pathway (Rasopathies) (Tidyman and Rauen, 2009) and the transforming growth factor- β pathway (TGF- β signalopathies) (Cannaerts et al., 2015). Here, we define the newest member of the signalopathies, the G α s-PKA pathway signalopathies. G α s-PKA pathway signalopathies are defined as a family of diseases caused by germline, postzygotic, and somatic mutations

in the $G_{\alpha s}$ -PKA pathway, with mutations commonly seen in *GNAS*, *PRKACA*, and *PRKARIA*. In particular, we focus on endocrine and neoplastic diseases in which genetic data are strongly supported by mechanistic understanding of pathophysiology. With this review, we aim to bring together the existing body of knowledge surrounding aberrant pathway signaling in disease, bridging biochemistry, biology, physiology, and clinical practice under the umbrella of $G_{\alpha s}$ -PKA pathway signalopathies. By synthesizing the field, we hope to catalyze new efforts into the therapeutic targeting of a wide variety of human $G_{\alpha s}$ -PKA-driven diseases, ranging from endocrine and metabolic diseases to cancer.

II. $G_{\alpha s}$ -Protein Kinase A Pathway Basics

PKA is one of the best-characterized kinases and is a founding member of a large family of serine threonine kinases known as the ACG kinases (Hanks and Hunter, 1995). In 1991, PKA became the first kinase to have its crystal structure determined (Knighton et al., 1991a,b), and a similar architecture has now been characterized in over 550 structures to date. Traditionally, PKA exists as a tetrameric holoenzyme consisting of a homodimer of regulatory subunits (RI α , RI β , RII α , or RII β ; encoded by the *PRKARIA*, *PRKAR1B*, *PRKAR2A*, *PRKAR2B* genes, respectively) bound to two catalytic subunits (C α , C β , C γ , or the related C χ and C ψ ; encoded by *PRKACA*, *PRKACB*, *PRKACG*, *PRKX*, and *PRKY*, respectively) (Fig. 1, B and C) (Turnham and Scott, 2016; Taylor et al., 2021). Under physiologic conditions, PKA becomes active when the second messenger 3',5'-cAMP binds to the

cAMP binding domains (CBDs) of the regulatory subunits and unleashes activity of the catalytic subunits (Kim et al., 2006; Turnham and Scott, 2016) (Fig. 1C).

A. Fine-Tuning cAMP Levels

The level of cAMP in cells is tightly controlled by balancing production from adenylyl cyclase (AC) and degradation by phosphodiesterase (PDE) (Fig. 2A), of which there are 10 AC isoforms (Hanoune and Defer, 2001) and eight PDE families known to act on cAMP (an additional three PDEs are specific to cGMP) (Omori and Kotera, 2007). Upstream signals that feed into the cAMP-PKA pathway are largely provided by inputs from $G_{\alpha s}$ (stimulatory)-linked and $G_{\alpha i}$ (inhibitory)-linked heterotrimeric G protein-coupled receptors (GPCRs) on the cell surface (Fig. 2A). $G_{\alpha s}$ is encoded by *GNAS*, whereas $G_{\alpha i}$ is encoded by *GNAI1/2/3*. GPCR activity can be modulated by a variety of extracellular ligands, such as hormones, ultimately controlling the activation of their intracellularly coupled G proteins. Heterotrimeric G proteins consist of α , β , and γ subunits, of which there are several isoforms of each, including four major G_{α} families ($G_{\alpha s}$, $G_{\alpha i}$, $G_{\alpha q}$, $G_{\alpha 12/13}$). Upon activation, G proteins dissociate from the receptor and are capable of activating downstream effectors (Oldham and Hamm, 2008). The majority of AC isoforms reside at the membrane and are regulated by $G_{\alpha s}$ and $G_{\alpha i}$ (AC1-9). Additionally, some isoforms can be activated by $G_{\beta\gamma}$ (AC 2/4/7), but conversely, for AC5 and AC6, activation of $G_{\beta\gamma}$ and phosphorylation by PKA can initiate negative regulation of cyclase activity. Of note, some AC isoforms can be activated

ABBREVIATIONS: AC, adenylyl cyclase; ACTH, adrenocorticotrophic hormone; AKAP, A-kinase anchoring protein; AKAP, domain-containing protein; Akt, protein kinase B; AMPK, AMP-activated protein kinase; APC, adenomatous polyposis coli; AT F-1, activating transcription factor 1; BRAF, B-Raf protooncogene; BRCA1/2, breast cancer type 1/2 susceptibility protein; C, catalytic; CAR-T, chimeric antigen receptor T cell; CBD, cAMP binding domain; CBP, CREB-binding protein; CDKN2A, cyclin dependent kinase inhibitor 2a; CFTR, cystic fibrosis transmembrane conductance regulator; CK1 α , casein kinase 1 α ; CM, cardiac myxoma; CNG, cyclic nucleotide-gated; COX, cyclooxygenase; CRC, colorectal cancer; CRE, cAMP response element; CREB, cAMP responsive element binding protein; CREM, cAMP responsive element modulator; CRTIC, cAMP-regulated transcriptional coactivator; CSK, C-terminal Src kinase; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C motif chemokine receptor 4; D/D, dimerization/docking; DEP, Dishevelled, Egl-10 and Pleckstrin; DNAJB1, DnaJ homolog subfamily B member 1; DRP1, dynamin-related protein 1; EGFR, epidermal growth factor receptor; EPAC, exchange protein directly activated by cAMP; ERK, extracellular-signal-related kinase; FD, fibrous dysplasia; FI, functional interaction; FL-HCC, fibrolamellar hepatocellular carcinoma; GATA-4, GATA binding protein 4; GH, growth hormone; GLI, glioma-associated oncogene; GLP1R, glucagon-like peptide-1 receptor; GPCR, G protein-coupled receptor; GSK3, glycogen synthase kinase 3; GSKIP, glycogen synthase kinase 3 β interacting protein; HCN, hyperpolarization-activated, cyclic nucleotide-modulated; HER2, human epidermal growth factor receptor 2; HH, hedgehog; HSP70, heat shock protein 70; IL-6, interleukin 6; IPMN, intraductal papillary mucinous neoplasm; iPPSD, inactivating PTH/parathyroid hormone-related peptide signaling disorder; IS, inhibitory sequence; KCNQ1, potassium voltage-gated channel subfamily Q member 1; KRAS, KRAS proto-oncogene; LAT S1/2, large tumor suppressor kinase 1; LRP6, LDL related protein 6; LRRK2, leucine rich repeat kinase 2; MAPK, mitogen-activated protein kinase; MAS, McCune-Albright syndrome; MC₂R, melanocortin receptor; MSC, mesenchymal stem cell; Muc2, mucin 2; NMD, nonsense mediated decay; NSAID, nonsteroidal anti-inflammatory drug; PDAC, pancreatic adenocarcinoma; PDE, phosphodiesterase; PGE₂, prostaglandin E₂; P I3K, phosphoinositide 3-kinase; PKA, protein kinase A; PKI, protein kinase inhibitor; PMP, pseudomyxoma peritonei; POPDC, Popeye domain containing; P P1, protein phosphatase 1; PP2A, protein phosphatase 2A; PROTAC, proteolysis targeting chimera; PTC, papillary thyroid cancers; PTCH1, patched homolog 1; PTH, parathyroid hormone; PTHR, parathyroid hormone receptor; R, regulatory; RA, Ras association; RAF1, Raf-1 proto-oncogene; RAP1, Ras-related protein 1; RAP2, Ras-related protein 2; SA, sinoatrial; SF-1, steroidogenic factor 1; SHH, sonic hedgehog; SHH-MB, sonic hedgehog medulloblastoma; SIK2, salt inducible kinase 2; siRNA, small interfering RNA; SIRT6, sirtuin 6; SMAD, SMAD family member 4; SMO, Smoothened; SP HKAP, SP HK1-interactor and SRC, SRC protooncogene; SSSTR, somatostatin family of GPCRs; StAR, steroidogenic acute regulatory protein; TAZ, tafazzin; T CF, T-cell factor; T EAD, T EA domain transcription factor; T GF-(b), transforming growth factor (b); T P53, p53; TSHR, thyroid-stimulating hormone receptor; UPS, ubiquitin-proteasome system; UT R, untranslated region; XLAG, X-linked acrogigantism; YAP, yes-associated protein.




Fig. 1. (A) Protein kinase A is a central regulatory hub that mediates many physiologic processes, from hormonal growth and metabolism to transport and secretion. (B) Tables display the corresponding protein and gene names for each isoform of regulatory subunit and catalytic subunit. (C) Cartoon rendering of the PKA regulatory and catalytic subunit interactions. The interface of the catalytic subunit's N-lobe (white) and C-lobe (olive) forms the active site of the kinase, helping to coordinate ATP and substrate. When the regulatory subunit is bound to the catalytic subunit, the inhibitory sequence (IS) occupies the active site to maintain the PKA holoenzyme in its inactive state. PKA exists as a holoenzyme composed of two regulatory and two catalytic subunits, that is coordinated through interactions with the D/D domains, which also bind to AKAPs (see Fig. 5D). When cAMP binds to and inactivates the two cAMP binding domains (CBD-A and CBD-B in teal) of the regulatory subunit, the catalytic subunit is free to phosphorylate its substrates.

(AC1/3/8 through calmodulin) or inhibited (AC5/6) by physiologic levels of Ca²⁺ (Hanoune and Defer, 2001). Unlike the other isoforms, soluble AC (encoded by *ADCY10*) resides in the cytoplasm and inside the mitochondrial matrix, where it is responsive to changes in both calcium and bicarbonate (Tresguerres et al., 2011) (Fig. 2A). Additional details about adenylyl cyclase isoforms and their signaling activities have been previously reviewed (Hanoune and Defer, 2001; Schmid et al., 2014; Halls and Cooper, 2017; Sanchez-Collado et al., 2021).


Much like AC isoforms, the PDEs also have tissue-specific expression patterns and nonredundant function (Fig. 2B; Supplemental Table 1). Adding to the complexity of cAMP dynamics, many variants exist

for each PDE gene as a result of the use of alternate promoters and splicing effects. PDEs primarily differ in their amino terminus, which controls localization and regulation (Houslay and Adams, 2003; Bender and Beavo, 2006; Omori and Kotera, 2007). The majority of cAMP-hydrolyzing PDEs harbor PKA phosphorylation sites. Although the function of many sites remains unknown, in PDE3 and PDE4, PKA phosphorylation enhances catalytic activity, serving to provide negative feedback on cAMP levels. Interestingly, PDE3, whose cAMP-hydrolyzing activity can be competitively inhibited by cGMP, is regulated by phosphorylation from both PKA and the phosphoinositide 3-kinase (PI3K) pathway downstream of hormone and growth factor receptors (Bender and Beavo, 2006). In the PDE4 family, the long isoforms contain a PKA phosphorylation site, which can enhance PDE catalytic activity by 60%. PDE4B/C/D also have an extracellular-signal-related kinase (ERK) phosphorylation site that inhibits PDE activity. Activation of mitogen-activated protein kinase (MAPK) activity induces an initial increase in cAMP (through PDE inhibition), which by activating PKA will in turn stimulate PDEs, ultimately lowering cAMP levels again in a coordinated fashion. Conversely, short PDE4 isoforms, lacking the PKA phosphosite, are inhibited by ERK phosphorylation leading to increased cAMP, but this is complicated by differential upstream regulation of Raf-1 proto-oncogene (RAF1) and B-Raf proto-oncogene (BRAF) by PKA (see section 5. *G α s-Protein Kinase A Induced Therapeutic Resistance in Cancer*) (Houslay and Adams, 2003; Bender and Beavo, 2006). Additionally, all PDE4 members can be recruited to β -arrestins to control GPCR/G protein-mediated signaling (Bender and Beavo, 2006). This fact may explain why there seems to be a preference for PDE4 homozygous deletions in colorectal cancer, a tissue context that is responsive to GPCR-mediated prostaglandin signaling and pathway-dependent cell growth (see section 3. *GNAS and Protein Kinase A Link Inflammation to Cancer Initiation*). The function and roles of different PDE isoforms have been previously reviewed (Bender and Beavo, 2006; Omori and Kotera, 2007; DeNinno, 2012; Neves-Zaph, 2017; Blair and Baillie, 2019).

B. Regulatory Subunits

The PKA regulatory subunits each comprise an amino terminal dimerization/docking (D/D) domain that is joined by an intrinsically disordered linker segment to two consecutive CBDs at the carboxyl terminus (Fig. 1C). Of note, the four regulatory subunits are structurally similar but have diverse expression patterns and are functionally nonredundant. RI α and RII α are ubiquitously expressed, whereas RI β and RII β exhibit more tissue-specific expression (Kim et al., 2006) (Fig. 2B; Supplemental Table 1). The

A



B




Fig. 2. (A) Signaling through the PKA pathway involves upstream activation of *G_{αs}*-coupled GPCRs, which in turn activate AC to produce cAMP. Activation of *G_{αi}*-coupled GPCRs negatively regulates AC and cAMP production. Soluble AC (sAC) also contributes to cAMP production with activation by Ca^{2+} and HCO_3^- . Levels of cAMP in the cell are controlled by production from various ACs as well as degradation by PDEs. The PKA holoenzyme is a tetrameric complex consisting of two R subunits and two C subunits. AKAPs coordinate regulatory subunits and substrates. Additional binding

holoenzyme exists in an inactive state because the regulatory subunits' inhibitory sequence (IS), embedded within the linker region, occupies the active site of the catalytic subunit, acting as a pseudosubstrate or substrate (Fig. 1C). The main difference between type I (RI-containing) and type II (RII-containing) holoenzymes is that the IS of RII subunits can be autophosphorylated, whereas RI subunits act as pseudosubstrates. This has important implications for how the holoenzyme assembles and inhibits activity. Consequently, formation of a high-affinity type I holoenzyme requires the binding of ATP and two divalent metal ions (i.e., Mg²⁺), whereas type II holoenzymes will form with high affinity independent of ATP binding (Herberg and Taylor, 1993; Herberg et al., 1999; Amieux and McKnight, 2002; Kim et al., 2006; Wu et al., 2007; Taylor et al., 2012; Knape et al., 2017; Lu et al., 2019; Walker et al., 2019).

C. Catalytic Subunits

Upon cAMP binding to the regulatory subunits, the catalytic subunits become free to phosphorylate their substrates (Fig. 2A). C α 1 and C β 1 are ubiquitously expressed, whereas other C subunits and their splice variants display more limited, tissue-specific expression (Turnham and Scott, 2016; S \ddot{o} berg and Sk \ddot{a} lhegg, 2018; Taylor et al., 2021) (Fig. 2B; Supplemental Table 1). The catalytic subunit itself is composed of two lobes, a small N-lobe that contains the ATP binding site and a larger helix-rich C-lobe that is essential for substrate binding and coordinating the transfer of the phosphate from ATP to the substrate. The interface between the two lobes forms the active site cleft of the kinase (Knighton et al., 1991a) (Fig. 1C). Under physiologic conditions, the stable and fully active catalytic subunit is phosphorylated on its activation loop (Thr197) and C-terminal tail (S338) (Adams et al., 1995; Yonemoto et al., 1997). PKA facilitates the transfer of the gamma phosphate of ATP to serine or threonine residues preferentially in the context of the consensus Arg-Arg-x-Ser*/Thr*-hydrophobic motif, a phosphorylation motif that is quite similar to that of other AGC kinase family members (Kemp et al., 1977; Bramson et al., 1984).

D. Protein Kinase A Microdomains

Scaffolding molecules, known as A-kinase anchoring proteins (AKAPs), concurrently bind PKA regulatory subunits and protein substrates to form microdomains, or cAMP signaling islands, that facilitate substrate recognition, recruitment, and

phosphorylation, thereby enhancing PKA substrate specificity (Langeberg and Scott, 2015) (Fig. 2A). Additional enzymes (kinases, phosphatases, GTPases), signal transducers (receptors, channels), and pathway regulators (PDEs) can also associate with AKAPs, contributing to their ability to modulate PKA signaling (Greenwald and Saucerman, 2011; Torres-Quesada et al., 2017). Together, these AKAP-coordinated complexes facilitate the convergence and crosstalk of discrete signaling subnetworks. For instance, glycogen synthase kinase 3 β interacting protein (GSKIP) is capable of binding the PKA substrate glycogen synthase kinase 3 β (GSK3 β) to control β -catenin-dependent signaling, whereas AKAP11 binds GSK3 β to drive β -catenin independent signaling (Dema et al., 2016). Moreover, AKAP complexes coordinate spatial specificity of the phosphorylation event and enable targeting of PKA activity to particular subcellular locations. Nearly 50 different AKAPs have been identified, but with differential expression patterns (Fig. 2B; Supplemental Table 1) and alternative spliceforms also adding to the diversity, many of their binding partners and physiologic roles are still not fully understood (Torres-Quesada et al., 2017). Detailed reviews of what is known about the role of AKAPs have been compiled previously (Wong and Scott, 2004; Skroblin et al., 2010; Welch et al., 2010; Bucko and Scott, 2020; Omar and Scott, 2020).

In addition to physically restricting substrate access, PKA signaling is also regulated spatially by controlling local cAMP pools. Historically, it was thought that these cAMP microdomains were generated by localized AC inputs and restrained by PDEs, impeding diffusion throughout the cell (Mika et al., 2012). Recent studies have challenged this concept, demonstrating that at physiologic concentrations, cAMP is largely in a bound state and only diffuses upon displacement from or saturation of binding sites (i.e., upstream receptor/AC stimulation). These binding sites buffer cAMP diffusion throughout the cell, enabling PDEs to directly control cAMP compartments in their vicinity (10–60 nm) (Bock et al., 2020). To this end, recent work has also shown that RI α drives liquid-liquid phase separation as a mechanism to actively sequester cAMP, further contributing to cellular cAMP buffering (Zhang et al., 2020). Further supporting this concept of localized PKA activation, recent evidence has demonstrated that at physiologic cAMP concentrations, the PKA holoenzyme (as assessed by AKAP79 and type II holoenzyme interactions) does not physically dissociate upon cAMP

domains present on AKAPs facilitated the formation of protein complexes and targeting to discrete locations around the cell. Binding of cAMP to regulatory subunits causes dissociation of the holoenzyme, releasing catalytic subunits to phosphorylate substrates. (B) Expression of protein kinase A pathway components across normal tissues. Genes are grouped in families, and expression level is represented as the median of transcripts per million (TPM) (GTEx Portal). The heatmap displays expression from 0 to 200 TPM in blue and above 200 TPM in teal, with darker shades representing higher expression values.

to facilitate CREB-mediated transcription (Fig. 3A) (Rosenberg et al., 2002; Altarejos and Montminy, 2011; Sonntag et al., 2019). Of note, PP2A is emerging as a valuable therapeutic target in the treatment of PKA-driven cancers (see section V. *Targeting the G α s-Protein Kinase A Pathway Signalopathies*).

Over 10,000 accessible CRE binding sites have been identified in humans, including some likely to represent alternative or bidirectional promoters. However, the majority reside within 200 base pairs of transcription start sites. Together, this accounts for regulation of over 4000 genes (Impey et al., 2004; Zhang et al., 2005). Genes vary in their dependence on coactivators and CREB occupancy, ensuring that transcriptional activation is finely tuned to specific PKA stimuli (Altarejos and Montminy, 2011). CREB target genes highlight most of the key physiologic processes we will discuss, including regulation of PKA pathway activity, cell cycle entry, mitochondrial homeostasis, and metabolism (Fig. 1A). Interestingly, many CREB target genes are themselves transcription factors (e.g., c-Jun, c-Fos), adding a temporal layer to the importance of PKA-driven transcription (Impey et al., 2004; Zhang et al., 2005). It is important to note, however, that PKA also regulates transcriptional programs independent of CREB. As we will discuss later, PKA phosphorylates components of other pathways (e.g., Wnt, sonic hedgehog, Hippo) to regulate their transcriptional output (see section 3. *GNAS and Protein Kinase A Link Inflammation to Cancer Initiation* and 4. *GNAS-Protein Kinase A as Tumor Suppressors*). Together, transcriptional effects and gene expression regulation permeate almost every role of PKA (physiologic or aberrant).

F. Metabolic Regulation

Another one of the major physiologic roles of PKA is in regulation of glucose and lipid metabolism. Excess glucose in the body can be stored as glycogen (glycogenesis) in the liver or skeletal muscles. Coordinated activities of PKA (in response to glucagon or β -adrenergic receptor stimulation) help to regulate the breakdown of glycogen and mobilization of glucose in times of low nutrient intake. For instance, PKA directly phosphorylates to inhibit glycogen synthase, one of the major enzymes responsible for glycogenesis, and at the same time phosphorylates to activate glycogen phosphorylase kinase, one of the major enzymes responsible for glycogen breakdown (Han et al., 2016; Yang and Yang, 2016). When glycogen stores become depleted, PKA also participates in gluconeogenesis to elevate glucose levels. PKA acts through direct phosphorylation and regulation of enzymes participating in gluconeogenesis as well as transcriptional activation (Yang and Yang, 2016). The transcriptional response of PKA is mediated by CREB, and as such, small interfering RNA (siRNA)

knockdown of CREB in the liver decreases blood glucose levels and reduces expression of gluconeogenesis genes (Erion et al., 2009). Conversely, in a mouse model of CBP/CREB overactivity, gluconeogenesis is inappropriately activated during fed conditions, leading to glucose intolerance (Zhou et al., 2004). Genetic mouse models activating PKA C α and RI α (dominant negative) also recapitulate these effects on glycogen and gluconeogenesis (Niswender et al., 2005; Willis et al., 2011; Yang and Yang, 2016).

Lipogenesis is another process by which glucose can be stored, in this case by conversion to fatty acids. Fatty acids are eventually stored as triglycerides in lipid droplets. When energy levels drop, fatty acids can be liberated by lipolysis. PKA is anchored to lipid droplets by an AKAP and known to activate lipolysis in adipose tissue through several mechanisms, most notably through phosphorylation of perilipin A (Rogne and Taskén, 2014; Yang and Yang, 2016). The so-called gatekeeper of lipolysis, perilipin covers the outer surface of lipid droplets, preventing the action of lipases (Rogne and Taskén, 2014). PKA phosphorylates perilipin to induce conformational changes that allow lipases to access the lipid droplet (Brasaemle et al., 2009). PKA can also phosphorylate and activate the lipases adipose triglyceride lipase and hormone-sensitive lipase, which participate in the multistep process of lipolysis, converting triglycerides to free fatty acids (Rogne and Taskén, 2014; Yang and Yang, 2016).

As the G α s-PKA pathway is integral to many hormone-driven processes, it is not surprising that PKA is also heavily involved in steroidogenesis. Steroid hormones are small lipid signaling molecules derivative from cholesterol. PKA promotes cholesterol processing and steroid biosynthesis both directly through modulation of enzymes (cholesterol ester hydrolase) and transcriptionally through phosphorylation and activation of transcription factors [CREB, steroidogenic factor 1 (SF-1), GATA binding protein 4 (GATA -4)] (Dyson et al., 2009; Manna et al., 2009). In addition to transcriptional regulation, PKA also regulates steroidogenic acute regulatory protein (StAR) post-translationally. StAR is important for transporting cholesterol into the mitochondria, where it is processed. PKA phosphorylation is strictly required for activation of StAR, an event that is facilitated in part by AKAP1 anchoring of PKA to the mitochondrial outer membrane (Dyson et al., 2009; Manna et al., 2009).

Given the direct regulation of both glucose and lipid by the G α s-PKA pathway, many of the G α s-PKA pathway signalopathies have hyperglycemic or obesity-related phenotypes. For instance, mutational activation of PKA (as in Cushing syndrome) can lead to hyperglycemia, and several pathway mutations are linked to development of diabetes mellitus (Sharma et al., 2015; Tengholm and Gylfe, 2017) (see section B.

Endocrine and Metabolic Diseases). Although these mechanisms provide some explanation for the phenotypes in many *G α s*-PKA pathway signalopathies, it is important to recognize that PKA's role in metabolism is quite complicated, owing to the multilayer regulatory programs, including effects on enzyme activity, hormone secretion, and transcriptional responses.

G. Other cAMP Effectors

It is important to note that, although PKA is the major direct effector of cAMP, it is not the only one. When cAMP is free, it is capable of binding to and activating cyclic nucleotide-gated ion channels, exchange factors, and Popeye domain containing (POPDC) proteins (Fig. 3B). These additional cAMP-dependent signaling mechanisms are briefly described below.

Cyclic nucleotide-gated (CNG) channels are ion channels that participate primarily in the sensory processes of sight and smell, converting second messenger signals to voltage changes (Brown et al., 2006). CNG channels are nonselectively permeable to cations, but the action of Ca^{2+} predominates under physiologic conditions. Unlike other gated ion channels, CNG channels are not subject to desensitization; rather, they are regulated in their affinity for cyclic nucleotides. For instance, binding of Ca^{2+} /calmodulin or post-translational modifications can alter the channels' binding affinities. The various CNG channels also have differing innate affinities for cAMP versus cGMP, but in general, cAMP is the dominant signal in olfaction (Zagotta and Siegelbaum, 1996; Bradley et al., 2005). Sensory GPCRs function as signal detectors in both sight and smell processes. Olfactory GPCRs couple to *G α olf* (encoded by *GNAL*), which functions like *G α s* to stimulate AC and cAMP production, whereas rhodopsins (visual GPCRs) couple to transducin (*G α t*) (encoded by *GNAT1*) to induce cGMP hydrolysis, explaining the importance of cAMP to olfaction (Julius and Nathans, 2012).

Another class of cyclic nucleotide-gated ion channels, known as hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channels, function primarily at the sinoatrial (SA) node to maintain heart-beat. HCN channels are distinct from CNG channels in that they are regulated by membrane hyperpolarization in addition to binding of cyclic nucleotides (Brown et al., 2006; Biel, 2009). For HCN channels, the cyclic nucleotide binding domain serves an autoinhibitory function by making the channel more difficult to activate (through hyperpolarization) in the absence of cAMP (Wainger et al., 2001). In the SA node, stimulation of the sympathetic nervous system increases cAMP and facilitates channel opening in response to membrane hyperpolarization after an action potential. When activated, HCN channels allow the influx of cations, contributing to the slow

depolarization during diastole and priming the SA node for initiation of another action potential. HCN channels can also play a role in other excitable tissues like neurons (Brown et al., 2006; Biel, 2009).

Although the roles of CNG and HCN channels are very specific for regulating currents, the roles of exchange protein directly activated by cAMP (EPACs) are much broader. As guanine nucleotide exchange factors, EPACs activate the small GTPases Ras-related protein 1 and 2 (RAP 1 and RAP2, respectively). There are two EPAC proteins, EPAC1 and EPAC2 (encoded by *RAPGEF3* and *RAPGEF4*), which contain one and two CBDs, respectively. When cAMP binds to the CBD, a conformation change occurs to expose the critical residues that participate in the exchange of GDP for GTP to activate RAP1/2. EPAC1/2 are expressed in most tissues, and by modulating RAP activity, they play important roles in cell adhesion in many contexts. Much like PKA signaling, EPAC signaling is compartmentalized and controlled by local cAMP pools. EPACs use their domain structures, Dishevelled, Egl-10, and Pleckstrin (DEP) and Ras association (RA) domains, to target different cellular compartments and engage binding partners. Interestingly, PKA and EPAC participate in many of the same processes, with examples of both antagonistic and synergistic functions, and they have even been found in the same protein complexes. Of note, PKA is activated at much lower levels of cAMP than EPAC, providing another example of the dynamic responses to cAMP regulation (Gloerich and Bos, 2010).

The CBDs of PKA, CNG/HCN channels, and EPACs, are quite similar, but the POPDC proteins use a very different domain to bind cAMP, but still with a high affinity similar to that of PKA. POPDC proteins (encoded by *POPDC1*, *POPDC2*, and *POPDC3*) were named after Popeye the Sailor Man because they are highly expressed in striated muscle. POPDC proteins are heavily glycosylated and reside in the membrane, where they are involved in cell-cell contacts, vesicular transport, and epithelial morphology. They are expressed in many tissues but are primarily studied in the context of cardiac function and epithelial cell organization. Importantly, their dysfunction, downregulation, and mutation have been associated with arrhythmias, muscular dystrophy, and epithelial-to-mesenchymal transition effects in cancer (Schindler and Brand, 2016).

III. Mutational Landscape of the *G α s*-Protein Kinase A Pathway Signalopathies

The *G α s*-PKA pathway signalopathies represent a diverse group of diseases and disorders characterized by dysregulation of the *G α s*-PKA pathway. As we will discuss in the next sections, the *G α s*-PKA pathway signalopathies are defined by mutations, predominately in the *G α s* subunit of GPCRs (encoded by *GNAS*) or the PKA




Fig. 4. GNAS mutational themes in disease. (A) Lollipop plots depict the location of GNAS mutation along the gene body in genetic diseases. Both activating and inactivating mutations are depicted. The height of the lollipop is representative of pathogenic mutation number (ClinVar database) (Landrum et al., 2020). Below the gene body, colored circles depict the location of cancer mutations (COSMIC database) (Tate et al., 2019). The frequency of residue mutation (residue representing >1% of all GNAS mutations) is shown, with darker blue representing a larger proportion of GNAS mutations occurring at that residue. Hotspot mutations in the switch I and switch II domains are dominant in both genetic diseases and cancer. (B) Structure of the prototypical β_2 adrenergic receptor (β_2 AR) coupled to the heterotrimeric G α s G protein (protein data bank ID: 3SN6). Pathogenic mutations are shown in red spheres. Recurrent mutations are present in the nucleotide binding pocket. Other mutations are present at the receptor-G protein interface and in residues interacting with the G $\beta\gamma$ subunits. (C) Structure of G α s binding to adenylyl cyclase (PDB: 1AZS) highlights the mutations clustered in the nucleotide binding pocket (switch I and switch II).

holoenzyme (mainly *PRKACA* and *PRKARIA*). Given the diversity of clinical phenotypes, many groups have aimed to understand the specific mechanisms of mutational activation (or inactivation). Here, we will highlight what is known about the structural and functional significance of disease-associated mutations and integrate available data from inherited (Landrum et al., 2020) and somatic mutation databases (Kim and Zhou, 2019; Tate et al., 2019) to identify broader mutational themes that contribute to the G α s-PKA pathway signalopathies. Of note, in addition to drawing from publicly available databases, we also aim to highlight examples of mutational themes identified from the literature.

A. Mutations in GNAS

Mutations in GNAS are dominated by hotspot mutations at two residues, R201C/S/G/H/L and Q227L/K/R/H (Fig. 4A; Supplemental Tables 2 and 3). These residues are conserved across G α subunits and reside within the switch I and switch II regions, respectively, which universally characterize GTPases,

including small GTPases of the Ras superfamily. Switch I and switch II respond to changes in GTP and GDP binding by sensing the presence or absence of the gamma phosphate (Fig. 4, B and C). These residues are essential for GTPase activity, and thus, their mutation results in impaired GTPase function and constitutive activity (Sunahara et al., 1997; O'Hayre et al., 2013; Sprang, 2016). Recent work has also suggested that GNAS R201C may be capable of activating adenylyl cyclase and downstream signaling even in the presence of GDP, an event that is normally restricted to the GTP bound state (Hu and Shokat, 2018). Interestingly, R201 mutations are far more prevalent in human disease than Q227 (O'Hayre et al., 2013; Arang and Gutkind, 2020). This discrepancy is most striking in cancer, in which nearly 50% of all GNAS mutations are at R201, whereas only 2% are at Q227 (Fig. 4A; Supplemental Table 3). Little is known about why this preference occurs, but it could be linked to the biologic activity of the mutation, as is the case for another G protein, G α q (encoded by

GNAQ). For instance, uveal melanoma, the most common cancer of the eye, is almost exclusively caused by *GNAQ* mutations at residue Q209 (corresponding to *GNAS* Q227), whereas Sturge-Weber syndrome, characterized by angiomas or tumors of small blood vessels, is caused by *GNAQ* R183 mutations (corresponding to *GNAS* R201). *GNAQ* R183 mutants are responsive to signal termination by regulator of G protein signaling proteins, whereas Q209 mutants are not. This highlights that Q209 mutants are more active and consequently drive more extensive proliferation (O'Hayre et al., 2013; Shirley et al., 2013; Arang and Gutkind, 2020). Unlike $G\alpha_q$, $G\alpha_s$ does not bind regulator of G protein signaling proteins as a mechanism to turn off signaling (Natochin and Artemyev, 1998a,b). Additionally, *GNAS* Q227 mutants have higher intrinsic activity than R201 mutants, contributing to greater proliferation and secretion (Landis et al., 1989; Ham et al., 1997). In the case of $G\alpha_s$, fine-tuned regulation is critical, as too much or too little activity can be incompatible with life (Yu et al., 1998; Khan et al., 2018). Together, these findings suggest that Q227 mutations may not be tolerated in many contexts; thus, R201 mutations may be biologically selected.

Similar to mutations, spliceforms of $G\alpha_s$ also seem to contribute to this tight regulation of activity, with differential splice preference in disease states, such as obesity, hypertension, and diabetes (Novotny and Svoboda, 1998). The long isoform (inclusion of exon 3) has a lower binding affinity for GDP, making it more easily exchanged for GTP and therefore more easily activated (Seifert et al., 1998). In fact, coupling of the long isoform to the glucagon receptor enhances glucagon binding affinity as much as 10-fold (Unson et al., 2000). Despite these findings, the direct disease-causing ability of either spliceform has yet to be established. Finally, although diseases may have preferential ways to activate $G\alpha_s$, mutation of many different residues can disable $G\alpha_s$ activity, as missense mutations have been found in almost every exon of *GNAS*, with many of them leading to truncation mutations and haploinsufficiency (Weinstein et al., 2004) (Fig. 4A; Supplemental Table 2). Of note, there are also point mutations at the receptor-G protein interface (E392K and L388R) that are likely loss of function based on the patients' clinical phenotype, suggesting that disruption of receptor-G protein contacts represents another mutational mechanism (Fig. 4B). Ultimately, these data highlight that achieving the proper balance of $G\alpha_s$ activity is critical, and thus, its dysregulation is closely tied to disease.

B. Mutations in Protein Kinase A Catalytic Subunits

Since PKA functions as a holoenzyme, the mutational themes in PKA are quite different than the hotspot mutations we observe in $G\alpha_s$. Among the $G\alpha_s$ -

PKA pathway signalopathies, Cushing syndrome caused by adrenocortical adenomas is the disease most commonly caused by mutations in PKA catalytic subunits and serves as an excellent example of activation themes exploited by mutations (see section 2. *Cushing Syndrome and Adrenocortical Adenomas*). Likely because of its ubiquitous expression and functional roles in many tissues (Fig. 2B; Supplemental Table 1), the majority of mutations occur in *PRKACA* or *C α* . As mentioned previously, each catalytic subunit is composed of two lobes, the N-lobe, harboring the ATP binding site, and the C-lobe, responsible for substrate binding (Figs. 1C and 5A). The interface of these two lobes forms the active site, an interaction that is largely mediated by the binding of ATP and facilitates the opening and closing of this active site cleft along with substrate engagement. This interface also contacts the IS that is embedded in the intrinsically disordered linker region of each regulatory subunit (Figs. 1C and 5B). When the holoenzyme is inactive, the IS is locked into the active site of the C subunit, which prevents the binding of substrates (Johnson et al., 2001; Taylor et al., 2012). A sequence similar to the IS is also found in protein kinase inhibitor (PKI) isoforms, where it also acts as a pseudosubstrate. Briefly, PKIs are endogenous peptide inhibitors of PKA that are expressed in a variety of human tissues. When catalytic subunits are free, PKIs bind to and block PKA activation in response to cAMP, primarily operating in the cytoplasm or nucleus (Liu et al., 2020) (see section 2. *Peptide Inhibitors of the Catalytic Subunit*).

The most frequent mutation in PKA *C α* is L206R, which lies near the interface of the N- and C-lobes, and contributes to the R:C interface as well as substrate recognition (Fig. 5, A and B; Supplemental Tables 2 and 3). Consequently, this mutation disrupts critical contacts and leads to PKA activation by multiple mechanisms (Walker et al., 2019). First, the L206R mutation disrupts interactions between *C α* and the regulatory subunits, leading to constitutive activity even in the absence of cAMP (Calebiro et al., 2014; Röck et al., 2015). L206 (or 205 depending on numbering conventions), along with other residues, is part of a hydrophobic pocket that binds substrates as well as the regulatory subunits' IS (Fig. 5B). Introduction of a more bulky, positively charged residue disrupts this hydrophobic interaction sterically and chemically (Moore et al., 2003; Taylor et al., 2012; Calebiro et al., 2014). As alluded to previously, the residues in the active site are critical for controlling the activity and regulation of *C α* as well as for substrate recognition. They are important not only for intermolecular contacts but also for intramolecular or allosteric interactions. By measuring chemical shift perturbations through NMR, it is evident that wild-




Fig. 5. Protein kinase A mutational themes. (A) Lollipop plots of *PRKACA* pathogenic mutations in genetic diseases (ClinVar database) (Landrum et al., 2020). The frequency of residue mutation in cancer (residues representing >1% of all *PRKACA* mutations) is depicted below (COSMIC database) (Tate et al., 2019). Darker blue represents that a greater proportion of *PRKACA* mutations occur at that residue. (B) Structure of $C\alpha$ in complex with $RI\alpha$ (protein data bank ID: 5JR7). Pathogenic mutations are depicted as red spheres. *PRKACA* mutations lie at the interface of the catalytic and regulatory subunits, whereas *PRKAR1A* mutations are distributed throughout the protein. (C) As in (A), lollipop plots of genetic disease mutations in *PRKACB* and frequency of residue mutation in cancer below. (D) Structure of the R binding domain of AKAP10 in complex with $RI\alpha$ (PDB: 3IM4) [dotted line connects to the same region of $RI\alpha$ as shown in (B)]. Mutations of unknown significance (shown in yellow) reside within the D/D domain that mediates regulatory subunit dimerization and AKAP binding. (E) As in (A) and (C), lollipop plots and cancer residue frequency illustrate that no recurrent mutations occur in *PRKAR1A*.

type and L206R $C\alpha$ have dramatically different allosteric networks that alter the normal binding cooperativity between ATP and substrates. Ultimately, this results in an inability of L206R to achieve a fully closed state. Similarly, molecular dynamics simulations reveal that L206R has a much broader conformational range than wild-type $C\alpha$. Together, the disruption of normal allosteric interactions and protein conformations results in an altered substrate specificity (Walker et al., 2019, 2021). This altered substrate profile includes decreased activity toward canonical substrates and increase activity toward noncanonical substrates, particularly those with negatively charged (instead of hydrophobic) residues after the consensus phosphorylation motif (Arg-Arg-x-Ser*/Thr*-hydrophobic). Although the intrinsic activity of the $C\alpha$ L206R does not seem to differ from the wild type, the altered substrate profile may contribute to aberrant signaling (Calebiro et al., 2014; Lubner et al., 2017; Luzi et al., 2018; Bathon et al., 2019; Walker et al., 2019, 2021).

Most Cushing syndrome mutations as well as cancer mutations in $C\alpha$ (W197, L199_C200insW, C200_G201insV, S213R, E249Q) are located in the C-lobe near the active site cleft and contribute to peptide recognition. This region also includes the binding surface for the regulatory subunits (Fig. 5A; Supplemental Table 3). Because of their location in this critical region, it is thought that these mutations achieve PKA activation through mechanisms similar to L206R (Luzi et al., 2018; Walker et al., 2019; Walker et al., 2021). The E32V mutation is the only mutation that resides away from the active site, but similar to the other Cushing mutations, E32V also disrupts intramolecular allosteric interactions, leading to loss of binding cooperativity and aberrant activity (Ronchi et al., 2016; Walker et al., 2019, 2021). In fact, there is direct relationship between ATP-substrate binding cooperativity and intramolecular allosteric conformational changes, highlighting that this is a common feature disrupted by Cushing syndrome mutations (Walker et al., 2021). Recently, additional

point mutations in both *PRKACA* and *PRKACB* have been described in several $G_{\alpha s}$ -PKA pathway signalopathies, including Cushing syndrome. Like many of the C_{α} mutations mentioned above, C_{β} mutations S54L and H88R/N are located in a region critical for ATP and substrate binding near the active site. Interestingly, S54L and H88R/N both show increased sensitivity to cAMP as a result of reduced stability of the respective PKA holoenzymes and C:PKI interactions (Espiard et al., 2018; Palencia-Campos et al., 2020; Taylor et al., 2021) (Fig. 5C; Supplemental Tables 2 and 3). Similarly, other recently characterized mutations C_{α} G137R and C_{β} G235R have reduced affinity for regulatory subunits and, consequently, increased PKA kinase activity at low cAMP levels. Although C_{α} G137R and C_{β} G235R do not affect ATP binding, they do reside in the area that makes contacts with regulatory subunits as well as PKI (Palencia-Campos et al., 2020) (Fig. 5, A, B, and C; Supplemental Table 2). Together, these mutations highlight holoenzyme destabilization or defects in PKI signaling as alternative mechanisms to enhance PKA activity without altering intrinsic kinase activity (Espiard et al., 2018; Palencia-Campos et al., 2020).

C. Mutations in Protein Kinase A Regulatory Subunits

Destabilization of the PKA holoenzyme and disruption of regulatory-catalytic subunit contacts is the major mutational theme underlying the $G_{\alpha s}$ -PKA pathway signalopathies. Although we have already discussed the role of catalytic subunits in these interactions, mutation of regulatory subunits is actually the most frequently observed alteration (Fig. 5, B, D, and E; Supplemental Table 2). In fact, over 130 molecular defects in *PRKARIA*, or RI_{α} , have been associated with $G_{\alpha s}$ -PKA pathway signalopathies (*PRKARIA* Mutation Database, <https://prkar1a.nichd.nih.gov/>). As is the case for PKA C_{α} , most mutations occur in RI_{α} , likely due to its ubiquitous expression and functional importance in many tissues (Fig. 2B; Supplemental Table 1). These mutations span the length of the protein, ranging from missense mutations and premature stop codons to insertions and deletions, with deletions as large as 4 kb described (Kirschner et al., 2000a; Horvath et al., 2008, 2010). The loss-of-function nature explains why there are no recurrent mutations in *PRKARIA* found in cancer (Fig. 5E; Supplemental Table 3). This pattern of gene mutations throughout the gene length is well established for known tumor suppressor genes in cancer (Vogelstein et al., 2013). Mutations may lead to altered function, alternative protein expression, and even absence of protein. Many of the premature stop codons or small insertions and deletions lead to nonsense mediated decay (NMD), representing 90% of *PRKARIA* mutations (Greene et al., 2008; Bertherat

et al., 2009; Horvath et al., 2010). NMD occurs at the mRNA level as a normal quality-control mechanism to prevent the translation of truncated proteins. Strong NMD mutations typically occur at least 50 base pairs upstream of the final exon-exon junction (Brognia and Wen, 2009). For these NMD mutations, the mutant protein is not expressed, leading to 50% reduction in RI_{α} protein and consequently haploinsufficiency. PKA activity is ultimately enhanced because of disruption of the normal holoenzyme stoichiometry (Horvath et al., 2010). Alterations that occur in the last exon actually escape NMD and are translated (Veugelers et al., 2004). Interestingly, some of these mutations, specifically those coding for an elongated protein, are subject to proteasomal degradation and result in haploinsufficiency as well (Patronas et al., 2012).

Although most *PRKARIA* mutations result in haploinsufficiency due to mRNA NMD or protein degradation, the mutations that successfully evade these quality-control mechanisms, forming alternative RI_{α} protein, actually contribute to more severe disease (Meoli et al., 2008; Horvath et al., 2010). On a biochemical level, they are also incredibly informative of PKA holoenzyme dynamics. For instance, there are two regions of RI_{α} that are critical to catalytic subunit binding, one of which is within the first CBD (CBD-A) (Fig. 5, B and E). Disruption of this interaction site by mutation results in increased PKA activity independent of cAMP levels, as the mutant RI_{α} is unable to bind the catalytic subunit (Greene et al., 2008; Meoli et al., 2008). This is mirrored by large deletions that result in deletion of exon 3, which contains the IS, the other region critical to catalytic subunit binding (Greene et al., 2008; Horvath et al., 2008). There are also several mutations (D183Y, A213D, and G289W) that reside within the two cAMP binding domains (CBD-A and CBD-B) and have decreased binding affinity for cAMP but greater overall PKA activity. Other mutations, exhibiting similar decreased cAMP binding affinity, have been identified in critical regions such as the D/D domain (S9N), which alters protein conformation and disrupts the communication between the D/D domain, and the CBDs (Hamuro et al., 2004; Greene et al., 2008). These types of mutations may also disrupt AKAP scaffolding interactions, as the D/D domain mediates these contacts (Fig. 5, D and E). As mutations occur throughout the RI_{α} protein, it is thought that many of the missense mutations located outside of functional domains may contribute to PKA activation through similar disruption of conformational communication (Hamuro et al., 2004; Veugelers et al., 2004; Greene et al., 2008).

Most of the RI_{α} mutations we have discussed so far result in increased PKA activity. Conversely, there is

a whole class of RI α mutations that suppress PKA activity, leading to different pathologies. Given the underlying importance of holoenzyme stability, it is not surprising that these mutations stabilize the holoenzyme, often rendering it less sensitive to dissociation by cAMP. To this point, we observe many of the acrodysostosis mutations (discussed further in section 7. *Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Peptide Signaling Disorder*) cluster in the C terminus of the protein, the region where the two CBDs reside (Fig. 5E). Point mutations within the CBDs (CBD-A: Y175C, A213T and CBD-B: Q285R, G289E, A328V, R335L) as well as partial deletion of CBD-B (R368X, Q372X) make RI α resistant to cAMP, dampening PKA activity (Linglart et al., 2011;

Rhayem et al., 2015; Bruystens et al., 2016). CBD-B is particularly important because binding of cAMP to CBD-B results in a conformation change that exposes CBD-A (Kim et al., 2007). Perhaps the most interesting finding is related to residues A213 and G289. As mentioned previously, their mutation decreases cAMP binding; however, depending on the residue, this can lead to completely different clinical presentations. A213T and G289E result in acrodysostosis and inhibit PKA activity, whereas A213D and G289W result in Carney complex disease and activate PKA activity. Interestingly, although all mutations display decreased cAMP binding, RI α G289W is rapidly degraded, resulting in PKA activation. RI α A213D on the other hand has a reduced degradation rate but



Fig. 6. (A) Protein kinase A catalytic subunit fusion proteins identified in cancer. Colored lines on chromosome 1 (Chr 1) indicate the genomic position of *PRKACB* and *ATP1B1* (green). Chromosome 19 (Chr 19) harbors *DNAJB1* (red) and *PRKACA* (purple). Exon 1 of *DNAJB1* or *ATP1B1* is fused at the same position in *PRKACA* and *PRKACB* (exon 2–10). (B) *RET/ptc2* fusion protein identified in papillary thyroid cancer fuses the N terminus of *PRKARIA* on chromosome 17 (Chr 17, orange), including the D/D domain, with the tyrosine kinase domain of *RET* on chromosome 10 (Chr 10, pink). Two tyrosine residues are essential for mitogenic activity and participate in scaffolding interactions. (C) Prevalence of PKA pathway fusion proteins across cancer types (Fusion GDB) (Kim and Zhou, 2019). Among pathway genes, *GNAS* is the most common fusion partner.

appears to become inappropriately activated without holoenzyme dissociation and at extremely low cAMP levels. Of note, this increased activity is comparable with RI α WT at low cAMP levels but completely lost at high levels of cAMP (Rhayem et al., 2015).

D. Fusion Proteins: An Emerging Mutational Theme

As we discussed in the previous two sections, there are many mechanisms to disrupt normal PKA regulation and stability. The unexpected discovery of PKA fusion proteins in cancer has added yet another mechanism to the list. Honeyman et al., 2014 revealed that patients with fibrolamellar hepatocellular carcinoma (FL-HCC) express a chimeric RNA transcript that fuses the J domain of the molecular chaperone DnaJ homolog subfamily B member 1 (DNAJB1) in frame with PKA C α (*DNAJB1-PRKACA*) because of an ~400-kb deletion on chromosome 19 (Honeyman et al., 2014) (Fig. 6A). On a molecular level, the fusion protein retains kinase activity (Honeyman et al., 2014; Riggle et al., 2016) and normal contacts with PKI (Cheung et al., 2015) and Ri α (Cao et al., 2019) and RII β (Lu et al., 2020) regulatory subunits. The fusion protein also retains interactions with AKAPs (including atypical AKAPs that associate with the amino terminal region of C α) (Cheung et al., 2015; Riggle et al., 2016) and even interactions with heat shock protein 70 (HSP70) through the fused J domain (Turnham et al., 2019). Surprisingly, however, the fusion protein does disrupt normal RI α -mediated liquid-liquid phase separation and cAMP compartmentalization, potentially contributing to its oncogenic activity (Zhang et al., 2020). Furthermore, because the fusion protein is expressed from the DNAJB1 promoter, it results in relative overexpression compared with wild-type PKA C α , which may be augmented by enhanced mRNA stability due to loss of 3' untranslated region (UTR) regulation (Riggle et al., 2016). While the fusion protein maintains similar intrinsic kinase activity, the DNAJB1-PRKACA fusion protein may also achieve increased PKA activity due to increased responsiveness to cAMP, likely due to decreased holoenzyme stability and/or disruption of allosteric regulation (Cheung et al., 2015; Riggle et al., 2016; Lu et al., 2020). Importantly, the dynamic features of the PKI complex are also significantly altered (Olivieri et al., 2021). Recently, additional PKA fusion proteins involving ATP1B1 as the N-terminal fusion partner (ATP1B1-PRKACA and ATP1B1-PRKACB) have also been described to share a similar breakpoint as DNAJB1-PRKACA and exhibit increased catalytic subunit expression due to use of the ATP1B1 promoter (Nakamura et al., 2015; Singhi et al., 2020; Vyas et al., 2020) (Fig. 6A).

Although the PKA catalytic subunit fusion proteins are certainly the most striking examples, they are not the only fusion proteins that exist within the PKA

pathway. In papillary thyroid cancers (PTCs), fusions of *PRKARIA* and the *RET* receptor tyrosine kinase have been described. Termed RET/ptc2, these chimeras fuse the N terminus of RI α with the tyrosine kinase domain of RET (Lanzi et al., 1992) (Fig. 6B; Supplemental Table 4). Interestingly, the D/D domain is the most important region of RI α required to mediate mitogenic activity when fused to the RET tyrosine kinase domain. Since RI α exists as a dimer, it is believed that the D/D domain facilitates fusion protein dimerization (a required step in normal receptor tyrosine kinase activation) and subsequent activation of RET, as the same proliferative effects can be observed with substitution of the epidermal growth factor receptor (EGFR) tyrosine kinase domain for that of RET (Durick et al., 1995, 1996). In fact, the contribution of dimerization domains from N-terminal fusions partners is well documented to drive constitutive dimerization and activation of other receptor tyrosine kinase fusion proteins (Nelson et al., 2017). Interestingly, there are two tyrosine residues conserved within the RET portion of the fusion protein that are also essential to mitogenic activity, likely as a result of their participation in scaffolding interactions when phosphorylated (Durick et al., 1995, 1996) (Fig. 6B). Although the effect of RET/ptc2 on PKA signaling is still unknown, given the importance of the G α s-PKA pathway in thyroid pathophysiology, RET/ptc2 fusion could be a mechanism whereby activation of an oncogene (*RET*) and inactivation of a tumor suppressor (*PRKARIA*) function together to drive transformation (Santoro and Carlomagno, 2013).

Given our mechanistic understanding of PKA fusion proteins, it is surprising that *GNAS* is actually the most common fusion partner, with fusion proteins present across many cancer types (Fig. 6C; Supplemental Table 4). Although little is known about the function of these fusion proteins, the prevalence in highly pathway-dependent cancers, such as those of the adrenal and thyroid glands, suggests that they could be functionally active in some way. Although *GNAS* lacks a truly recurrent fusion partner like *DNAJB1-PRKACA*, there are still some patterns that emerge. Interestingly, the majority of breakpoints cluster at similar genomic coordinates, fusing the 5' coding sequence of *GNAS* with another gene. In addition to *GNAS*, other common pathway fusion partners include *PDE4D* and *ADCY9* (Fig. 6C; Supplemental Table 4). Although these findings are certainly intriguing, much work is still required to understand whether these fusion proteins are expressed and functionally important. As we have seen with other mutations in the pathway, degradation (i.e., NMD of *PRKARIA* mutants) could also be an important mutational mechanism used by fusion proteins.




Fig. 7. (A) Network map of protein kinase A pathway mutations in genetic diseases. Outline of each node shows the functional significance of corresponding mutations, with benign variants or variants of unknown significance in green and pathogenic mutations or risk factors in red. Size of the node represents the number of mutations classified as pathogenic, likely pathogenic, or risk factor in ClinVar (Landrum et al., 2020). Pie charts within the node are colored by frequency of disease phenotypes associated with mutations in each node. With arrows indicating that some form of regulation exists between the nodes. Dashed edges represent FIs predicted by Reactome, and dotted edges indicate FIs predicted by STRING (score > 0.75). Disease phenotype abbreviations: BMIQ19, Body Mass Index Quantitative Trait Locus 19; LCCS8, lethal congenital contracture syndrome 8.

E. Expanding the Mutational Themes

Although the G α s-PKA pathway signalopathies are dominated by somatic and germline mutation of the key signaling nodes, *GNAS*, *PRKACA*, and *PRKAR1A*, additional mechanisms of pathway dysregulation continue to emerge, representing additional disease phenotypes (Fig. 7A; Supplemental Table 2). Mutations in several PDEs have been reported in G α s-PKA pathway signalopathies characterized by both pathway activation and inhibition (see section IV. *Human G α s-Protein Kinase A Pathway Signalopathies*). Further analysis is required to better understand the function and prevalence of these types of mutations in disease. As we highlight through this review, the role of specific GPCRs reaches across many G α s-PKA pathway signalopathies. Recent studies have begun to understand the patterns of mutation in GPCRs, highlighting the importance of critical regions such as the DRY and NPxxY motifs in altering activity (Raimondi et al., 2019). This is a promising area of research from both a biologic and therapeutic perspective, helping to differentiate between passenger

mutations and disease drivers. Additionally, mutations in the other subunits of the heterotrimeric G protein (i.e., G β 1 or *GNB1*), have been described as functionally significant (Brockmann et al., 2017; Zimmermannova et al., 2017). Unlike GPCRs and G proteins, the role of mutations in AKAP scaffolds remain largely unexplored. A prime example of the functional importance of AKAP9 mutations is in long-QT syndrome (Fig. 7A; Supplemental Table 2), in which patients suffer from irregular heartbeat due to issues with ionic currents in the heart. AKAP9 forms a critical complex with a potassium channel subunit, potassium voltage-gated channel subfamily Q member 1 (KCNQ1). Phosphorylation of KCNQ1 by PKA is required for repolarization after a cardiac action potential. The S1570L mutation in AKAP9 disrupts the KCNQ1 interaction, reduces phosphorylation, and most importantly renders the potassium channel functionally unresponsive to cAMP (Chen et al., 2007). Several reports have documented mutations in other pathway components, including *PRKAR1B*, a mutation thought to disrupt catalytic or AKAP binding, as well as gain-of-function mutations in *ADCY5* (Fig. 7A;

Supplemental Table 2). To date, these mutations have primarily been observed in neurologic and neurodegenerative diseases such as familial dyskinesia and Alzheimer disease (Chen et al., 2014; Wong et al., 2014; Marbach et al., 2021). Although we focus primarily on endocrine and neoplastic diseases in this review because of the strength of data linking genetics to disease mechanism, the role of PKA in neurologic diseases is certainly an emerging family of *G α s*-PKA pathway signalopathies. For instance, PKA dysregulation may contribute to Alzheimer, Huntington, and Parkinson diseases, but these disease mechanisms and their therapeutic opportunities are still poorly understood (Dagda and Das Banerjee, 2015; Gregg et al., 2017).

Overt mutation and genomic alteration are not the only mechanisms of pathway dysregulation. We have already discussed the potential role of aberrant splicing in *GNAS*, but many members of the *G α s*-PKA pathway are subject to regulation by splicing, including tissue-specific isoforms of PKA catalytic subunits (Søberg et al., 2017) and signalosome-specific AKAP spliceforms (Wong and Scott, 2004). Furthermore, recent work has suggested that disease phenotypes may be associated with single nucleotide polymorphisms in specific GPCR isoforms (Marti-Solano et al., 2020). As we will discuss later, the role of autocrine and paracrine (onocrine) pathway activation can also contribute to aberrant signaling. Overproduction of pathway ligands can certainly contribute to disease, as is the case for COX-2 overexpression-driven prostaglandin E₂ (PGE₂) production in colorectal cancer (see section 3. *GNAS and Protein Kinase A Link Inflammation to Cancer Initiation*). Finally, pathogenic mutation of PKA phosphosites is emerging as a mechanism of disease. For instance, Parkinson disease mutations in leucine rich repeat kinase 2 (encoded by *LRRK2*), highlight the specific mutation of PKA phosphosites known to regulate *LRRK2* activity (Muda et al., 2014). It is important to synthesize the mutational themes and mechanisms of dysregulation that define the *G α s*-PKA pathway signalopathies. This is a critical step necessary to connect the genomic and biochemical findings with clinical manifestations and ultimately catalyze the development of new, effective therapies.

IV. Human *G α s*-Protein Kinase A Pathway Signalopathies

A. Infectious Diseases

1. Cholera. Perhaps one of the best examples of *G α s*-PKA pathway-mediated pathophysiology is the severe diarrhea caused by infection with *Vibrio cholera*, or cholera. Cholera continues to be a global health concern, contributing to hundreds of thousands of deaths each year (Ali et al., 2015). Cholera toxin has a unique ability to ADP-ribosylate *G α s* at

arginine 201. The addition of an ADP-ribose group inhibits the GTPase activity of *G α s* and renders it constitutively active in a manner similar to the disease-associated R201 mutations (discussed in section A. *Mutations in GNAS*) (Landis et al., 1989; Kaper et al., 1995). Overactivation of *G α s* by cholera toxin leads to cAMP production and PKA activation in the intestinal epithelium (Fig. 8A). In crypt cells, PKA activity enhances secretion of Cl⁻ into the intestinal lumen due to direct regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) channel. Under normal physiologic conditions, the degree of phosphorylation of four PKA phosphosites controls the degree of CFTR channel opening. Thus, overactive PKA in response to cholera leads to maximal channel opening. In villous cells, PKA also functions to decrease Cl⁻ absorption by inhibiting Na⁺/Cl⁻ cotransporters and Na⁺/H⁺ exchangers (Goodman and Percy, 2005). As a result of osmotic imbalance, water rapidly moves out of cells into the intestinal lumen, overwhelming reabsorption mechanisms and producing severe, watery diarrhea and dehydration that can prove deadly if left untreated (Fig. 8A). Interestingly, patients with cystic fibrosis are resistant to the effects of cholera toxin as a result of mutations in the CFTR channel. Notably, the majority of patients harbor the F508del mutation in the regulatory region of CFTR. This mutation causes PKA phosphorylation defects that alter trafficking through the endoplasmic reticulum and Golgi to the cell surface as well as disrupt the conformational cues induced by PKA phosphorylation that are critical to channel opening (Kaper et al., 1995; Goodman and Percy, 2005; Bharati and Ganguly, 2011; Chin et al., 2017).

B. Endocrine and Metabolic Diseases

1. Carney Complex. Carney complex is a rare disease that is characterized by multiple neoplasms of both endocrine (commonly adrenal, pituitary, or thyroid glands and gonadal tissues) and nonendocrine tissues (commonly heart, skin, or eye). First described in 1985, only about 750 individuals have been diagnosed worldwide (Correa et al., 2015). Interestingly, 70% of the cases are familial, following autosomal dominant inheritance patterns, with the majority of patients having inactivating mutations in *PRKARIA* (Kirschner et al., 2000b; Bertherat et al., 2009). Additionally, 35% of sporadic cases are also caused by these same mutations (Kirschner et al., 2000b). In fact, Carney complex was the first disease to be associated with mutations in the PKA holoenzyme (Kamilaris et al., 2019). As mentioned previously, the vast majority of mutations are not actually expressed due to NMD, creating *PRKARIA* haploinsufficiency, ultimately resulting in catalytic subunit hyperactivity (Bertherat et al., 2009). Aligned with this concept, a patient with Carney complex with copy number gains

in *PRKACB* has also been documented (Forlino et al., 2014).

Carney complex is a heterogeneous disease with typical onset around age 20, but some patients have even been diagnosed as children (Correa et al., 2015). Interestingly, patients with *PRKARIA* mutations tend to present at a younger age with specific phenotypes (Bertherat et al., 2009). Most patients present with Cushing syndrome (see section 2. *Cushing Syndrome and Adrenocortical Adenomas*) and endocrine phenotypes. One of the most common physical characteristics is the presence of pigmented skin lesions, like café-au-lait spots, caused by the hyperproliferation of melanocytes (also seen in McCune-Albright syndrome; see section 4. *Fibrous Dysplasia and McCune-Albright Syndrome*). Another common characteristic is cardiac myxoma, a neoplasm of the heart. Cardiac myxoma represents a major cause of mortality in Carney complex because of its rapid growth and recurrence, resulting in obstruction of blood flow in the heart (see section 3. *Cardiac Myxoma*) (Wang et al., 2018b). Finally, the most common endocrine phenotype is primary pigmented nodular adrenocortical

disease, affecting up to 60% of patients with Carney complex. As the name suggests, it manifests as pigmented nodules on the adrenal gland (Bertherat et al., 2009). This results in adrenocorticotrophic hormone (ACTH)-independent Cushing syndrome, which is discussed in the next section. Interestingly, primary pigmented nodular adrenocortical disease can occur outside of Carney complex and not only is caused by mutations in *PRKARIA* but can also be caused by *PDE8B* or *PDE11A* mutations (Bertherat et al., 2009; Kamilaris et al., 2019) (Fig. 7A; Supplemental Table 2). This highlights that overactive PKA is a driver of this disease, regardless of how it is achieved.

Similarly, the physical manifestations of the disease are in line with the importance of PKA signaling to the cell types affected by Carney complex. In these tissues, normal programs such as growth and development and energy metabolism are driven by the hormone-GPCR-G α s-PKA signal transduction axis (see section F. *Metabolic Regulation* for more information on energy metabolism). Acting through cAMP second messengers, PKA mediates systemic responses to hormones of the pituitary, adrenal gland, thyroid,




Fig. 8. G α s-PKA pathway signalopathy pathophysiology. (A) Pathophysiology of cholera. Cholera is an intestinal parasite that enters the digestive tract when consumed via contaminated water. In the intestinal epithelium, cholera toxin ADP-ribosylates and activates G α s, leading to overactivation of PKA. PKA directly phosphorylates the CFTR to facilitate channel opening. Efflux of chloride ions disrupts normal ionic gradients, and water passes into the intestinal lumen to compensate. Consequently, the clinical manifestations of cholera include watery diarrhea and dehydration. (B) Cushing syndrome pathophysiology. ACTH is secreted by the pituitary gland in the brain and travels through the bloodstream to the adrenal gland located on top of the kidney. ACTH binds to the melanocortin receptor (MC₂R) on the surface of adrenocortical cells to activate PKA and stimulate cortisol secretion. In Cushing syndrome, loss-of-function mutation in R1 α (or gain-of-function mutation in C α) leads to persistent PKA activation and excess cortisol secretion. Clinical manifestations of the disease exacerbate the effects of cortisol and include hypertension, hyperglycemia, and obesity. (C) Fibrous dysplasia pathophysiology. Fibrous dysplasia is a postzygotic disease caused by activating mutation in *GNAS*. Persistent activation of PKA in mesenchymal stem cells impairs proper differentiation to adipocyte, chondrocyte, and osteogenic lineages. In particular, accumulation of osteogenic precursors shifts the balance of osteoblasts and osteoclasts to favor bone resorption by osteoclasts. Resulting clinical manifestation of the disease includes brittle bone and frequent fracture or deformity.

parathyroid, and hypothalamus as well as more local responses in tissue such as the pancreas, kidney, liver, and gonads (Tilley and Fry, 2015). Of note, individual mutations in their cognate GPCRs can also cause endocrine phenotypes related to Carney complex or other *G α s*-PKA pathway signalopathies (Lania et al., 2006). However, when dysregulation of this signaling occurs through loss of RI α function, it typically results in neoplastic growth and tumorigenesis across these tissues. In fact, as evidence to the importance of PKA in global growth and development, *Prkaca* knockout mice weigh 65% less than control littermates and exhibit a significant growth delay (Skålhegg et al., 2002).

2. Cushing Syndrome and Adrenocortical Adenomas. Cushing syndrome is a rare disease that affects around two individuals per million per year across the world (Steffensen et al., 2010). It can present with very broad symptoms, including hypertension, hyperglycemia, obesity, skin changes, mood disorders, and other hormonal changes. Although these symptoms can have multiple etiologies, Cushing syndrome is specifically characterized by exposure to excess cortisol (Sharma et al., 2015). Cortisol is a hormone that helps control the stress response by regulating blood pressure and blood sugar as well as dampening the immune response. The release of cortisol is regulated by ACTH, which is secreted by the pituitary glands at the base of the brain. Once in the bloodstream, ACTH travels to the adrenal gland, located on top of the kidneys, where it binds the melanocortin receptor (MC₂R). MC₂R is a *G α s*-linked GPCR located on the surface of the adrenocortical cells, which when stimulated activates PKA to trigger cortisol secretion (Fig. 8B).

Cushing syndrome has many etiologies, including overuse of glucocorticoid medication, ACTH-secreting pituitary tumors (termed Cushing disease), or cortisol-secreting adrenocortical adenomas (Sharma et al., 2015). Although rare, Cushing syndrome can also have genetic causes that converge on overactivation of the PKA pathway. One of the most common genetic causes of Cushing syndrome is the *PRKACA* L206R mutation. As mentioned previously, L206R disrupts regulatory subunit contacts, leading to constitutive PKA activity. This mutation, along with loss-of-function mutations in *PRKARIA*, underlie ACTH-independent Cushing syndrome (Fig. 8B). Similarly, germline *PRKACA* copy number gains (Beuschlein et al., 2014; Lodish et al., 2015) and somatic *PRKACB* S54L mutations can also cause cortisol-producing adrenocortical adenomas/hyperplasias and Cushing syndrome (Espiard et al., 2018). Somatic mutations in *GNAS* and *PDE8D* have also been identified (Espiard et al., 2018). In general, patients with PKA gene mutations have earlier onset of disease with more

comorbidities. There is some evidence, at least for germline *PRKACA* amplifications, that this is a dose-dependent effect, with patients harboring *PRKACA* triplication having the most severe symptoms and earliest onset (Lodish et al., 2015). Interestingly, patients with *GNAS* and *PRKACA* mutations have smaller tumor sizes, which is a sign that the tumor is capable of efficient cortisol production and secretion (Goh et al., 2014). This finding is also in line with the role of cAMP in controlling regulated exocytosis, which contributes to hormone secretion in endocrine cells. For instance, in the pituitary, cAMP increases the size of secretory granules (Seino and Shibasaki, 2005), and in the adrenal gland, basal PKA signaling is required to maintain the vesicle pools that are primed and ready to be exocytosed (Nagy et al., 2004). In general, increase in intracellular Ca²⁺ is the main driver of exocytosis, but cAMP can also modulate the response at several different levels through mechanisms involving both PKA and EPAC.

Although Cushing syndrome is the most prominent diagnosis, primary macronodular adrenal hyperplasia is a related disorder that reflects a spectrum of disease ranging from subclinical hypercortisolism all the way to overt Cushing syndrome. Of note, it can also be part of the manifestations of McCune-Albright syndrome (see section 4. *Fibrous Dysplasia and McCune-Albright Syndrome*) (De Venanzi et al., 2014). It is characterized by large functional nodules on the adrenal gland that alter cortisol secretion. Although rare, primary macronodular adrenal hyperplasia can be caused by activating mutations in *MC2R* (encoding MC₂R) (Hiroi et al., 1998; Swords et al., 2004) or *GNAS* (Fragoso et al., 2003; Hsiao et al., 2009).

3. Cardiac Myxoma. Cardiac myxomas (CMs) can occur in the context of Carney complex, and this accounts for about 7% of all CM cases (Milunsky et al., 1998). The vast majority of the patients with Carney complex have loss-of-function mutations in *PRKARIA* (70%) (Bertherat et al., 2009; Wang et al., 2018b). For these patients, CMs typically present earlier in life (with frequent reoccurrence) and can affect any chamber of the heart with multiple lesions. Conversely, isolated sporadic CMs typically occur as a single lesion in middle-aged women (mean age 51 years) and preferentially in the left atria (Carney, 1985; Reijnen, 1995; Stratakis et al., 2001). Interestingly, it is estimated that anywhere from 31% (Maleszewski et al., 2014) to 64% (He et al., 2017) of isolated sporadic CMs are also caused by loss-of-function mutations in *PRKARIA*. Although the vast majority of CMs are sporadic, there are also a few reports of familial CMs not associated with Carney complex. Typically, these familial mutations follow autosomal dominant inheritance. For instance, in one family, both the father (44 years of age) and daughter (20 years of age) developed

CM as a result of the V164D frameshift deletion (c.491_492delTG) in *PRKARIA*. The woman's uncle and brother did not harbor the mutation and had no signs of CM to date (Ma et al., 2019). CMs are the most common primary tumor in the heart, and although they are benign, they can cause significant morbidity and mortality because of their location (Reynen, 1995). The mechanism of tumorigenesis for CM is not fully understood, but it is thought that mesenchymal stem cells (MSCs) from the endocardium and epicardium are the cell of origin (Di Vito et al., 2015). Effects on this MSC population may also account for *GNAS* mutations found in intramuscular and cellular myxomas (>90% *GNAS* mutants) (Sunitsch et al., 2018). Of note, MSCs are also the cell of origin for fibrous dysplasia, which is discussed in the next section.

4. Fibrous Dysplasia and McCune-Albright Syndrome. Fibrous dysplasia (FD) is a rare skeletal disorder that is characterized by painful and brittle bones that are prone to fracture and deformity. The clinical presentations can be very heterogeneous, affecting one bone (monostotic) or multiple bones (polyostotic) with variable severity. FD can also present with additional manifestation of café-au-lait spots or endocrine hyperfunction, which is termed McCune-Albright syndrome (MAS) (Feller et al., 2009; Riminucci et al., 2010). Additionally, if FD presents with intramuscular myxomas, tumors of musculoskeletal soft tissue, it is termed Mazabraud syndrome. FD/MAS is caused by postzygotic somatic activating mutations in *GNAS* (*GNAS* R201C/H) (Fig. 8C); thus, the disease is not inherited. The heterogeneity of FD/MAS results from somatic mosaicism, wherein some cells inherit the defect, whereas others do not. The tissues involved in FD/MAS arise from all three embryonic germ layers (ectoderm, endoderm, mesoderm), suggesting that in most cases the mutation may be acquired prior to gastrulation, before cell lineage decisions are made (Riminucci et al., 2006; Feller et al., 2009).

Recent studies by our groups and others have demonstrated that expression of *GNAS* activating mutations in mesenchymal/skeletal stem cells is necessary and sufficient to drive FD development in mouse models (Zhao et al., 2018). Interestingly, germline expression of the FD mutation is embryonic lethal (Khan et al., 2018), but when expression is induced during embryogenesis or postnatally, FD lesions develop rapidly (Zhao et al., 2018). The severity of the disease, however, is not linked to stage of development in which the mutation is acquired but, rather, the degree to which mutated cells contribute to critical functions within the tissues (Riminucci et al., 2006; Feller et al., 2009). For instance, patients with a higher ratio of mutated cells to normal cells in the

osteogenic progenitor pool will develop more severe FD, whereas patients with a higher ratio of normal cells to mutant cells will display milder phenotypes. In fact, isolation of bone marrow stroma progenitors from patients with FD revealed that the stroma is a mosaic of mutant and normal cells. Mosaic stromal marrow engrafts into immunocompromised mice, whereas purified mutant marrow fails to engraft (Bianco et al., 1998). Therefore, it has been proposed that there is a "critical mass" of mutated cells that are necessary to drive symptomatic disease (Riminucci et al., 2006; Feller et al., 2009).

Under normal physiologic conditions, bone is constantly being remodeled, which is a balance between bone production by osteoblasts and bone resorption by osteoclasts. Overactivation of G α s signaling through PKA induces proliferation of osteogenic precursors but impairs proper differentiation of osteoblasts and mineralization while enhancing osteoclast differentiation (Riminucci et al., 1997; Zhao et al., 2018) (Fig. 8C). Ultimately, this shifts the balance toward bone resorption, which is a histologic marker of FD in patients.

5. Acromegaly, Gigantism, and Pituitary Tumors. Acromegaly and gigantism are rare diseases characterized by overproduction of growth hormone (GH). GH is normally secreted by the pituitary gland into the bloodstream, where it travels to the liver to stimulate insulin-like growth factor-1 production and growth of bones and body tissues. Gigantism occurs early in childhood before growth plate fusion, resulting in dramatic vertical growth, whereas acromegaly occurs in adulthood and is characterized by growth and swelling of many body tissues, including hands, feet, nose, lips, jaw, and brow (Hannah-Shmouni et al., 2016). In most cases, acromegaly and gigantism are caused by somatotropinoma or GH-secreting pituitary tumors. The majority of GH-secreting pituitary tumors occur sporadically, but there are a few examples of familial cases. The most common sporadic alteration in acromegaly is *GNAS* activating mutations (40%–60%) (Freda et al., 2007; Hage et al., 2018). Typically, these patients have smaller tumors but very high GH secretion, highlighting again the physiologic role of the cAMP in secretion. Of note, no mutations have been identified in the *PRKACA* or *PRKACB* (Larkin et al., 2014), and *GNAS* mutations specifically enrich in GH-secreting pituitary tumors over other subtypes of pituitary tumors (Bi et al., 2017). In about 10% of gigantism, patients have very-early-onset disease (before the age of 4), known as X-linked acrogigantism (XLAG). In addition to overproduction of GH, patients with XLAG also overproduce the hormone prolactin. XLAG is caused by duplications in *GPR101*, an orphan GPCR on the X chromosome. XLAG predominates in females, but some males also acquire

sporadic mutations (Iacovazzo and Korbonits, 2016; Gadelha et al., 2017). Additionally, there have been two independent families that display *GPR101* duplications. *GPR101* is predicted to couple to *G α s* and has been shown to stimulate cAMP production in vitro; however, there is some evidence it could couple to *G α i* as well (Bates et al., 2006; Martin et al., 2015; Iacovazzo and Korbonits, 2016).

Acromegaly and gigantism are also associated with Carney complex and McCune-Albright syndrome, but in these cases, it is generally caused by hyperplasia of the somatotrophs, GH-secreting cells in the pituitary, instead of overt tumors. In Carney complex, most patients have *PRKARIA* loss-of-function mutations, leading to PKA activation and GH and prolactin excess, but only about 10% of patients actually present with acromegaly. For McCune-Albright syndrome, a smaller percentage of patients have pituitary involvement, but of those, 36% develop gigantism, whereas the other 64% develop acromegaly (Boikos and Stratakis, 2007; Gadelha et al., 2017).

6. Hyperthyroidism. Hyperthyroidism is a disease in which the thyroid gland is overactive, producing too much of the hormones that control metabolism, triiodothyronine and tetraiodothyronine. This leads to increased appetite and unintentional weight loss, rapid and irregular heartbeat, restlessness, and potentially goiter (enlargement of the thyroid gland) (De Leo et al., 2016). Hyperthyroidism can have many causes, but as previously mentioned, it can be a component of Carney complex and McCune-Albright syndrome. Whether patients present as part of a broader syndrome, these nonautoimmune hyperthyroidisms can be caused by activating mutations in the thyroid-stimulating hormone receptor (*TSHR*, encoded by *TSHR*) or *GNAS*. As a GPCR, *TSHR* couples to *G α s* to control secretion of triiodothyronine and tetraiodothyronine, but activating mutations in this pathway can cause thyroid adenomas that autonomously secrete hormones (Hébrant et al., 2011; Lacka and Maciejewski, 2015). Of these thyroid adenomas, 5%–10% are caused by *GNAS* mutations, and 70%–80% are caused by *TSHR* mutations (Palos-Paz et al., 2008; Nishihara et al., 2009). A recent report suggested that for hot thyroid nodules (nodules that preferential take up radioactive iodine, generally with excess thyroid-stimulating hormone secretion), *GNAS* and *TSHR* are the only driver mutations, with a clear preference for *TSHR* mutations (Stephenson et al., 2020). Over 30 different mutations in *TSHR* have been documented. Some mutations have been identified in adenomas as well as sporadic and familial cases, whereas others have preference for specific subsets (Hébrant et al., 2011). The reason for this preference is a balance between mutation expression and strength of activation. Strong clonal mutations are

likely to cause adenomas and sporadic hyperthyroidism, whereas weaker germline mutations expressed in all cells are likely to cause familial cases. Although there is no defined syndrome, it is probable that particularly strong germline *TSHR* mutations are embryonic lethal since thyroid hormones are critical to fetal development (Lacka and Maciejewski, 2015).

7. Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Peptide Signaling Disorder. Unlike the other diseases discussed so far, inactivating parathyroid hormone/parathyroid hormone-related peptide signaling disorder (iPPSD), represents a heterogeneous group of disorders that is characterized by inactivating defects in the *G α s*-PKA signaling pathway. Clinical features of this disease are diverse and overlapping among subtypes. Common features include skeletal deformities (brachydactyly, short stature), obesity, cognitive impairment, and hormone insensitivity, leading to improper mineral metabolism and delayed reproductive development, among other manifestations (Mantovani and Elli, 2018, 2019). The current iPPSD nomenclature encompasses diseases such as Blomstrand chondrodysplasia/Eiken syndrome, pseudohypoparathyroidism, acrodysostosis, Albright hereditary osteodystrophy, and progressive osseous heteroplasia, but the specific distinctions are beyond the scope of this review (Mantovani and Elli, 2019). Here, we will focus on the molecular underpinnings of the iPPSD subtypes.

The clinical features of iPPSD highlight the physiologic roles of PTH signaling in a wide variety of developmental and homeostatic mechanisms. PTH is secreted from the parathyroid glands located in the neck to regulate calcium and phosphate homeostasis by signaling through the parathyroid hormone receptor (PTHr). PTHr is a *G α s*-coupled GPCR that is expressed at particularly high levels in the bone and kidney. Not surprisingly, inactivating mutations in PTHr (*PTH1R*) cause iPPSD1 with predominately skeletal defects. *G α s* itself is also subject to heterozygous loss-of-function mutations or, more commonly, genomic imprinting that reduces *G α s* mRNA and protein levels by around 50% (iPPSD2/3) (Turan and Bastepe, 2015; Mantovani and Elli, 2019). Clinical phenotypes, particularly heterotopic ossification, are recapitulated in mice with *Gnas* knockout in mesenchymal progenitor cells (Regard et al., 2013). *GNAS* is also subject to tissue-specific maternal imprinting or loss of paternally imprinted methylation patterns in particular regions on the *GNAS* locus. Patients with loss of function in *G α s* display variable resistance to hormones, including PTH, thyroid-stimulating hormone, gonadotropin, and GHRH, which determine their clinical manifestations (Mantovani and Elli, 2018, 2019). For instance, all patients of these subtypes display bone and adipose phenotypes due to

biallelic expression of G α s in these tissues, whereas individuals with maternally inherited loss of function will present with additional cognitive and endocrine phenotype due to paternal imprinting of G α s in these tissues (Mantovani et al., 2004; Long et al., 2007; Mouallem et al., 2008; Turan and Bastepe, 2015). In line with the importance of the G α s-PKA signaling pathway, mutations in RI α , PDE4D, and PDE3A characterize the remainder of the molecularly defined iPPSD subtypes (iPPSD4/5/6) (Mantovani and Elli, 2019). Of particular note, mutations in PDE3A further highlight the importance of cAMP in driving the pathophysiology of iPPSD. As mentioned previously, PDE3 family members can hydrolyze both cAMP and cGMP. Interestingly, mutations in PDE3A have been shown to enhance the cAMP-hydrolyzing activity without altering enzymatic activity toward cGMP, ultimately resulting in reduced cellular cAMP levels (Maass et al., 2015; Ercu et al., 2020).

C. Neoplasms and Carcinomas

Thus far, we have highlighted the role of PKA signaling in neoplasms of the adrenal, pituitary, thyroid, gonads, and even heart due to both germline or somatic mutations in the pathway, all members of the broad and overlapping endocrine and metabolic G α s-PKA pathway signalopathies. Many of these neoplasms are monogenetic and inherently accompanied by endocrine hyperactivity, a process in which it is evident overactive G α s-PKA signaling is the driver of pathophysiology. In the context of cancer, however, disease is rarely the result of a single mutation but, rather, a complex polygenetic network subject to the biology of diverse tissues and other modulatory inputs like inflammation and immune evasion. With the precision medicine revolution and rapid advances in cancer genomics, we can finally begin to appreciate a broader role of G α s-PKA in cancer as both an oncogenic driver and tumor suppressor. By leveraging our knowledge of mutational themes and G α s-PKA-mediated pathophysiology, we can begin to understand many cancers as emerging G α s-PKA pathway signalopathies.

1. *GNAS-Protein Kinase A as Oncogenes: Beyond Endocrine Tumors.* A real shock to the field came with the discovery of a PKA fusion protein that drives a rare form of liver cancer (<1% of cases), known as FL-HCC (Honeyman et al., 2014). Affecting children and young adults with no underlying pathology, FL-HCC could not be more different from the majority of liver cancers, which affect adults with liver damage commonly due to viral infection or alcoholism. As mentioned previously, patients with FL-HCC were found to express an in-frame fusion of DNAJB1 with PKA C α (*DNAJB1-PRKACA*) that resulted in increased PKA activity due to relative overexpression of the catalytic subunit (Riggle et al., 2016), but

importantly, overexpression of *PRKACA* does not completely recapitulate the oncogenicity of the fusion protein (Kasthuber et al., 2017) (see section D. *Fusion Proteins: An Emerging Mutational Theme*) (Fig. 6A). To date, across multiple studies, *DNAJB1-PRKACA* has been identified in nearly 80% of patients with FL-HCC (Cornella et al., 2015). Of note, several patients with FL-HCC lacking the DNAJB1-PRKACA fusion protein, but with a history of Carney complex and other tumors, exhibited a complete loss of RI α protein instead (Graham et al., 2018). Recent studies have pointed to an even broader role of PKA fusion proteins, including additional fusions with PRKACB and ATP1B1, suggesting that they may also be driver oncogenes in extrahepatic cholangiocarcinoma, intraductal oncocytic papillary neoplasms, and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and bile duct (Nakamura et al., 2015; Singhi et al., 2020; Vyas et al., 2020) (Fig. 6A).

Although *DNAJB1-PRKACA* in FL-HCC clearly establishes PKA as an oncogenic driver, broader analysis of cancer genomes by our group revealed that *GNAS* is the most highly mutated G protein, harboring mutations in over 4% of all sequenced tumors to date, with the majority representing hotspot mutations (O'Hayre et al., 2013; Wu et al., 2019; Arang and Gutkind, 2020). Surprisingly, we and others have noted that among *GNAS* mutated cancers, there is a clear enrichment of gastrointestinal cancers, including colorectal adenocarcinoma (4%–10%), stomach adenocarcinoma (6%–10%), and pancreatic adenocarcinoma (5%–12%), a finding which extends to GPCRs and other G protein subunits (O'Hayre et al., 2013; Innamorati et al., 2018; Wu et al., 2019; Arang and Gutkind, 2020). *GNAS* and PKA also seem to be particularly important to neuroendocrine cancers of the pancreas, prostate, liver, and lung (Deeble et al., 2007; Boora et al., 2015; Kasthuber et al., 2017; Innamorati et al., 2018; Coles et al., 2020). Expanding on these observations, we find that *GNAS* mutation frequency is even more significant in less-studied cancers, such as those of the bone (40%) and the peritoneum (53%) (Fig. 9A; Supplemental Table 5). Although *GNAS* mutation is recognized for its importance in cancer and is routinely included in clinical sequencing panels, such as FoundationOne (<https://www.foundationmedicine.com/>), analysis of the broader pathway reveals that mutations occur at every node. There are particularly good examples of each, such as *ADCY2* mutations in liver (20%), *PDE4D* mutations in prostate (25%), and SPHK1-interactor and AKAP domain-containing protein (*SPHKAP*) in skin (26%) (Fig. 9A; Supplemental Table 5). Given that there are many genes representing each node of the pathway, when we consider the mutation frequency of each gene family, it becomes




Fig. 9. Protein kinase A pathway mutations in cancer. (A) Frequency of specific pathway gene mutation across several tumor and cancer types. Heatmap is colored by mutation frequency (0% to >50%), with darker purple representing higher mutational frequency. All gene mutations from whole genome sequencing data sets are included (COSMIC database) (Tate et al., 2019). (B) Frequency of pathway mutation grouped by gene family across tumor and cancer types. A sample is considered to have a pathway mutation if it harbors at least one mutation in a family gene member.

clear that some gene families are preferentially mutated in certain tissues; for instance, *GNAS* mutations predominate in hormone-sensitive tissues (Fig. 9B; Supplemental Table 5). Somewhat strikingly, we find that adenylyl cyclase mutations constitute the bulk of the mutations across many tissue types. Intriguingly, AKAPs are mainly mutated in the stomach and pancreas, whereas PKA catalytic subunits have a consistent low level of mutation across most tissues (Fig. 9B; Supplemental Table 5). Of important note, most patient samples harbor only one or two pathway mutations (57%), with the majority of those (41%) being single pathway mutations (Supplemental Table 5). As we discussed previously, there is limited knowledge on the functional importance of mutations within these other nodes of the pathway (see section

E. Expanding the Mutational Themes), but given the emergence of genomic medicine and the success of targeted therapies, the role of the *Gαs*-PKA pathway in cancer certainly warrants further study. For the remainder of this review, we will highlight examples of the clinical and biologic function of the *Gαs*-PKA pathway in cancer.

2. Mucin Production Drives Clinical Phenotypes. One of the most striking and clinically relevant features of *GNAS* mutant cancers is their high level of mucin production across several tissue types (lung, stomach, bile duct, pancreas, appendix, colorectum, and gonads) (Innamorati et al., 2018). Mucins are large glycoproteins, either secreted or membrane-bound, with important physiologic and homeostatic roles. In the intestine, mucin provides the first line of defense

against microbes and is critical to preserving epithelial barrier integrity. Mucins also have important structural roles to help physically maintain the microvilli architecture that is so important to intestinal function (Pelaseyed and Hansson, 2020). Consequently, the dysregulation of mucin can have profound impacts on disease. For instance, mucin 2 (encoded by *Muc2*) knockout mice have defects in goblet cell differentiation. This results in increased epithelial cell proliferation and migration coupled with decreased apoptosis and lack of acidic mucin production. Ultimately, these *Muc2* knockout mice spontaneously develop tumors in the small and large intestine that progress to invasive carcinoma (Velcich et al., 2002). Interestingly, the G α s-PKA pathway is known to directly regulate MUC2 expression through the G protein-coupled E-type prostanoid receptor 4 in the intestine. PKA-mediated activation of CREB triggers binding to the CRE in the *MUC2* promoter and transcriptional upregulation (Nishikawa et al., 2013; Dilly et al., 2017). In pancreatic ductal cells, *GNAS* mutation is known to dramatically increase the expression of another mucin, *MUC5AC*. *MUC5AC* is one of the predominant mucins overexpressed in IPMNs of the pancreas, which commonly harbor *GNAS* hotspot mutations (discussed below) (Ideno et al., 2013; Komatsu et al., 2014). Transcriptional upregulation of mucin production is also augmented by the role of cAMP and PKA in vesicular transport. PKA is involved in constitutive transport of vesicles through the trans-Golgi network to the cell surface (Muñiz et al., 1996). Specifically, AKAPs anchor PKA to the cytoplasmic surface of the endoplasmic reticulum (AKAP1) and Golgi (AKAP1/9), where it can be activated in response to extracellular stimulation (Rios et al., 1992; Huang et al., 1999; Ma and Taylor, 2008; Mavillard et al., 2010).

At a molecular level, mucin overexpression in cancer has been implicated in dysregulation of cell polarity and disruption of proper cell-cell contacts. Further, mucin can facilitate aberrant oncogenic signaling, such as β -catenin activation, and receptor tyrosine kinase oligomerization and activation (Kaur et al., 2013; Pelaseyed and Hansson, 2020; Pothuraju et al., 2020). Mucin is also thought to play an important role in modulating the tumor microenvironment, serving as a bridge to nutrient-rich stroma through neoangiogenesis as well as by providing immunosuppressive mechanisms to evade immune surveillance. In addition to biologic effects on the tumor microenvironment, mucin can also serve as a physical barrier, sequestering local growth factors and protecting neoplastic cells from cytotoxic agents (Hollingsworth and Swanson, 2004; Kaur et al., 2013). Consequently, mucinous adenocarcinoma (in which >50% of the tumor mass is mucin) and tumors with a mucinous

component (<50% of tumor mass is mucin) are implicated, with poor prognosis and chemoresistance across many tissue types (Schiavone et al., 2011; Lee et al., 2013; Kajiyama et al., 2014; Asare et al., 2016; Xie et al., 2018). Of note, pseudomyxoma peritonei (PMP) is one of the most devastating examples of mucin dictating clinical outcomes, for which the 5-year survival rate of high-grade disease is only 23% (Nummela et al., 2015). PMP is an extremely rare subtype of mucinous adenocarcinoma (typically originating from the appendix) in which the peritoneal cavity is colonized by mucin-secreting neoplastic cells. The excess mucin (>90% of tumor volume, dominated by MUC2 and a lesser extent MUC5AC) (O'Connell et al., 2002) overtakes the peritoneum, obstructing normal intestinal function and ultimately killing the patient. *GNAS* hotspot mutations are found in 63% of all PMPs, including both low- and high-grade disease (56% and 70%, respectively). Currently, the only therapeutic options for these patients are reductive surgery and intraperitoneal chemotherapy, which have significant treatment-associated morbidity. Thus, targeting the G α s-PKA pathway as a means to limit mucin production has been proposed for patients with PMP (Nummela et al., 2015). Interestingly, in recurrent PMP, patients with *GNAS* mutations have poorer outcomes after chemotherapy, but it is uncertain whether this is because of the biology of *GNAS* mutants or whether *GNAS* is a biomarker of therapeutic resistance (discussed in section 5. *G α s-Protein Kinase A Induced Therapeutic Resistance in Cancer*) (Pietrantonio et al., 2016).

When considering the prevalence of *GNAS* mutations in PMP, among other cancer subtypes, another trend that becomes rapidly apparent is a co-occurrence with mutations in the *KRAS* proto-oncogene (encoded by *KRAS*) Interestingly, 63%–72% of *GNAS* mutant PMPs also harbor *KRAS* mutations (Nummela et al., 2015; Ang et al., 2018). Furthermore, in mucinous neoplasms of the appendix, 69% of patients with *GNAS* mutations actually harbor *GNAS* and *KRAS* comutations. Nearly all of these patients had low-grade histology (Alakus et al., 2014). Another study corroborated this, finding that 50% of patients with low-grade appendiceal mucinous neoplasm were positive for both *GNAS* and *KRAS* mutations (Nishikawa et al., 2013). Interestingly, 38%–43% of patients with IPMNs of the pancreas, which are analogous low-grade lesions of the pancreas, harbor both *GNAS* and *KRAS* mutations (Molin et al., 2013; Amato et al., 2014). Furthermore, 58% of villous adenocarcinomas of the colorectum, which are characterized by noninvasive tissue architecture (similar to low-grade appendiceal mucinous neoplasm and IPMN) and profound mucin production are also *GNAS* and *KRAS* comutants (Yamada et

al., 2012). Together these co-occurrence patterns highlight that *GNAS* and *KRAS* mutation give rise to unique biology in neoplastic diseases that cannot be achieved by either gene alone.

3. *GNAS* and Protein Kinase A Link Inflammation to Cancer Initiation. Consistent with clinical evidence that *GNAS* mutations are predominantly found in benign, noninvasive lesions, mouse models reveal that *GNAS* mutation alone is insufficient to induce epithelial tumorigenesis (Wilson et al., 2010; Patra et al., 2018). Our team showed that, in the context of *KRAS* mutations in the pancreas, *GNAS* drives lesions toward the cystic lineage; together, these comutants form well differentiated, mucinous cysts that resemble IPMNs, instead of noncystic pancreatic intraepithelial neoplasias. Somewhat counterintuitively, *GNAS* R201C expression does not accelerate *KRAS*-driven progression to pancreatic adenocarcinoma (PDAC). Instead, inactivation of tumor suppressors, like p53 (*TP53*), cyclin dependent kinase inhibitor 2a (*CDKN2A*), or SMAD family member 4 (*SMAD4*), are needed to facilitate efficient progression to PDAC (Ideno et al., 2018; Patra et al., 2018). Interestingly, in the context of PDAC, *GNAS* R201C expression through activation of PKA actually attenuates aggressiveness and invasiveness due to epithelial differentiation (Pattabiraman et al., 2016; Ideno et al., 2018). This is supported by clinical evidence that patients with *GNAS* mutant have a better overall survival in appendix cancer (Ang et al., 2018). However, in small cell lung cancer, a neuroendocrine disease, *GNAS* and PKA activity is critical to cancer stem cell maintenance and increases rate of initiation and progression (Coles et al., 2020). This suggests that *GNAS* and PKA can play disparate roles within the various stages from neoplastic initiation to carcinogenic progression. Analysis of colorectal tissues on this spectrum from adenoma to carcinoma revealed that the frequency of *GNAS* mutation drops with progression. For instance, adenomas had the highest frequency of mutation, followed by carcinomas with residual benign adenoma, carcinomas with adenoma, and regions of invasion, and finally, no mutants were detected in pure carcinomas (Zauber et al., 2016). This suggests that in epithelial tissues, *GNAS* is most important in early initiation events. Indeed, several studies have highlighted that *GNAS* mutation can accelerate tumorigenesis (Wilson et al., 2010; Ideno et al., 2018; Patra et al., 2018; Coles et al., 2020). Given that tumors are heterogeneous, *GNAS* may confer a selective advantage initially, in which context additional mutational insults, like *KRAS* and subsequently *TP53*, can drive malignant growth ultimately independent of *GNAS* mutation. To this end, sequencing of normal human colon crypts unsurprisingly shows that *KRAS* and *TP53* mutations are rare,

suggesting that they are more important in intermediate and late events. However, reanalysis of available data highlights 55% of normal crypts harbored *GNAS* mutations (five of nine subjects), supporting the notion that *GNAS* may be important in neoplastic initiation and tumorigenesis (Lee-Six et al., 2019).

This idea of *GNAS* mutations participating in neoplastic initiation tracks well given the established Vogelgram of colorectal cancer (CRC) mutation accumulation. In the original model, *KRAS* mutations participated in intermediate events, facilitating the progression of adenomas, whereas *TP53* loss served as the final barrier to carcinogenesis (Fearon and Vogelstein, 1990). As we have gained more understanding of the molecular events involved in carcinogenesis, COX-2-mediated inflammation has been defined as one of the earliest events in initiation (Markowitz and Bertagnolli, 2009). COX-2 is not expressed under normal conditions but is rapidly upregulated in response to stress and inflammatory stimuli. Naturally, COX-2 has become a prominent biomarker in colorectal cancer and many others, including lung (Hida et al., 1998), pancreas (Tucker et al., 1999), breast (Ristimäki et al., 2002), liver (Shiota et al., 1999), esophagus (Zimmermann et al., 1999), cervix (Ryu et al., 2000), and skin cancer (Buckman et al., 1998). COX-2 is the inducible form of the COX enzymes, which converts arachidonic acid to lipid signaling molecules, including prostaglandins and thromboxanes. These inflammatory mediators are ligands for a number of GPCRs in the prostanoid family (Hata and Breyer, 2004). Most notably, PGE₂ is the ligand for two G_{αs}-coupled GPCRs, E-type prostanoid receptors 2 and 4 (encoded by the *PTGER2* and *PTGER4* genes, respectively). PGE₂ has been shown to increase proliferation in colon cancer cells and mediate activation of β-catenin (through G_{αs}) and other mitogenic signaling molecules, like phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) (through G_{βγ} effects) (Castellone et al., 2005).

Frequent and early genomic alteration in the adenomatous polyposis coli (APC) gene are often concurrent with COX-2 overexpression in early initiation events of CRC (Fearon and Vogelstein, 1990; Markowitz and Bertagnolli, 2009), thus highlighting the interplay between their regulated pathways. APC acts as a major tumor suppressor in CRC, inhibiting the Wnt-β-catenin signaling route (Kolligs et al., 2002). The Wnt pathway is a major determinant of cell fate decisions, helping to promote stem cell maintenance and tissue renewal from embryogenesis to adulthood. Consequently, these normal programs are frequently co-opted by disease. Wnt signaling controls β-catenin, a coactivator that drives transcription through binding of nuclear transcription factors (i.e., T-cell factor or TCF). When the pathway is inactive, β-catenin is




Fig. 10. Aberrant protein kinase A pathway activity leads to dysregulation of signaling and transcriptional programs. (A) Wnt and PKA activity drive β -catenin-mediated gene transcription. Canonically, Wnt binds to Frizzled receptors and coreceptors like LPL receptor related protein 6 (LRP 6) on the surface of the cell to inhibit the activity of the destruction complex. Destruction complex members include APC, GSK3, CK1 α , and Axin. Inhibition of this complex releases β -catenin to drive target gene transcription through the transcription factor TCF. Production of PGE $_2$ through COX-2 leads to activation of G α s-coupled GPCRs, E-type prostanoid receptor 2 (EP2), and E-type prostanoid receptor 4 (EP4). Activation of G α s leads to direct phosphorylation and inhibition of GSK3 as well as stabilizing phosphorylation of β -catenin. These effects coupled with the direct binding of G α s to Axin lead to accumulation of β -catenin and activation of target gene transcription. (B) PKA inhibits Hippo pathway and YAP/TEAD-mediated transcription. The Hippo pathway is regulated by a kinase cascade whereby the upstream kinase MST phosphorylates and activates LATS kinase. Phosphorylation of YAP by LATS inactivates YAP through cytoplasmic sequestration and degradation. PKA-mediated phosphorylation of LATS, among other mechanisms, also inhibits YAP activity and consequently blocks target gene transcription through TEAD. (C) PKA regulates hedgehog (HH) signaling in the cilium to inhibit G α i transcriptional activity. When HH ligand is present, it binds to and inhibits the receptor Patched (PTCH1), allowing the G α i-like GPCR SMO to traffic to the ciliary membrane. SMO inhibits cAMP production and PKA activity, allowing G α i-mediated transcription to proceed. When HH ligand is absent, PTCH1 constitutively inhibits SMO and allows the G α s-coupled GPCR GPR161 to traffic to the ciliary membrane. When present at the membrane, GPR161 stimulates cAMP production and PKA activity. PKA in turn phosphorylates and inhibits G α i, eventually leading to its degradation.

sequestered in the cytoplasm by a protein complex termed the destruction complex and ultimately targeted for degradation (Fig. 10A). This destruction complex consists of key molecules like GSK3, casein kinase 1 α (CK1 α), Axin, and APC. CK1 α and GSK3 provide the phosphorylation signals that target β -catenin for ubiquitination and degradation. Canonically, the pathway becomes activated by extracellular Wnts or changes in adherens junctions (Angers and Moon, 2009; Valenta et al., 2012). However, the G α s-PKA pathway can modulate β -catenin activity at several levels (Fig. 10A). When activated by receptors, G α s has been shown to bind to Axin, leading to the stabilization and activation of β -catenin (Castellone et al., 2005). Many components of the destruction complex

are also phosphorylated by PKA. The predominant mechanisms highlight the ability of PKA to phosphorylate and inhibit GSK3, releasing β -catenin to enter the nucleus (Fang et al., 2000). This, coupled with direct PKA phosphorylation of β -catenin to inhibit ubiquitination and degradation, helps drive β -catenin-mediated transcription (Hino et al., 2005). These mechanisms have important biologic consequences, including stem cell maintenance and tissue regeneration and repair (Goessling et al., 2009; Wang et al., 2016). Crosstalk with the G α s-PKA pathway is also particularly important for the endocrine G α s-PKA pathway signalopathies (Walczak and Hammer, 2015). For instance, β -catenin expression is very strong in adrenal tumors and Carney complex

caused by genetic defects in the *G α s*-PKA pathway (Almeida et al., 2012). This contributes to dysregulated Wnt signaling and loss of cell cycle control (Almeida et al., 2010). In CRC, activation of the Wnt- β -catenin pathway by *G α s*-PKA may represent a key event in CRC initiation and progression, whether it is achieved by mutations in *GNAS* or perhaps more often by PGE₂ and COX-2-initiated, *G α s*-linked GPCR signaling (Castellone et al., 2005; Wu et al., 2019).

Aligned with this perspective, PGE₂ dramatically increases intestinal tumor burden in CRC mouse models, and the inhibition of PGE₂ production with COX-2 inhibitors, such as by nonsteroidal anti-inflammatory drugs (NSAIDs), reduces tumor burden (Hansen-Petrik et al., 2002; Kawamori et al., 2003; Wang and DuBois, 2010). In humans, retrospective studies have revealed a reduced incidence of colorectal cancer with prolonged NSAID use, and NSAIDs can directly reduce polyp size and number in patients with familial CRC. Unfortunately, the clinical response to NSAIDs is incomplete, and long-term use can have limiting toxicities (Giardiello et al., 1993; Brown and DuBois, 2005). Of available NSAIDs, aspirin has been used successfully long-term in cardiovascular disease. In these patient populations, aspirin has also been shown to reduce CRC incidence and mortality. Interestingly, the benefit of aspirin in chemoprevention was most pronounced after 10 years (Chan et al., 2005; Chubak et al., 2015; Drew et al., 2016). One mechanism by which aspirin is thought to reduce mortality is by preventing metastasis, particularly in the progression of local adenoma to metastatic disease (Rothwell et al., 2012). Given the consistent efficacy of aspirin and other NSAIDs in chemoprevention, numerous clinical trials have tested their efficacy in other settings. Notably, NSAIDs have shown efficacy in some adjuvant settings but failed when operating as single-agent chemotherapeutics (Brown and DuBois, 2005; Wang and DuBois, 2010). The clinical efficacy of NSAIDs as chemopreventive agents, but failure as chemotherapeutics, highlights the true complexity of prostaglandin signaling. It is likely that PGE₂ and others participate in autocrine and paracrine signaling loops that involve both tumor, stroma, and immune components. To this end, *G α s*-PKA activation, downstream of the proton-sensing GPCR GPR68, has been shown to drive the secretion of interleukin 6 (IL-6) from cancer-associated fibroblasts and subsequent proliferation of PDAC in trans (Wiley et al., 2018). Further, *G α s*-linked GPCRs, like prostanoid (Zelenay et al., 2015; Böttcher et al., 2018; Pelly et al., 2021) and adenosine receptors (Visser et al., 2000; Novitskiy et al., 2008; Young et al., 2014; Young et al., 2018),

contribute to tumor immune evasion and drive immune suppression by dampening T-cell responses, as well as interfering with immune cell migration and maturation. For example, these mechanisms can include direct PKA-mediated phosphorylation of C-terminal Src kinase (CSK) and other components involved in T-cell receptor signaling and activation, as well as PGE₂-mediated suppression of chemokine production and dendritic cell recruitment (Wehbi and Taskén, 2016; Böttcher et al., 2018). Recent evidence also points to the specific role of PKA *C β 2* (an immune-specific spliceform) in regulating immune responses in inflammatory disease (Moen et al., 2017). Together, this highlights that the *G α s*-PKA pathway can participate in tumor initiation and progression through autocrine and paracrine (onco-crine) mechanisms (Wu et al., 2019). Even in the absence of overt mutations, these onco-crine signals can have important effects throughout the tumor microenvironment, including contributions to a cancer immune evasion and therapeutic resistance (see section 5. *G α s-Protein Kinase A Induced Therapeutic Resistance in Cancer*).

4. *GNAS-Protein Kinase A as Tumor Suppressors.* Thus far, our discussions of the *G α s*-PKA pathway in cancer have focused on the role of *GNAS* and *DNAJB1-PRKACA* as oncogenes. Paradoxically, however, there are several examples in which the *G α s*-PKA pathway functions as a tumor suppressor. A study by our group unexpectedly found that genetic ablation of *Gnas* or inhibition of PKA in the epidermis was sufficient to drive basal cell carcinoma, with dramatic expansion of the stem cell compartment residing in the hair follicle. Conversely, overactivation of the pathway with the *GNAS* R201C mutation drove the same stem cell population to terminal differentiation and exhaustion. Mechanistically, stem cell expansion in the hair follicle is controlled by PKA-mediated repression of yes-associated protein (YAP) and glioma-associated oncogene (GLI) transcriptional activity, with no effect on other stem cell programs like Wnt (Iglesias-Bartolome et al., 2015). Of note, PKA has been shown to repress YAP activity in pancreatic cancer (in which PKA functions as an oncogene) but still induce a differentiation phenotype (Ideno et al., 2018). Much like *GNAS* and PKA, YAP has also been shown to behave as either an oncogene or a tumor suppressor depending on the cellular context.

The Hippo pathway controls growth, differentiation, and cell death, balancing these processes to ensure proper organ development and size. In mammals, YAP and tafazzin (TAZ) are the main effectors that regulate transcriptional output through binding to transcription factors like TEA domain transcription factor (TEAD) in the nucleus. YAP/TAZ are regulated by phosphorylation from upstream kinases large

tumor suppressor kinase 1 and 2 (LATS 1/2), whereby phosphorylation induces YAP/TAZ cytoplasmic sequestration and subsequent degradation (Fig. 10B). LATS1/2 in turn can be regulated by many upstream signals, including GPCRs. G α s-coupled GPCRs activate LATS1/2 to repress YAP/TAZ (Yu et al., 2012). PKA directly phosphorylates LATS1/2 to enhance its kinase activity, and mutation of the PKA phosphosites abrogates PKA regulation of LATS1/2 while other regulatory mechanisms remain intact (Kim et al., 2013) (Fig. 10B). Physiologically, this is important because PKA is known to induce adipogenesis and neurogenesis through suppression of YAP (Kim et al., 2013; Yu et al., 2013). In general, YAP phosphorylation and inactivation is critical for cell cycle exit and terminal differentiation, and it is thought that PKA contributes to this regulation (Lee et al., 2008; Kim et al., 2013). This can explain in part why many neoplasms and cancers characterized by G α s-PKA pathway activation are of well differentiated histology and typically less proliferative or low-grade (as discussed previously, see section 3. *GNAS and Protein Kinase A Link Inflammation to Cancer Initiation*).

In line with the additional effects of G α s on GLI in basal cell carcinoma, low *GNAS* expression is also a feature of the sonic hedgehog (SHH) subtype of medulloblastoma (SHH-MB). Medulloblastoma is the most common pediatric brain cancer, with SHH-MB representing 30% of patients (Kijima and Kanemura, 2016). Within this subtype, activation of the SHH pathway (through multiple mechanisms) is thought to drive tumor initiation. Interestingly, patients with SHH-MB with low *GNAS* expression have significantly worse prognosis compared with patients with high *GNAS* expression (50% 5-month survival versus 100% 5-month survival). Similar to the hair follicle model, knockout of *Gnas* in neural progenitor cells induced expansion of this stem cell population in neonatal mice that progressively developed into a tumor resembling medulloblastoma by adulthood. The tumors were marked by upregulation of GLI and SHH signaling with no effect on the Wnt pathway, a pattern that matches the signature of patients with SHH-MB (He et al., 2014). Around 6% of patients with SHH-MB actually have *GNAS* mutations, including frameshift and nonsense inactivating mutations (He et al., 2014; Huh et al., 2014; Kool et al., 2014). Perhaps more surprisingly through, around 80% of SHH-MBs overexpress C-X-C motif chemokine receptor 4 (CXCR4), which is a G α i-coupled GPCR (Sengupta et al., 2012). These patients are typically younger (~50% were infants) with desmoplastic histology (He et al., 2014). Although CXCR4 is not often mutated, CXCR4 and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), are markers of poor prognosis and earlier onset in other brain tumors, like

gliomas (Calatozzolo et al., 2006; Bian et al., 2007). For these patients, cAMP elevating agents, such as PDE inhibitors, have been proposed as potential therapeutic options (Rao et al., 2016).

The importance of G α s in the SHH-MB subtype of pediatric brain cancer reflects the fundamental importance of G α s-PKA in brain development. As a testament to its importance, *Gnas* homozygous knockout mice are embryonic lethal (Yu et al., 1998). Similarly, only 27% of *Prkaca* homozygous knockout mice survive past weaning (Skaalhegg et al., 2002). As mentioned previously, both *C α 1* and *C β 1* are ubiquitously expressed and capable of some degree of compensation. Therefore, it is not surprising that *C α* and *C β 1* double knockout mice are embryonic lethal. Restoration of one allele in either gene (*C α* or *C β 1*) confers survival, but mice die from severe neural tube defects. Histologically, these mice have an expansion of cell types that are dependent on hedgehog (HH) signaling (Huang et al., 2002).

In a more pathway-specific fashion, PKA is known to regulate HH signaling, both SHH and Indian hedgehog, within the context of cilia. Interestingly, the ciliary structure is essential to proper signaling and development controlled by the HH pathway, a feature that is not shared by other developmental programs. The GLI family of transcription factors are the main effectors that respond to upstream stimulus from HH ligands. In the absence of pathway stimulation, GLI is sequestered and eventually degraded (Carballo et al., 2018). AKAPs position PKA at the base of the cilium, where the catalytic subunit phosphorylates GLI to facilitate GLI's proteolytic processing and degradation, ultimately preventing transcriptional activation (Fig. 10C). Recent work has demonstrated that the G α s-coupled GPCR, GPR161, contains an AKAP domain enabling it to directly recruit PKA to cilia (Bachmann et al., 2016). Of note, GPR161 is regulated by trafficking and only capable of signaling when it is present on the ciliary membrane (Bangs and Anderson, 2017). Activation of GPR161, among other G α s-coupled GPCRs, is important to trigger production of cAMP and subsequent PKA activation. Generally, PKA activity is quite high when HH ligand is absent (Tschaikner et al., 2020). However, when HH is present, the G α i-like-coupled GPCR Smoothed (SMO) traffics to the cilium to trigger a reduction in cAMP levels and inhibition of PKA activity (Ogden et al., 2008), allowing full-length GLI to activate transcription. This trafficking is regulated by the binding of HH to its receptor patched homolog 1 (PTCH1) at the membrane, thereby relieving the inhibition on SMO (Bangs and Anderson, 2017). Recent evidence has also demonstrated that SMO can directly inhibit PKA through binding to the free catalytic subunits at the membrane (Arveseth et al., 2021) (Fig. 10C). Numerous other GPCRs, such as

CXCR4 (G α i-coupled) and PAC1 (G α s-coupled), can also contribute to the modulation of ciliary cAMP levels and PKA activity, although some of these roles are complex and cell type-dependent (Niewiadomski et al., 2013; Mukhopadhyay and Rohatgi, 2014; Schou et al., 2015; Mykytyn and Askwith, 2017; Amarante et al., 2018; Tschalkner et al., 2020). Ultimately, the degree of GLI transcriptional output is dependent on the level of PKA activity as a balance of these various inputs (Tschalkner et al., 2020). Consequently, the overexpression of PKA C α is sufficient to inhibit SHH-stimulated proliferation and induce differentiation (Barzi et al., 2010). Recently, several mutations in C α and C β , which display increased sensitivity to cAMP, show reduced HH pathway activation (Palencia-Campos et al., 2020). Conversely, deletion of G α s in the mouse augments SHH signaling with developmental defects that mirror PKA deletion, or deletion of other negative regulators of the SHH pathway (Regard et al., 2013). SHH signaling is particularly important in guiding development of the nervous system and limb patterns, whereas Indian hedgehog is important in skeletal development (Bangs and Anderson, 2017). This explains why patients with loss-of-function mutation in the G α s-PKA pathway can develop SHH-MB or severe skeletal deformities as part of iPPSD (discussed previously, see section 7. *Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Peptide Signaling Disorder*). Furthermore, recent reports have described mutations in *PRKACA* that cause skeletal ciliopathies (Palencia-Campos et al., 2020; Hammarsjö et al., 2021).

5. G α s-Protein Kinase A Induced Therapeutic Resistance in Cancer. Our discussions have already highlighted some features of the G α s-PKA pathway that contribute to therapeutic resistance, including supporting an immune suppressive tumor microenvironment, and clinical evidence of poor outcomes and chemoresistance due to mucinous disease. Here, we will focus on additional evidence of the therapeutic resistance potential of the G α s-PKA pathway in cancer.

Building on the evidence of *GNAS* and *KRAS* functioning as codrivers of carcinogenesis, several unbiased studies have identified G α s and PKA as key drivers of resistance to MAPK pathway inhibition. In metastatic melanoma, about half of all patients have *BRAF* mutations and are primarily treated with *BRAF* inhibitors. Although most patients have clinical responses, approximately 20% of patients with *BRAF* mutation have intrinsic resistance to *BRAF* inhibitors (Sanchez et al., 2018). Unfortunately, many initial responders later develop acquired resistance from genetic (60%) or epigenetic and transcriptomic (40%) changes, primarily through reactivation of

MAPK signaling outputs (Kakadia et al., 2018). Several studies have aimed at understanding these mechanisms of resistance and reactivation. Gain-of-function open reading frame and CRISPR activation screens in *BRAF* V600E melanomas have been used to identify programs that confer resistance to multiple *BRAF* and MAPK inhibitors. Surprisingly, GPCRs were consistently among the top hits, many of them being G α s-coupled (Johannessen et al., 2013; Konermann et al., 2015). Downstream, *ADCY9* and PKA C α also confer resistance to MAPK inhibitors, with PKA C α having a higher score than even *RAF1*. Further analysis revealed that PKA via *CREB* was able to activate transcriptional programs that MAPK normally activates (Johannessen et al., 2013). In melanocytes, there is a fine balance between MAPK control of proliferation and cAMP control of differentiation (Dumaz et al., 2006). This balance is achieved in part because PKA can phosphorylate and inhibit *RAF1*, while *BRAF* continues signaling downstream to *ERK* (Cook and McCormick, 1993; Dhillon et al., 2002). Interestingly, when *RAS* is mutated, *RAF1* predominantly signals to *ERK*, a program that *BRAF* controls when it is mutated. This type of compensatory crosstalk is the basis for PKA-mediated resistance to MAPK pathway inhibition. Of note, this crosstalk is not present in all cell types, e.g., fibroblasts (Dumaz et al., 2006).

As we discussed previously, inflammatory signaling through COX2-PGE₂-G α s contributes to the pathogenesis of many cancers. Recently, this pathway has also been implicated as a mechanism of resistance to combination *BRAF* and MAPK pathway inhibition in *BRAF* V600E colorectal cancer. Using a high-throughput kinase activity screen, the SRC proto-oncogene (SRC) was identified as having increased activity after inhibitor treatment. SRC in particular was shown to initiate a proinflammatory autocrine loop mediated by PGE₂ and G α s that was sensitive to COX2 inhibition. Dramatically, the addition of a COX2 inhibitor to two or three drug combinations targeting the MAPK pathway led to greater rates of tumor regression in patient-derived xenograft resistance models (Ruiz-Saenz et al., submitted manuscript). The mechanisms of resistance through COX2-PGE₂-G α s and PKA include survival of cancer stem cells as well as immune suppression (Tong et al., 2018). In *BRAF* V600E mutant melanoma, for instance, COX-2 was shown to drive tumor immune escape, a response that underlines the preclinical synergy of COX-2 inhibitors in combination with immune checkpoint blockade (Zelenay et al., 2015). Similarly, the ability of PKA to drive tumor immune evasion has also limited the efficacy of other immune-based therapies such as chimeric antigen receptor T cells (CAR-Ts) (Newick et al., 2016). This suppression of

CAR-Ts and T cells in general is mediated by PKA/AKAP associations that negatively regulate T-cell function (Ruppelt et al., 2007). Interestingly, disruption of this PKA/AKAP interaction can improve CAR-T efficacy and enhance tumor killing (Newick et al., 2016). Building on the understanding of these immune suppressive mechanisms (see section 3. *GNAS and Protein Kinase A Link Inflammation to Cancer Initiation*), NSAIDs as well as prostanoid and adenosine receptor antagonists are being investigated as agents to combat tumor immune evasion and enhance the clinical efficacy of immune therapies (Leone et al., 2015; Hamada et al., 2017; Take et al., 2020). Finally, the G α s-PKA pathway has effects on migration and metastasis. This role is somewhat controversial, as PKA has been shown to drive epithelial differentiation, instead of the epithelial-to-mesenchymal transition phenotypes generally recognized as metastatic (Pattabiraman et al., 2016). However, PKA is also known to play a role in cytoskeletal changes through direct AKAP interactions that are required for many of the hallmarks of cell migration (Howe, 2004). Importantly, it seems that these effects are context-dependent, since G α s and PKA serve as a central regulatory hub integrating many signaling pathways and biologic functions.

PKA can also contribute to therapeutic resistance by co-opting other normal mechanisms, including energy adaptation. The mitochondria are the main producers of energy in the cell; thus, maintaining mitochondrial homeostasis is critically important to cell health. Mitochondrial homeostasis represents a dynamic balance between fusion (joining) and fission (division) events. PKA is particularly well studied in its ability to inhibit mitochondrial fission through phosphorylation of dynamin-related protein 1 (DRP1), a dynamin-like GTPase. DRP1 functions to bring mitochondrial membranes close to each other to facilitate fission events. PKA phosphorylation at serine 637 inhibits DRP1 GTPase activity and recruitment to the mitochondria (Chang and Blackstone, 2007). By inhibiting fission, fusion is allowed to proceed, resulting in elongated mitochondria and increased respiration. Increased cAMP and PKA activity has also been linked to decreased mitophagy and ultimately control of mitochondrial recycling; however, it remains unclear whether this is primarily due to increased fusion or additional effects of cAMP and PKA. Together, the actions of the cAMP-PKA pathway on the mitochondria provide a prosurvival signal (Di Benedetto et al., 2018; Ould Amer and Hebert-Chate-lain, 2018). Under physiologic conditions of low nutrients, cells elongate mitochondria to compensate. Interestingly, this physiologic adaptation can be exploited by cancer cells, which, although somewhat counterintuitive, rely heavily on glycolysis for energy

(Vander Heiden et al., 2009). For instance, KRAS transformed cells die in low-glucose conditions, but activation of cAMP/PKA rescues their survival under these conditions. PKA-mediated activation of mitochondrial respiration ramps up oxidative phosphorylation and ATP levels (Acin-Perez et al., 2009; Palorini et al., 2013; Ould Amer and Hebert-Chate-lain, 2018). Coupled with reduction in reactive oxidative species and increased autophagy, cAMP and PKA metabolically rewire cells to promote survival (Palorini et al., 2013; Palorini et al., 2016; Ould Amer and Hebert-Chate-lain, 2018). Under physiologic conditions of low nutrients, PKA also liberates energy from glycogen and lipid stores through direct phosphorylation, as well as transcriptional regulation, of the enzymes involved in these processes (Rogne and Taskén, 2014; Yang and Yang, 2016) (see section *F. Metabolic Regulation*). However, it remains unclear to what extent cancer cells exploit these energy sources. Together, energy adaptation mechanisms and prosurvival signals provide some insight as to why *GNAS* and PKA serve as biomarkers of therapeutic resistance in many cancer types and further why *GNAS* and *KRAS* often comutate in cancer.

Finally, the role of G α s and PKA in resistance can be seen clinically in breast cancer, a tissue type in which *GNAS* mutations are rarely found. One study profiled circulating free DNA before and after treatment with targeted therapy in metastatic, human epidermal growth factor receptor 2–positive (HER2+) breast cancer. Surprisingly, they found that *GNAS* mutations were only present in patients that were resistant to targeted therapy (Ye et al., 2017). Similarly, *PRKACA* transcripts were elevated in HER2+ patients that were resistant to trastuzumab (HER2 inhibitor) (Moody et al., 2015). In vitro models of resistance have also demonstrated that knockdown of *PRKAR2A*, to activate PKA, confers partial resistance to trastuzimab (Gu et al., 2009). Unlike in melanoma, this resistance could not be explained by MAPK pathway reactivation but, rather, by restoration of antiapoptotic signaling (Moody et al., 2015). In another subtype of breast cancer, estrogen receptor–expressing, patients receive antiestrogen therapies such as tamoxifen. Tamoxifen binds to estrogen receptor α to induce a conformation that prevents its activation and signaling. Interestingly, PKA has been found to phosphorylate the estrogen receptor α , an interaction coordinated by AKAP13. This phosphorylation prevents the inhibitory conformational change induced by tamoxifen and renders tamoxifen ineffective (Michalides et al., 2004; Bentin Toaldo et al., 2015). *GNAS* amplifications have been identified in 20% of HER2+ breast cancers and 13% of hormone receptor–positive breast cancers (Kan et al., 2010). Although further studies are required, it is tempting

to suggest that *GNAS* amplification may serve as a biomarker, predicting resistance to therapy in breast cancer. Here, we have highlighted several known mechanisms of therapeutic resistance, but there are certainly additional mechanisms yet to be described. Together, these findings highlight again the diversity and complexity of *G α s* and PKA signaling and their roles in the diversity of the *G α s*-PKA pathway signalopathies.

V. Targeting the *G α s*-Protein Kinase A Pathway Signalopathies

Given the breadth of the *G α s*-PKA pathway signalopathies, it is tempting to imagine how valuable a magic bullet PKA drug, potentially a life-changing resource for families with germline *G α s*-PKA pathway signalopathies, like Carney complex, could be. Although throughout this review we have often distilled diseases down to mutational themes, all circling back to simple activation or inactivation of the *G α s*-PKA pathway, we have also taken care to highlight the complexity that underlies all of these signaling events. We must acknowledge the role of local microdomains and specific isoforms that allow PKA to mediate disparate yet parallel functions and of course recognize the diverse inputs that modulate their activity. This complexity may seem like a liability at first glance. However, as we continue to understand the specifics of each signaling defect more deeply, it may provide a unique opportunity to carve out a therapeutic window. Current standard of care for the *G α s*-PKA pathway signalopathies, particularly those characterized by developmental defects or neoplasia, involve surgical and palliative treatments (Sharma et al., 2015; Javaid et al., 2019). These treatments do not address the true cause of the disease but instead highlight the value of targeted approaches.

A. Targeting G Protein-Coupled Receptors and G Protein-Coupled Receptor Ligands

When considering how to target the *G α s*-PKA pathway signalopathies, the natural first step lies at the cell surface with receptors. GPCRs are the target of approximately one-third of all clinically approved small-molecule drugs (Santos et al., 2017). Nearly every family of GPCR has been targeted by either an approved drug or one in clinical development, including both small molecules and peptides. GPCR drugs have proven to be tremendously effective in diseases such as heart failure and asthma, in which drugs targeting β -adrenergic receptors, among others, can improve heart function and cause airways dilation, respectively (Wang et al., 2018a; Wendell et al., 2020). As the *G α s*-PKA pathway signalopathies largely focus on genetic diseases with endocrine and neoplastic phenotypes, here we will focus on the therapeutic

potential of GPCRs in these settings, with the ability to modulate both *G α s*- and *G α i*-coupled receptors with agonists and antagonists, depending on the role of the pathway in the disease. This strategy has already proven effective in several *G α s*-PKA pathway signalopathies. For example, somatostatin receptor analogs have been used to treat acromegaly for years, and a new analog, pasireotide, was recently approved for Cushing syndrome (Freda, 2002; McKeage, 2013). Somatostatin is the endogenous peptide ligand for the *G α i*-coupled somatostatin family of GPCRs (SSTRs), but its use is limited clinically because of its extremely short half-life. Several peptide analogs have been developed to improve the half-life and with variable selectivity for somatostatin receptor subtypes. In acromegaly, 50%–60% of all patients benefit from somatostatin analogs, showing reduced GH and insulin-like growth factor-1 secretion as well as tumor shrinkage; however, surgery is often still the first line of therapy (Freda, 2002). In Cushing syndrome, pasireotide specifically targets SSTR5, which is highly expressed on ACTH-secreting pituitary tumors. Activation of SSTR5 reduces ACTH secretion and subsequently cortisol secretion. However, SSTR5 is also expressed on pancreatic β -cells, in which pasireotide inhibits insulin secretion and can exacerbate hyperglycemia, even contributing to the development of diabetes mellitus as a side effect in some patients (McKeage, 2013; Colao et al., 2014). To counteract these adverse events, patients are often administered GLP-1 agonists, targeting the *G α s*-coupled glucagon-like peptide-1 receptor (GLP1R) (Colao et al., 2014). GLP-1 agonists are commonly used to treat type II diabetes and obesity apart from Cushing syndrome because of their ability to increase insulin secretion and control appetite (Miller et al., 2014). Although GPCRs have proven to be great targets, no clinical drugs are available to target *G α s* or *G α i* directly (Campbell and Smrcka, 2018).

Other therapeutic approaches related to GPCRs are aimed at limiting ligand production, as is the case for many of the drugs used to treat Cushing syndrome and hyperthyroidism, which broadly inhibit steroidogenesis or hormone synthesis to limit hormone production (Sharma et al., 2015; De Leo et al., 2016). In the case of adrenal or pituitary adenomas that automatically secrete hormone, surgical removal of the tumor is a common approach (Sharma et al., 2015). For hereditary hyperthyroidism, patients typically receive radioactive iodine or surgery to remove the thyroid, but antithyroid drugs may also be used to interfere with thyroid hormone production, as some patients present at a young age (Hébrant et al., 2011; De Leo et al., 2016). Similarly, we have also discussed the use of COX-2 inhibitors as a means to limit prostaglandin production in colorectal cancer (see section

3. *GNAS and Protein Kinase A Link Inflammation to Cancer Initiation*). As evident from clinical studies, the side effects of this type of approach can largely limit the efficacy (Brown and DuBois, 2005). Furthermore, some patients, particularly those with genetic mutation of the PKA holoenzyme, are inherently resistant to these types of upstream modulation.

B. Targeting the Protein Kinase A Holoenzyme Directly

Although most kinases are manipulated by selective protein kinase inhibitors that target the active site cleft, there are a variety of ways to interfere with the PKA holoenzyme. In addition to small-molecule inhibitors, such as H89, that mimic ATP (Hidaka et al., 1984), high-affinity inhibitory peptides have been derived from the endogenous PKI (Cheng et al., 1985). In addition, analogs of cAMP differentially target type I versus type II regulatory subunits (Schwede et al., 2000), and isoform-selective peptides can disrupt holoenzyme targeting (Wang et al., 2014, 2015; Bendzun et al., 2018). Although many of these strategies hold promise, currently there are no clinical-grade drugs that target PKA specifically.

1. *ATP Analog Inhibitors of the Catalytic Subunit*. The most commonly used small-molecule inhibitors are the high-affinity, ATP-competitive isoquinolinesulfonyl protein kinase inhibitors, such as H89, H7, and H8 (Hidaka et al., 1984; Chijiwa et al., 1990; Engh et al., 1996; Lochner and Moolman, 2006); natural product derivative KT-5720 (Kase et al., 1987); or staurosporine (Meggio et al., 1995). Although these are very effective inhibitors, they have low specificity and inhibit several other kinases in the AGC family of protein kinases and hence should not be considered specific inhibitors (Lochner and Moolman, 2006; Murray, 2008). Of course, these inhibitors also do not discriminate between the PKA isoforms, thus limiting their clinical translatability.

2. *Peptide Inhibitors of the Catalytic Subunit*. To overcome the concerns of specificity, derivatives of the substrate-competitive, heat-stable PKI (encoded by *PKIA*, *PKIB*, and *PKIG*) can be used. PKI(5-24) has low-nanomolar inhibition constants and is absolutely specific for PKA (Cheng et al., 1985). PKI(5-24) can be modified by myristylation, which allows for membrane permeation (Eichholtz et al., 1993); however, it can also be expressed recombinantly in cells to overcome delivery issues. A hydrocarbon-stapled version of a PKI-derived sequence provides another excellent tool as a membrane-permeable, highly selective inhibitor of the catalytic subunits acting with low-subnanomolar affinity (Manschwet et al., 2019).

3. *Bisubstrate Inhibitors of the Catalytic Subunit*. A combination of the two cosubstrate inhibitors, ATP and peptide, would be the logical consequence, and indeed, such bisubstrate analog inhibitors termed

ARC-type inhibitors have been developed by linking an adenosine analog (either an adenosine derivative or ATP inhibitor) and an arginine-rich peptide (Lavogina et al., 2010). A series of ARC-type inhibitors have been designed with low-nanomolar or even picomolar affinities and efficacy against PKA C α and C β (Ricouart et al., 1991; Enkvist et al., 2006; Enkvist et al., 2007; Lavogina et al., 2010; Nonga et al., 2020). Recent work has demonstrated that ARC inhibitors can also be engineered to have greater selectivity for mutant C β over wild-type C β (Nonga et al., 2020). Although ARC inhibitors have primarily been used as tool compounds, including fluorescently conjugated ARCs, recent advances have drastically improved their pharmacokinetic properties, making them poised for future application in a therapeutic context (Lavogina et al., 2010).

4. *Targeting the Regulatory Subunits with cAMP Analogs*. In contrast to the ATP analog inhibitors that target the catalytic subunit, cAMP analogs have been engineered with specificity for the two classes of regulatory subunits (RI and RII). Both activators and inhibitors have been developed (Christensen et al., 2003). Achieving PKA regulatory subunit specificity has been a special challenge, as other proteins such as cGMP-dependent protein kinases, EPACs, CNG channels, PDEs, and cyclases all have cyclic nucleotide binding domains (Berman et al., 2005; Holz et al., 2008) (see section *G. Other cAMP Effectors*). By modifying the oxygens of the cyclic phosphate, chemists generated cAMP agonists (Sp analogs) and antagonists (Rp analogs). Global inhibition can be achieved with the Rp analogs, which bind to but do not promote dissociation of the holoenzyme (Rothermel and Parker Botelho, 1988; Christensen et al., 2003). By comparing the activity of type I inhibitors, like Rp-8-Br-cAMPS, with the activity of nonselective inhibitors, like Rp-cAMPS, it is possible to discriminate between the activities of the two holoenzymes (Gjertsen et al., 1995; Christensen et al., 2003; Farquhar et al., 2008). Similarly, the combination of different agonists can achieve some level of isoform-specific activation, but this still remains a challenge in the field (Robinson-Steiner and Corbin, 1983). However, leveraging regulatory subunit agonists and antagonists has facilitated the high-quality purification of PKA holoenzymes as well as free regulatory subunits (Bertinetti et al., 2009; Hanke et al., 2011). Unfortunately, many of these cAMP analogs suffer from poor membrane permeability, limiting their efficacy if delivered extracellularly. To overcome this, membrane-permeable versions of the cAMP analogs have been developed as prodrugs. When cleaved by cytosolic esterases, the analog is free to act inside the cell (Chepurny et al., 2013; Schwede et al., 2015). Care must be taken, however, because the effective

concentration of the released nucleotide inside the cell may vary, and extremely high levels of cAMP may perturb other cyclic nucleotide signaling.

5. Inhibitors of A-Kinase Anchoring Protein Binding. PKA specificity is also highly dependent on targeting to specific sites in the cell. Targeting is typically mediated by binding to AKAPs that contain a high-affinity helical binding motif that interacts with the D/D domains of the regulatory subunits. Naturally, peptides have been developed to disrupt this interaction, nonselectively perturbing the interactions with both type I and type II interactions (Carr et al., 1992; Herberg et al., 2000). Over time, this led to development of peptides specific to type I or type II, although these peptides still suffered from limited cell permeability (Calejo and Taskén, 2015). Now, isoform-specific, cell-permeant stapled peptides have been engineered that can selectively disrupt the targeting of type I and type II holoenzymes (Wang et al., 2014, 2015; Kennedy and Scott, 2015; Bendzun et al., 2018). Unfortunately, these peptides still lack clinical utility because of their unfavorable pharmacokinetics and relative inability to distinguish among specific AKAP interactions (Calejo and Taskén, 2015). Reagents have also been developed to disrupt other AKAP binders, such as PDEs and phosphatases, but as AKAPs have multiple binding partners, it has been difficult to translate this disruption to direct modulation of cellular consequences (Bucko and Scott, 2020; Omar and Scott, 2020). To begin to answer these difficult questions of microdomain dynamics, a promising new tool has been developed using AKAP targeting sequences as a means to localize drug delivery to specific PKA microdomains, such as those present at the centrosome. Although this approach, called local kinase inhibition, is still in its infancy, conceptually it holds a lot of promise in understanding AKAP interactions more directly and ultimately enhancing the specificity of PKA modulation (Bucko et al., 2019). Finally, small-molecule AKAP disrupters represent another promising approach with potential for clinical translation. Protein-protein interactions have been notoriously difficult to target with small molecules, but the advances in high-throughput screening have made this approach more feasible (Calejo and Taskén, 2015). Several groups have applied these approaches recently to identify disrupters of AKAP interactions (Gold et al., 2013; Schächterle et al., 2015). Although there are real challenges, huge potential lies in the ability to apply these small-molecule disrupters to specific AKAP complexes in disease settings; for instance, disruption of the PKA/AKAP interactions that mediate immune suppression in T cells in cancer (see section 5. *G α s-Protein Kinase A Induced Therapeutic Resistance in Cancer*).

6. Emerging Approaches. As we discussed, many of the G α s-PKA pathway signalopathies are driven by specific hotspot point mutations, like GNAS R201C or PRKACA L206R, so generating mutation-specific drugs could be a viable therapeutic option. Recently, this strategy has shown clinical promise, most notably by targeting the mutant cysteine of KRAS G12C with drug electrophiles (Ostrem et al., 2013). It has been proposed that this same method could also be applied to target GNAS R201C mutants in cancer (Visscher et al., 2016). Although PKA is not amenable to targeting with drug electrophiles, the PKA C α L206R mutation does have reduced affinity for its endogenous inhibitor PKI compared with wild-type PKA C α , whereas the small-molecule inhibitor H89 still retains its efficacy. This opens the possibility of exploiting this differential binding to selectively target PKA C α mutants. However, significant challenges remain, as H89 retains its efficacy because it is an ATP-competitive inhibitor. As alluded to previously, this class of drug is susceptible to multiple off-target effects on other kinases, making it a liability in the clinical setting (Luzy et al., 2018). In an effort to identify drugs that do not act as ATP-competitive inhibitors of PKA, high-throughput screening platforms based on fluorescence polarization have been developed and proven capable of identifying allosteric agonists and antagonists (Saldanha et al., 2006; Brown et al., 2013). Some promise has also been shown for antisense oligonucleotides targeting R1 α in combination with chemotherapy in cancer (Goel et al., 2006; Almeida et al., 2012). The mechanism is not completely understood, but the compensatory increase in RII β protein could be important in restoring the balance of type I and type II holoenzyme signaling (Nesterova et al., 2000). Similarly, although many of the PKA C α mutations have been linked to altered substrate profiles and decreased preference toward canonical substrates. It is plausible that restoring activity toward key substrates may also serve as an additional therapeutic avenue (Lubner et al., 2017).

C. Degradation of Pathway Components

Another promising approach to targeting the G α s-PKA pathway directly is in targeting the stability of pathway components. This strategy has garnered huge interest in the past few years with the development of small-molecule inhibitors termed proteolysis targeting chimeras (PROTACs). PROTACs consist of an element targeting the protein of interest as well as an element targeting an E3 ubiquitin ligase that are linked together, facilitating target degradation through endogenous ubiquitin-proteasome system (UPS) machinery (Gao et al., 2020). This technology has been hailed for its exquisite specificity and ability to target “undruggable” proteins because it can take advantage of any binding site on the protein and does

not require that the binding interferes with catalytic activity (Mullard, 2021). PROTACs hold particular promise for targeting the G α s-PKA pathway because several components of the pathway are already known to be regulated by the UPS, including GPCRs, G proteins, PKA, PDEs, and AKAPs (Rinaldi et al., 2015). For instance, under physiologic conditions, the UPS contributes to desensitization of GPCRs at the plasma membrane after stimulation (Rinaldi et al., 2015; Skieterska et al., 2017). Furthermore, levels of G α s and PKA catalytic subunits are also regulated by ubiquitination and degradation in response to pathway stimulation (Naviglio et al., 2004; Nagai et al., 2010; Rinaldi et al., 2019). In contrast to desensitization mechanisms that control receptor and G protein in response to stimulus, the UPS can also provide feedforward regulation of pathway activity, as is the case for regulation of PKA regulatory subunits. Specifically, regulatory subunits associate with Praja2, a RING E3-ubiquitin ligase that also functions as an AKAP. When PKA becomes activated, the catalytic subunit dissociates from the regulatory subunits and phosphorylates Praja2, stimulating the ubiquitination and degradation of the regulatory subunits, thereby potentiating PKA activity (Lignitto et al., 2011). Interestingly, PKA is also capable of regulating the stability of other proteins through the UPS (VerPlank et al., 2019). For instance, cAMP signaling has been shown to downregulate levels of p300 and sirtuin 6 (SIRT 6) through their ubiquitin-dependent proteasomal degradation (Jeong et al., 2013; Kim and Juhn, 2015).

To date, PDE4 and CBP/p300 represent the only G α s-PKA pathway components with small-molecule degraders designed against them (Ohoka et al., 2017; Vannam et al., 2021). As PROTACs and targeted degrader technology advances, components of the G α s-PKA pathway certainly represent promising targets. With the first PROTACs now demonstrating positive clinical responses and favorable safety profiles (Mullard, 2020), there is also tremendous potential to translate these compounds into clinical drugs for use in the G α s-PKA pathway signalopathies.

D. Targeting Protein Kinase A Indirectly

Given the significant hurdles in targeting PKA directly, another therapeutic strategy is to modulate cAMP levels. The tool compound forskolin, an activator of adenylyl cyclase (Seamon et al., 1981), is commonly used, and adenylyl cyclase inhibitors are less common (Bitterman et al., 2013). PDE-targeting drugs have been much more tractable clinically. Inhibitors targeting cAMP-hydrolyzing PDEs are approved for the treatment of cardiovascular, airway, and inflammatory diseases (PDE3 and PDE4 inhibitors), but to our knowledge have not been used to treat any G α s-PKA pathway signalopathies.

Unfortunately, these drugs are largely limited by side effects (Boswell-Smith et al., 2006). Currently, there are several compounds in development aimed to minimize side effects by targeting specific PDE4 isoforms as well as PDE7 and PDE8 (Martinez and Gil, 2014). For the G α s-PKA pathway signalopathies, the application of cAMP-specific PDE inhibitors is particularly promising for the treatment of SHH-MB (Rao et al., 2016). Although many of the G α s-PKA pathway signalopathies exploit activation of the G α s-PKA pathway, PDE activators may also have therapeutic benefit. Recently, a novel positive allosteric modulator of PDE4 showed promise in models of autosomal dominant polycystic kidney disease, a disease driven by chronically elevated cAMP (Omar et al., 2019). Other mechanisms of targeting PKA indirectly include activation of phosphatases. Results in vivo have suggested that inhibition of PKA via activation of the phosphatase PP2A may be a valuable therapeutic approach in small cell lung cancer (Coles et al., 2020). However, given the relative nonselectivity of phosphatases like PP2A, further work is necessary to establish the translational potential of this type of therapeutic approach.

E. Synthetic Lethality Approaches

Finally, given the complexity of the G α s-PKA pathway, particularly in polygenetic diseases like cancer, finding specific, context-dependent vulnerabilities could be extremely valuable. Synthetic lethality stems from the idea that, in cancer, if you target one gene program either genetically or with a drug, you may shift the reliance of that cancer to another program. By specifically leveraging the vulnerabilities of the cancer cell over normal cells, targeting a secondary program will ultimately prove lethal to the cancer while sparing the normal tissue (Kaelin, 2005). The most notable example of this is the use of poly(ADP-ribose) polymerase inhibitors in breast cancer type 1/2 susceptibility protein (*BRCA1/2*) mutant cancer that are DNA damage-deficient (Ashworth and Lord, 2018). Synthetic lethality are largely identified by large chemical or genetic screens (Kaelin, 2005). To this end, recent work by our group has demonstrated that this approach is feasible to identify synthetic lethal vulnerabilities in a G α q-driven cancer, uveal melanoma, and is now the subject of ongoing clinical trials (Feng et al., 2019; Paradis et al., 2021) (ClinicalTrials.gov, NCT04720417). Furthermore, recent work has also shown that cancer cell growth driven by the DNAJ-PRKACA fusion protein in liver cells can be selectively targeted by HSP70 inhibitors because of a scaffolding interaction unique to the fusion protein (Turnham et al., 2019). As we discussed throughout this review, alteration of the G α s-PKA pathway is accompanied by unique phenotypes. Ultimately, these unique cell states could be leveraged to

exploit single and multimodal synthetic lethal therapies for the treatment of the $G\alpha s$ -PKA pathway signalopathies.

VI. Conclusion

For the first time, we have defined the $G\alpha s$ -PKA pathway signalopathies as a family of germline, post-zygotic, and somatic diseases driven by dysregulation of the $G\alpha s$ -PKA pathway. The $G\alpha s$ -PKA pathway signalopathies cover a diverse range of pathophysiology, and this diversity mirrors the physiologic roles of $G\alpha s$ -PKA pathway signaling, contributing to fundamental processes from gene transcription and intracellular trafficking to cellular differentiation and organismal development. On a cellular level, owing to isoform specificity and scaffolding interactions, PKA is localized to distinct microdomains. This feature enables PKA to integrate signals from multiple inputs and participate at multiple levels within the same physiologic process. Similarly, PKA is also uniquely poised to mediate the same molecular action across multiple areas of physiology (i.e., regulation of ion channels). Consequently, the $G\alpha s$ -PKA pathway signalopathies can be characterized by diseases that exploit either pathway activation or inactivation. We find that the major themes of activation include aberrant upstream inputs (GPCR and $G\alpha s$ activation) as well as disruption of PKA holoenzyme stability (loss of RI α or loss of R:C contacts), with recent evidence also suggesting the role of an altered PKA substrate profile. Conversely, there are many ways to inactivate the pathway, affecting almost every signaling node without consistent hotspot mutations.

From a clinical perspective, these mutational themes are primarily represented in monogenetic, endocrine, bone, and metabolic disorders, largely altering hormone function and developmental events. With this review, we now highlight how the same mutational themes, depending on the tissue and cell context, enable the $G\alpha s$ -PKA pathway to act as both an oncogenic driver and a tumor suppressor in cancer. Dysregulated signaling through the $G\alpha s$ -PKA pathway is accompanied by unique phenotypes in cancer, including enhanced mucin production, which makes *GNAS*, in particular, a promising biomarker. However, as genomics has informed us about the ability of *GNAS* to cooperate with *KRAS* in cancer initiation, it has also failed to appreciate the complex connections within the tumor microenvironment. These complex interactions ultimately contribute to the ability of the $G\alpha s$ -PKA pathway to drive therapeutic resistance.

Naturally, PKA has been the target of significant drug development efforts, but unfortunately, kinase cross-reactivity and complex biology have proven to be substantial hurdles. Conceptually, the tetrameric holoenzyme structure provides a unique landscape for

bisppecific compounds to flourish. An idea that could even extend to targeting of specific microdomains using AKAP motifs. Promising new approaches are aimed at targeting the pathway with degraders as well as leveraging context specificity to target synthetic lethal interactions. With these new perspectives on the capabilities of the $G\alpha s$ -PKA pathway and its promise as a therapeutic target, there is a tremendous opportunity to explore new connections among the $G\alpha s$ -PKA pathway signalopathies, linking seemingly disparate fields through a common signaling mechanism. More importantly, by synthesizing the field, we hope to provide a blueprint for therapeutic advances in treating the human $G\alpha s$ -PKA pathway signalopathies.

Acknowledgments

The authors would like to acknowledge Dr. Alexandr Kornev at the University of California, San Diego, for his help preparing PKA structure graphics. The authors would also like to thank Dr. Daniela Bertinetti at the University of Kassel and Dr. Bjørn Steen Skålhegg at the University of Oslo for their helpful discussions related to cAMP analogs and mouse models of PKA, respectively. Finally, the authors would like to acknowledge the use of BioRender.com in creating many of our graphics.

Authorship Contributions

Performed data analysis: D.J.R., F.R., N.A.

Wrote or contributed to the writing of the manuscript: D.J.R., F.W.H., S.S.T., J.S.G.

References

- Acin-Perez R, Salazar E, Kamenetsky M, Buck J, Levin LR, and Manfredi G (2009) Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. *Cell Metab* 9:265–276.
- Adams JA, McGlone ML, Gibson R and Taylor SS (1995) Phosphorylation modulates catalytic function and regulation in the cAMP-dependent protein kinase. *Biochemistry* 34:2447–2454.
- Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, et al. (2014) Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. *Genome Med* 6:43.
- Alberini CM, Ghirardi M, Metz R and Kandel ER (1994) C/EBP is an immediate-early gene required for the consolidation of long-term facilitation in *Aplysia*. *Cell* 76:1099–1114.
- Ali M, Nelson AR, Lopez AL, and Sack DA (2015) Updated global burden of cholera in endemic countries. *PLoS Negl Trop Dis* 9:e0003832–e0003832.
- Almeida MQ, Azevedo MF, Xekouki P, Bimpaki EI, Horvath A, Collins MT, Karaviti LP, Jeha GS, Bhattacharyya N, Cheadle C, et al. (2012) Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic *GNAS* mutations. *J Clin Endocrinol Metab* 97:E687–E693.
- Almeida MQ, Muchow M, Boikos S, Bauer AJ, Griffin KJ, Tsang KM, Cheadle C, Watkins T, Wen F, Starost MF, et al. (2010) Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53 \pm or Rb1 \pm backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. *Hum Mol Genet* 19:1387–1398.
- Altarejos JY and Montminy M (2011) CREB and the CREC co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* 12:141–151.
- Amarante MK, Vitiello GAF, Rosa MH, Mancilla IA, and Watanabe MAE (2018) Potential use of CXCL12/CXCR4 and sonic hedgehog pathways as therapeutic targets in medulloblastoma. *Acta Oncol* 57:1134–1142.
- Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, et al. (2014) Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. *J Pathol* 233:217–227.
- Amieue PS and McKnight GS (2002) The essential role of RI alpha in the maintenance of regulated PKA activity. *Ann N Y Acad Sci* 968:75–95.
- Ang CS-P, Shen JP, Hardy-Abeloos CJ, Huang JK, Ross JS, Miller VA, Jacobs MT, Chen IL, Xu D, Ali SM, et al. (2018) Genomic landscape of appendiceal neoplasms. *JCO Precis Oncol* 2:1–18.
- Angers S and Moon RT (2009) Proximal events in Wnt signal transduction. *Nat Rev Mol Cell Biol* 10:468–477.
- Arang N and Gutkind JS (2020) G protein-coupled receptors and heterotrimeric G proteins as cancer drivers. *FEBS Lett* 594:4201–4232.

- Arveseth CD, Happ JT, Hedeon DS, Zhu JF, Capener JL, Klatt Shaw D, Deshpande I, Liang J, Xu J, Stubben SL, et al. (2021) Smoothed transduces Hedgehog signals via activity-dependent sequestration of PKA catalytic subunits. *PLoS Biol* **19**:e3001191.
- Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, Weiser MR, and Overman MJ (2016) The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. *Cancer* **122**:213–221.
- Ashworth A and Lord CJ (2018) Synthetic lethal therapies for cancer: what's next after PARP inhibitors? *Nat Rev Clin Oncol* **15**:564–576.
- Bachmann VA, Mayrhofer JE, Ilouz R, Tschakner P, Raffener P, Röck R, Courcelles M, Apelt F, Lu T-W, Baillie GS, et al. (2016) Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling. *Proc Natl Acad Sci USA* **113**:7786–7791.
- Bacsikai BJ, Hochner B, Mahaut-Smith M, Adams SR, Kaang BK, Kandel ER and Tsien RY (1993) Spatially resolved dynamics of cAMP and protein kinase A subunits in Aplysia sensory neurons. *Science* **260**:222–226.
- Bangs F and Anderson KV (2017) Primary cilia and mammalian hedgehog signaling. *Cold Spring Harb Perspect Biol* **9**:a028175.
- Barzi M, Berenguer J, Menendez A, Alvarez-Rodriguez R, and Pons S (2010) Sonic-hedgehog-mediated proliferation requires the localization of PKA to the cilium base. *J Cell Sci* **123**:62–69.
- Bates B, Zhang L, Nawoschik S, Kodangattil S, Tseng E, Kopsco D, Kramer A, Shan Q, Taylor N, Johnson J, et al. (2006) Characterization of Gpr101 expression and G-protein coupling selectivity. *Brain Res* **1087**:1–14.
- Bathion K, Weigand I, Vanselow JT, Ronchi CL, Sbierra S, Schlosser A, Fassnacht M and Calebro D (2019) Alterations in protein kinase A substrate specificity as a potential cause of cushing syndrome. *Endocrinology* **160**:447–459.
- Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. *Pharmacol Rev* **58**:488–520.
- Bendzun NG, Dörfler S, Autenrieth K, Bertinetti D, Machal EMF, Kennedy EJ, and Herberg FW (2018) Investigating PKA-RII specificity using analogs of the PKA:AKAP peptide inhibitor STAD-2. *Bioorg Med Chem* **26**:1174–1178.
- Bentin Toaldo C, Alexi X, Beelen K, Kok M, Hauptmann M, Jansen M, Berns E, Neefjes J, Linn S, Michalides R, et al. (2015) Protein kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. *BMC Cancer* **15**:588.
- Berman HM, Ten Eyck LF, Goodsell DS, Haste NM, Kornev A, and Taylor SS (2005) The cAMP binding domain: an ancient signaling module. *Proc Natl Acad Sci USA* **102**:45–50.
- Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, René-Corail F, Stergiopoulos S, Bourdeau I, et al. (2009) Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. *J Clin Endocrinol Metab* **94**:2085–2091.
- Bertinetti D, Schweinsberg S, Hanke SE, Schwede F, Bertinetti O, Drewianka S, Genieser HG, and Herberg FW (2009) Chemical tools selectively target components of the PKA system. *BMC Chem Biol* **9**:3.
- Beuschlein F, Fassnacht M, Assié G, Calebro D, Stratakis CA, Osswald A, Ronchi CL, Wieland T, Sbierra S, Faucz FR, et al. (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. *N Engl J Med* **370**:1019–1028.
- Bharati K and Ganguly NK (2011) Cholera toxin: a paradigm of a multifunctional protein. *Indian J Med Res* **133**:179–187.
- Bi WL, Greenwald NF, Ramkissoon SH, Abdalthagafi M, Coy SM, Ligon KL, Mei Y, MacConaill L, Ducar M, Min L, Santagata S, Kaiser UB, Beroukhi M, Laws ER, Jr. and Dunn IF (2017) Clinical identification of oncogenic drivers and copy-number alterations in pituitary tumors. *Endocrinology* **158**:2284–2291.
- Bian X, Yang S, Chen J, Ping Y, Zhou X, Wang Q, Jiang X, Gong W, Xiao H, Du L, Chen Z, Zhao W, Shi J and Wang JM (2007) Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. *Neurosurgery* **61**:570–579.
- Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, and Robey PG (1998) Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. *J Clin Invest* **101**:1737–1744.
- Biel M (2009) Cyclic nucleotide-regulated cation channels. *J Biol Chem* **284**:9017–9021.
- Bitterman JL, Ramos-Espiritu L, Diaz A, Levin LR, and Buck J (2013) Pharmacological distinction between soluble and transmembrane adenylyl cyclases. *J Pharmacol Exp Ther* **347**:589–598.
- Blair CM and Baillie GS (2019) Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes. *Biochem Soc Trans* **47**:1405–1414.
- Bock A, Annibale P, Konrad C, Hannawacker A, Anton SE, Maiellaro I, Zabel U, Sivaramkrishnan S, Falcke M, and Lohse MJ (2020) Optical mapping of cAMP signaling at the nanometer scale. *Cell* **182**:1519–1530.e1517.
- Boikos SA and Stratakis CA (2007) Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. *Hum Mol Genet* **16**:R80–R87.
- Boora GK, Kanwar R, Kulkarni AA, Pleticha J, Ames M, Schroth G, Beutler AS, and Banck MS (2015) Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. *Cancer Genet* **208**:374–381.
- Boswell-Smith V, Spina D, and Page CP (2006) Phosphodiesterase inhibitors. *Br J Pharmacol* **147** (Suppl 1):S252–S257.
- Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrero M, Sammiceli S, Rogers NC, Sahai E, Zelenay S, and Reis e Sousa C (2018) NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. *Cell* **172**:1022–1037.e1014.
- Bradley J, Reisert J, and Frings S (2005) Regulation of cyclic nucleotide-gated channels. *Curr Opin Neurobiol* **15**:343–349.
- Bramson HN, Kaiser ET, and Mildvan AS (1984) Mechanistic studies of cAMP-dependent protein kinase action. *CRC Crit Rev Biochem* **15**:93–124.
- Brasasemle DL, Subramanian V, Garcia A, Marcinkiewicz A, and Rothenberg A (2009) Perilipin A and the control of triacylglycerol metabolism. *Mol Cell Biochem* **326**:15–21.
- Brockmann M, Blomen VA, Nieuwenhuis J, Stickel E, Raaben B, Bleijerveld OB, Altelaar AFM, Jae LT, and Brummelkamp TR (2017) Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. *Nature* **546**:307–311.
- Brogna S and Wen J (2009) Nonsense-mediated mRNA decay (NMD) mechanisms. *Nat Struct Mol Biol* **16**:107–113.
- Brown JR and DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. *J Clin Oncol* **23**:2840–2855.
- Brown RL, Strassmaier T, Brady JD, and Karpen JW (2006) The pharmacology of cyclic nucleotide-gated channels: emerging from the darkness. *Curr Pharm Des* **12**:3597–3613.
- Brown SH, Cheng CY, Saldanha SA, Wu J, Cottam HB, Sankaran B, and Taylor SS (2013) Implementing fluorescence anisotropy screening and crystallographic analysis to define PKA isoform-selective activation by cAMP analogs. *ACS Chem Biol* **8**:2164–2172.
- Brunelli M, Castellucci V, and Kandel ER (1976) Synaptic facilitation and behavioral sensitization in Aplysia: possible role of serotonin and cyclic AMP. *Science* **194**:1178–1181.
- Bruystens JG, Wu J, Fortezzo A, Del Rio J, Nielsen C, Blumenthal DK, Rock R, Stefan E, and Taylor SS (2016) Structure of a PKA RI α recurrent acrolystosis mutant explains defective cAMP-dependent activation. *J Mol Biol* **428** (24 Pt B):4890–4904.
- Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, and Pentland AP (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. *Carcinogenesis* **19**:723–729.
- Bucko PJ and Scott JD (2020) Drugs that regulate local cell signaling: AKAP targeting as a therapeutic option. *Annu Rev Pharmacol Toxicol* **61**:361–379.
- Bucko PJ, Lombard CK, Rathbun L, Garcia I, Bhat A, Wordeman L, Smith FD, Maly DJ, Hehny H, and Scott JD (2019) Subcellular drug targeting illuminates local kinase action. *eLife* **8**:e52220.
- Calatozolo C, Maderna E, Pollo B, Gelati M, Marras C, Silvani A, Croci D, Boiardi A, and Salmaggi A (2006) Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. *Cancer Biol Ther* **5**:827–832.
- Calebro D, Hannawacker A, Lyga S, Bathion K, Zabel U, Ronchi C, Beuschlein F, Reincke M, Lorenz K, Allolio B, et al. (2014) PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit. *Nat Commun* **5**:5680.
- Calejo AI and Taskén K (2015) Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins. *Front Pharmacol* **6**:192.
- Campbell AP and Smrcka AV (2018) Targeting G protein-coupled receptor signalling by blocking G proteins. *Nat Rev Drug Discov* **17**:789–803.
- Cannaerts E, van de Beek G, Verstraeten A, Van Laer L, and Loeyls B (2015) TGF- β signalopathies as a paradigm for translational medicine. *Eur J Med Genet* **58**:695–703.
- Cao B, Lu TW, Martinez Fiesco JA, Tomasini M, Fan L, Simon SM, Taylor SS, and Zhang P (2019) Structures of the PKA RI α holoenzyme with the FLHCC driver J-PKAcx or wild-type PKAcx. *Structure* **27**:816–828.e814.
- Carballo GB, Honorato JR, de Lopes GFP, and Spohr TCLSE (2018) A highlight on Sonic hedgehog pathway. *Cell Commun Signal* **16**:11.
- Carney JA (1985) Differences between nonfamilial and familial cardiac myxoma. *Am J Surg Pathol* **9**:53–55.
- Carr DW, Stofko-Hahn RE, Fraser ID, Cone RD, and Scott JD (1992) Localization of the cAMP-dependent protein kinase to the postsynaptic densities by A-kinase anchoring proteins. Characterization of AKAP 79. *J Biol Chem* **267**:16816–16823.
- Castellone MD, Teramoto H, Williams BO, Druey KM, and Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. *Science* **310**:1504–1510.
- Castellucci VF, Kandel ER, Schwartz JH, Wilson FD, Nairn AC, and Greengard P (1980) Intracellular injection of the catalytic subunit of cyclic AMP-dependent protein kinase simulates facilitation of transmitter release underlying behavioral sensitization in Aplysia. *Proc Natl Acad Sci USA* **77**:7492–7496.
- Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, and Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. *JAMA* **294**:914–923.
- Chang C-R and Blackstone C (2007) Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. *J Biol Chem* **282**:21583–21587.
- Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, and Kass RS (2007) Mutation of an A-kinase-anchoring protein causes long-QT syndrome. *Proc Natl Acad Sci USA* **104**:20990–20995.
- Chen Y-Z, Friedman JR, Chen D-H, Chan GC-K, Bloss CS, Hisama FM, Topol SE, Carson AR, Pham PH, Bonkowski ES, et al. (2014) Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia. *Ann Neurol* **75**:542–549.
- Cheng HC, van Patten SM, Smith AJ, and Walsh DA (1985) An active twenty-amino-acid-residue peptide derived from the inhibitor protein of the cyclic AMP-dependent protein kinase. *Biochem J* **231**:655–661.
- Chepurny OG, Bertinetti D, Diskar M, Leech CA, Afshari P, Tsalkova T, Cheng X, Schwede F, Genieser HG, Herberg FW, et al. (2013) Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag. *Mol Endocrinol* **27**:1267–1282.
- Cheung J, Ginter C, Cassidy M, Franklin MC, Rudolph MJ, Robine N, Darnell RB, and Hendrickson WA (2015) Structural insights into mis-regulation of protein kinase A in human tumors. *Proc Natl Acad Sci USA* **112**:1374–1379.

- Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, and Hidaka H (1990) Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isouinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. *J Biol Chem* **265**:5267–5272.
- Chin S, Hung M, and Bear CE (2017) Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants. *Cell Mol Life Sci* **74**:57–66.
- Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK, Martinez A, Maenhaut C, Bos JL, Genieser HG, et al. (2003) cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. *J Biol Chem* **278**:35394–35402.
- Chubak J, Kamineni A, Buist DSM, Anderson ML, and Whitlock EP (2015) U.S. Preventive services task force evidence syntheses, formerly systematic evidence reviews, in aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the US Preventive Services Task Force, Agency for Healthcare Research and Quality (US), Rockville (MD).
- Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, and Casanueva FF (2014) Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. *Pituitary* **17**:180–186.
- Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drains AP, et al. (2020) Unbiased proteomic profiling uncovers a targetable GNAS/PP2A axis in small cell lung cancer stem cells. *Cancer Cell* **38**:129–143.e7.
- Cook S and McCormick F (1993) Inhibition by cAMP of Ras-dependent activation of Raf. *Science* **262**:1069–1072.
- Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesu M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrillo F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, and Llovet JM (2015) Unique genomic profile of fibrolamellar hepatocellular carcinoma. *Gastroenterology* **148**:806–818.e810.
- Correa R, Salpea P, and Stratakis CA (2015) Carney complex: an update. *Eur J Endocrinol* **173**:M85–M97.
- Dagda RK and Das Banerjee T (2015) Role of protein kinase A in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseases. *Rev Neurosci* **26**:359–370.
- Dash PK, Hochner B and Kandel ER (1990) Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. *Nature* **345**:718–721.
- De Leo S, Lee SY and Braverman LE (2016) Hyperthyroidism. *Lancet* **388**:906–918.
- De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, and Lacroix A (2014) Primary bilateral macronodular adrenal hyperplasia. *Curr Opin Endocrinol Diabetes Obes* **21**:177–184.
- Deeble PD, Cox ME, Frierson Jr HF, Sikes RA, Palmer JB, Davidson RJ, Casarez EV, Amorino GP, and Parsons SJ (2007) Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. *Cancer Res* **67**:3663–3672.
- Dema A, Schröter MF, Perets E, Skrobilin P, Moutty MC, Deak VA, Birchmeier W, and Klussmann E (2016) The A-kinase anchoring protein (AKAP) glycogen synthase kinase 3 β interaction protein (GSKIP) regulates β -catenin through its interactions with both protein kinase A (PKA) and GSK3 β . *J Biol Chem* **291**:19618–19630.
- DeNinno MP (2012) Future directions in phosphodiesterase drug discovery. *Bioorg Med Chem Lett* **22**:6794–6800.
- Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, and Kolch W (2002) Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. *Mol Cell Biol* **22**:3237–3246.
- Di Benedetto G, Gerbino A, and Lefkimiatis K (2018) Shaping mitochondrial dynamics: the role of cAMP signalling. *Biochem Biophys Res Commun* **500**:65–74.
- Di Vito A, Mignogna C, and Donato G (2015) The mysterious pathways of cardiac myxomas: a review of histogenesis, pathogenesis and pathology. *Histopathology* **66**:321–332.
- Dilly AK, Honick BD, Lee YJ, Guo ZS, Zeh HJ, Bartlett DL, and Choudry HA (2017) Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei. *Oncotarget* **8**:106888–106900.
- Drew DA, Cao Y, and Chan AT (2016) Aspirin and colorectal cancer: the promise of precision chemoprevention. *Nat Rev Cancer* **16**:173–186.
- Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, and Marais R (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. *Cancer Res* **66**:9483–9491.
- Durick K, Wu RY, Gill GN, and Taylor SS (1996) Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. *J Biol Chem* **271**:12691–12694.
- Durick K, Yao VJ, Borrello MG, Bongarzone I, Pierotti MA, and Taylor SS (1995) Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2. *J Biol Chem* **270**:24642–24645.
- Dyson MT, Kowalewski MP, Manna PR, and Stocco DM (2009) The differential regulation of steroidogenic acute regulatory protein-mediated steroidogenesis by type I and type II PKA in MA-10 cells. *Mol Cell Endocrinol* **300**:94–103.
- Eichholtz T, de Bont DB, de Widt J, Liskamp RM, and Ploegh HL (1993) A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. *J Biol Chem* **268**:1982–1986.
- Engl RA, Girod A, Kinzel V, Huber R, and Bossemeyer D (1996) Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isouinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. *J Biol Chem* **271**:26157–26164.
- Enkvist E, Lavogina D, Raidaru G, Vaasa A, Viil I, Lust M, Viht K, and Uri A (2006) Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. *J Med Chem* **49**:7150–7159.
- Enkvist E, Raidaru G, Vaasa A, Pehk T, Lavogina D, and Uri A (2007) Carbocyclic 3'-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. *Bioorg Med Chem Lett* **17**:5336–5339.
- Ercu M, Markó L, Schächterle C, Tsvetkov D, Cui Y, Maghsodi S, Bartolomeaus TUP, Maass PG, Zühlke K, Gregersen N, et al. (2020) Phosphodiesterase 3A and arterial hypertension. *Circulation* **142**:133–149.
- Erion DM, Ignatova ID, Yonemitsu S, Nagai Y, Chatterjee P, Weismann D, Hsiao JJ, Zhang D, Iwasaki T, Stark R, et al. (2009) Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. *Cell Metab* **10**:499–506.
- Espiard S, Knappe MJ, Bathon K, Assié G, Rizk-Rabin M, Faillet S, Luscap-Rondof W, Abid D, Guignat L, Calebiro D, et al. (2018) Activating PRKACB somatic mutation in cortisol-producing adenomas. *JCI Insight* **3**:e98296.
- Fang X, Yu SX, Lu Y, Bast Jr RC, Woodgett JR, and Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proc Natl Acad Sci USA* **97**:11960–11965.
- Farquhar MJ, Harris HJ, Diskar M, Jones S, Mee CJ, Nielsen SU, Brimacombe CL, Molina S, Toms GL, Maurel P, et al. (2008) Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. *J Virol* **82**:8797–8811.
- Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. *Cell* **61**:759–767.
- Feller L, Wood NH, Khammissa RAG, Lemmer J, and Raubenheimer EJ (2009) The nature of fibrous dysplasia. *Head Face Med* **5**:22.
- Feng X, Arang N, Rigracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, et al. (2019) A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the hippo pathway through FAK. *Cancer Cell* **35**:457–472.e5.
- Forlino A, Vetro A, Garavelli L, Ciccone R, London E, Stratakis CA, and Zuffardi O (2014) PRKACB and Carney complex. *N Engl J Med* **370**:1065–1067.
- Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC, Lucon AM, and Mendonca BB (2003) Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. *J Clin Endocrinol Metab* **88**:2147–2151.
- Freda PU (2002) Somatostatin analogs in acromegaly. *J Clin Endocrinol Metab* **87**:3013–3018.
- Freda PU, Chung WK, Matsuoka N, Walsh JE, Kanibir MN, Kleinman G, Wang Y, Bruce JN, and Post KD (2007) Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission. *Pituitary* **10**:275–282.
- Gadella MR, Kasuki L, and Korbonits M (2017) The genetic background of acromegaly. *Pituitary* **20**:10–21.
- Gao H, Sun X, and Rao Y (2020) PROTAC technology: opportunities and challenges. *ACS Med Chem Lett* **11**:237–240.
- Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hyland LM, Celano P, Booker SV, Robinson CR, and Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N Engl J Med* **328**:1313–1316.
- Gjertsen BT, Mellgren G, Otten A, Maronde E, Genieser HG, Jastorff B, Vintermyr OK, McKnight GS, and Døskeland SO (1995) Novel (Rp)-cAMPs analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action. *J Biol Chem* **270**:20599–20607.
- Gloerich M and Bos JL (2010) Epac: defining a new mechanism for cAMP action. *Annu Rev Pharmacol Toxicol* **50**:355–375.
- Goel S, Desai K, Macapinlac M, Wadler S, Goldberg G, Fields A, Einstein M, Volterra F, Wong B, Martin R, et al. (2006) A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. *Invest New Drugs* **24**:125–134.
- Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT, and Zon LI (2009) Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. *Cell* **136**:1136–1147.
- Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW, Korah R, Suttrop AC, Dietrich D, et al. (2014) Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors [published correction appears in *Nat Genet* (2014) **46**:759]. *Nat Genet* **46**:613–617.
- Gold MG, Fowler DM, Means CK, Pawson CT, Stephany JJ, Langeberg LK, Fields S, and Scott JD (2013) Engineering A-kinase anchoring protein (AKAP)-selective regulatory subunits of protein kinase A (PKA) through structure-based phage selection. *J Biol Chem* **288**:17111–17121.
- Goodman BE and Percy WH (2005) CFTR in cystic fibrosis and cholera: from membrane transport to clinical practice. *Adv Physiol Educ* **29**:75–82.
- Graham RP, Lackner C, Terracciano L, González-Cantú Y, Maleszewski JJ, Greipp PT, Simon SM, and Torbenson MS (2018) Fibrolamellar carcinoma in the Carney complex: PRKARIA loss instead of the classic DNAJB1-PRKACA fusion. *Hepatology* **68**:1441–1447.
- Greene EL, Horvath AD, Nesterova M, Giatzakis C, Bossis I, and Stratakis CA (2008) In vitro functional studies of naturally occurring pathogenic PRKARIA mutations that are not subject to nonsense mRNA decay. *Hum Mutat* **29**:633–639.
- Greenwald EC and Saucerman JJ (2011) Bigger, better, faster: principles and models of AKAP anchoring protein signaling. *J Cardiovasc Pharmacol* **58**:462–469.

- Greggio E, Bubacco L, and Russo I (2017) Cross-talk between LRRK2 and PKA: implication for Parkinson's disease? *Biochem Soc Trans* **45**:261–267.
- Gu L, Lau SK, Loera S, Somlo G, and Kane SE (2009) Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. *Clin Cancer Res* **15**:7196–7206.
- Hage M, Viengchareun S, Brunet E, Villa C, Pineau D, Bouligand J, Teglas JP, Adam C, Parker F, Lombès M, et al. (2018) Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas. *J Clin Endocrinol Metab* **103**:1929–1939.
- Halls ML and Cooper DMF (2017) Adenylyl cyclase signalling complexes - Pharmacological challenges and opportunities. *Pharmacol Ther* **172**:171–180.
- Ham J, Ivan M, Wynford-Thomas D, and Scanlon MF (1997) GH3 cells expressing constitutively active Gs alpha (Q227L) show enhanced hormone secretion and proliferation. *Mol Cell Endocrinol* **127**:41–47.
- Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, et al. (2017) Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. *J Clin Oncol* **35**:1836–1844.
- Hammarsjö A, Pettersson M, Chitayat D, Handa A, Anderlid B-M, Bartocci M, Basel D, Batkovskytė D, Belezá-Meireles A, Conner P, et al. (2021) High diagnostic yield in skeletal ciliopathies using massively parallel genome sequencing, structural variant screening and RNA analyses. *J Hum Genet* [published ahead of print].
- Hamuro Y, Anand GS, Kim JS, Juliano C, Stranz DD, Taylor SS, and Woods Jr VL (2004) Mapping intersubunit interactions of the regulatory subunit (RI α) in the type I holoenzyme of protein kinase A by amide hydrogen/deuterium exchange mass spectrometry (DXMS). *J Mol Biol* **340**:1185–1196.
- Han H-S, Kang G, Kim JS, Choi BH, and Koo S-H (2016) Regulation of glucose metabolism from a liver-centric perspective. *Exp Mol Med* **48**:e218.
- Hanke SE, Bertinetti D, Badel A, Schweinsberg S, Genieser HG, and Herberg FW (2011) Cyclic nucleotides as affinity tools: phosphorothioate cAMP analogues address specific PKA subproteomes. *N Biotechnol* **28**:294–301.
- Hanks SK and Hunter T (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. *FASEB J* **9**:576–596.
- Hannah-Shmouni F, Trivellin G, and Stratakis CA (2016) Genetics of gigantism and acromegaly. *Growth Horm IGF Res* **30**:31–37–41.
- Hanoun J and Defer N (2001) Regulation and role of adenylyl cyclase isoforms. *Annu Rev Pharmacol Toxicol* **41**:145–174.
- Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, and Whelan J (2002) Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. *Cancer Res* **62**:403–408.
- Hata AN and Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: molecular roles in inflammation and immune modulation. *Pharmacol Ther* **103**:147–166.
- He J, Sun M, Li E, Hou Y, Shepard MJ, Chen D, Pacak K, Wang C, Guo L, Zhuang Z, and Liu Y (2017) Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma. *Oncotarget* **8**:103968–103974.
- He X, Zhang L, Chen Y, Remke M, Shih D, Lu F, Wang H, Deng Y, Yu Y, Xia Y, et al. (2014) The G protein α subunit G α s is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. *Nat Med* **20**:1035–1042.
- Hébrant A, van Staveren WC, Maenhaut C, Dumont JE, and Leclère J (2011) Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. *Eur J Endocrinol* **164**:1–9.
- Herberg FW and Taylor SS (1993) Physiological inhibitors of the catalytic subunit of cAMP-dependent protein kinase: effect of MgATP on protein-protein interactions. *Biochemistry* **32**:14015–14022.
- Herberg FW, Doyle ML, Cox S, and Taylor SS (1999) Dissection of the nucleotide and metal-phosphate binding sites in cAMP-dependent protein kinase. *Biochemistry* **38**:6352–6360.
- Herberg FW, Maleszka A, Eide T, Vossebein L, and Tasken K (2000) Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding. *J Mol Biol* **298**:329–339.
- Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, and Takahashi T (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. *Cancer Res* **58**:3761–3764.
- Hidaka H, Inagaki M, Kawamoto S, and Sasaki Y (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. *Biochemistry* **23**:5036–5041.
- Hino S, Tanji C, Nakayama KI, and Kikuchi A (2005) Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. *Mol Cell Biol* **25**:9063–9072.
- Hiroi N, Yakushiji F, Shimojo M, Watanabe S, Sugano S, Yamaguchi N, and Miyachi Y (1998) Human ACTH hypersensitivity syndrome associated with abnormalities of the ACTH receptor gene. *Clin Endocrinol (Oxf)* **48**:129–134.
- Hollingsworth MA and Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. *Nat Rev Cancer* **4**:45–60.
- Holz GG, Chepurny OG, and Schwede F (2008) Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors. *Cell Signal* **20**:10–20.
- Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim, II, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, Germer S, Emde AK, Vacic V, Bhanot U, LaQuaglia MP, and Simon SM (2014) Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. *Science* **343**:1010–1014.
- Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libé R, Remmers E, René-Corail F, Faucz FR, et al. (2010) Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. *Hum Mutat* **31**:369–379.
- Horvath A, Bossis I, Giatzakis C, Levine E, Weinberg F, Meoli E, Robinson-White A, Siegel J, Soni P, Groussin L, et al. (2008) Large deletions of the PRKAR1A gene in Carney complex. *Clin Cancer Res* **14**:388–395.
- Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. *Biochem J* **370**:1–18.
- Howe AK (2004) Regulation of actin-based cell migration by cAMP/PKA. *Biochim Biophys Acta* **1692**:159–174.
- Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A, and Stratakis CA (2009) Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. *J Clin Endocrinol Metab* **94**:2930–2937.
- Hu Q and Shokat KM (2018) Disease-causing mutations in the G Protein Galphas subvert the roles of GDP and GTP. *Cell* **173**:1254–1264 e1211.
- Huang LJ, Wang L, Ma Y, Durick K, Perkins G, Deerinck TJ, Ellisman MH, and Taylor SS (1999) NH2-Terminal targeting motifs direct dual specificity A-kinase-anchoring protein 1 (D-AKAP1) to either mitochondria or endoplasmic reticulum. *J Cell Biol* **145**:951–959.
- Huang Y, Roelink H, and McKnight GS (2002) Protein kinase A deficiency causes axially localized neural tube defects in mice. *J Biol Chem* **277**:19889–19896.
- Huh JY, Kwon MJ, Seo KY, Kim MK, Chae KY, Kim SH, Ki CS, Yoon MS, and Kim DH (2014) Novel nonsense GNAS mutation in a 14-month-old boy with plate-like osteoma cutis and medulloblastoma. *J Dermatol* **41**:319–321.
- Iacovazzo D and Korbonits M (2016) Gigantism: X-linked acrogantism and GPR101 mutations. *Growth Horm IGF Res* **30**:31–64–69.
- Ideno N, Ohtsuka T, Kono H, Fujiwara K, Oda Y, Aishima S, Ito T, Ishigami K, Tokunaga S, Ohuchida K, et al. (2013) Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. *Ann Surg* **258**:141–151.
- Ideno N, Yamaguchi H, Ghosh B, Gupta S, Okumura T, Steffen DJ, Fisher CG, Wood LD, Singhi AD, Nakamura M, Gutkind JS, and Maitra A (2018) GNAS(R201C) induces pancreatic cystic neoplasms in mice that express activated KRAS by inhibiting YAP1 signaling. *Gastroenterology* **155**:1593–1607 e1512.
- Iglesias-Bartolome R, Torres D, Marone R, Feng X, Martin D, Simaan M, Chen M, Weinstein LS, Taylor SS, Molinolo AA, et al. (2015) Inactivation of a G α (s)-PKA tumour suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. *Nat Cell Biol* **17**:793–803.
- Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, McWeeney S, Dunn JJ, Mandel G, and Goodman RH (2004) Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. *Cell* **119**:1041–1054.
- Innamorati G, Wilkie TM, Kantheti HS, Valenti MT, Dalle Carbonare L, Giacomello L, Parenti M, Melisi D, and Bassi C (2018) The curious case of G α s gain-of-function in neoplasia. *BMC Cancer* **18**:293.
- Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, Arundel P, Shaw N, Pos VD, Underhill A, et al. (2019) Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. *Orphanet J Rare Dis* **14**:139.
- Jeong MJ, Kim EJ, Cho EA, Ye SK, Kang GH, and Juhn YS (2013) cAMP signalling decreases p300 protein levels by promoting its ubiquitin/proteasome dependent degradation via Epac and p38 MAPK in lung cancer cells. *FEBS Lett* **587**:1373–1378.
- Jho E (2018) Dual role of YAP: oncoprotein and tumor suppressor. *J Thorac Dis* **10** (Suppl 33):S3895–S3898.
- Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, and Garraway LA (2013) A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. *Nature* **504**:138–142.
- Johnson DA, Akamine P, Radzio-Andzelm E, Madhusudan M, and Taylor SS (2001) Dynamics of cAMP-dependent protein kinase. *Chem Rev* **101**:2243–2270.
- Julius D and Nathans J (2012) Signaling by sensory receptors. *Cold Spring Harb Perspect Biol* **4**:a005991.
- Kaelin Jr WG (2005) The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer* **5**:689–698.
- Kajiyama H, Mizuno M, Shibata K, Kawai M, Nagasaka T, and Kikkawa F (2014) Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. *Int J Clin Oncol* **19**:121–126.
- Kakadia S, Yarlagadda N, Awad R, Kundra M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, and Mahmoud F (2018) Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *OncoTargets Ther* **11**:7095–7107.
- Kamilaris CDC, Faucz FR, Voutetakis A, and Stratakis CA (2019) Carney Complex. *Exp Clin Endocrinol Diabetes* **127**:156–164.
- Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourbon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, and Seshagiri S (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. *Nature* **466**:869–873.
- Kandel ER (2012) The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. *Mol Brain* **5**:14.

- Kaper JB, Morris Jr JG, and Levine MM (1995) Cholera. *Clin Microbiol Rev* 8:48–86.
- Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M, Murakata C, Sato A, and Kaneko M (1987) K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. *Biochem Biophys Res Commun* 142:436–440.
- Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, Chen CC, Requena D, Tian S, Boshach B, Wilkinson JE, et al. (2017) *DNAJB1-PRKACA* fusion kinase interacts with β -catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. *Proc Natl Acad Sci USA* 114:13076–13084.
- Kaur S, Kumar S, Momi N, Sasson AR, and Batra SK (2013) Mucins in pancreatic cancer and its microenvironment. *Nat Rev Gastroenterol Hepatol* 10:607–620.
- Kawamori T, Uchiya N, Sugimura T, and Wakabayashi K (2003) Enhancement of colon carcinogenesis by prostaglandin E2 administration. *Carcinogenesis* 24:985–990.
- Kee BL, Arias J, and Montminy MR (1996) Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. *J Biol Chem* 271:2373–2375.
- Kemp BE, Graves DJ, Benjamin E, and Krebs EG (1977) Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase. *J Biol Chem* 252:4888–4894.
- Kennedy EJ and Scott JD (2015) Selective disruption of the AKAP signaling complexes. *Methods Mol Biol* 1294:137–150.
- Khan SK, Yadav PS, Elliott G, Hu DZ, Xu R, and Yang Y (2018) Induced *GnasR201H* expression from the endogenous *Gnas* locus causes fibrous dysplasia by up-regulating Wnt/ β -catenin signaling. *Proc Natl Acad Sci USA* 115:E418–E427.
- Kijima N and Kanemura Y (2016) Molecular classification of medulloblastoma. *Neurol Med Chir (Tokyo)* 56:687–697.
- Kim C, Cheng CY, Saldanha SA, and Taylor SS (2007) PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. *Cell* 130:1032–1043.
- Kim C, Vigil D, Anand G, and Taylor SS (2006) Structure and dynamics of PKA signaling proteins. *Eur J Cell Biol* 85:651–654.
- Kim EJ and Juhn YS (2015) Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway. *J Biol Chem* 290:9604–9613.
- Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S, and Lim D-S (2013) cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. *EMBO J* 32:1543–1555.
- Kim P and Zhou X (2019) FusionGDB: fusion gene annotation DataBase. *Nucleic Acids Res* 47 (D1):D994–D1004.
- Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, and Stratakis CA (2000a) Mutations of the gene encoding the protein kinase A type I- α regulatory subunit in patients with the Carney complex. *Nat Genet* 26:89–92.
- Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, and Stratakis CA (2000b) Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. *Hum Mol Genet* 9:3037–3046.
- Knape MJ, Ballez M, Burghardt NC, Zimmermann B, Bertinetti D, Kornev AP, and Herberg FW (2017) Divalent metal ions control activity and inhibition of protein kinases. *Metallomics* 9:1576–1584.
- Knighton D, Zheng J, Ten Eyck L, Ashford V, Xuong N, Taylor S, and Sowadski J (1991a) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. *Science* 253:407–414.
- Knighton DR, Zheng JH, Ten Eyck LF, Xuong NH, Taylor SS, and Sowadski JM (1991b) Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. *Science* 253:414–420.
- Kolligs FT, Bommer G, and Gökke B (2002) Wnt/ β -catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. *Digestion* 66:131–144.
- Komatsu H, Tanji E, Sakata N, Aoki T, Motoi F, Naitoh T, Katayose Y, Egawa S, Unno M, and Furukawa T (2014) A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. *PLoS One* 9:e87875.
- Konermann S, Brigham MD, Trevino AE, Joong J, Abudayyeh OO, Barceca C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, and Zhang F (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature* 517:583–588.
- Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, et al.; ICGC PedBrain Tumor Project (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell* 25:393–405.
- Lacka K and Maciejewski A (2015) Rare thyroid non-neoplastic diseases. *Thyroid Res* 8:5.
- Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, and Vallar L (1989) GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. *Nature* 340:692–696.
- Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, Hoffman D, Jang W, Kaur K, Liu C, et al. (2020) ClinVar: improvements to accessing data. *Nucleic Acids Res* 48 (D1):D835–D844.
- Langeberg LK and Scott JD (2015) Signalling scaffolds and local organization of cellular behaviour. *Nat Rev Mol Cell Biol* 16:232–244.
- Lania AG, Mantovani G, and Spada A (2006) Mechanisms of disease: mutations of G proteins and G-protein-coupled receptors in endocrine diseases. *Nat Clin Pract Endoc* 2:681–693.
- Lanzi C, Borrello MG, Bongarzone I, Migliazza A, Fusco A, Grieco M, Santoro M, Gambetta RA, Zunino F, Della Porta G, and et al. (1992) Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. *Oncogene* 7:2189–2194.
- Larkin SJ, Ferrau F, Karavitaki N, Hernández-Ramírez LC, Ansorge O, Grossman AB, and Korbonits M (2014) Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. *Eur J Endocrinol* 171:705–710.
- Lavogina D, Enkvist E, and Uri A (2010) Bisubstrate inhibitors of protein kinases: from principle to practical applications. *ChemMedChem* 5:23–34.
- Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, et al. (2013) Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. *Br J Cancer* 108:1978–1984.
- Lee JH, Kim TS, Yang TH, Koo BK, Oh SP, Lee KP, Oh HJ, Lee SH, Kong YY, Kim JM, et al. (2008) A crucial role of WW45 in developing epithelial tissues in the mouse. *EMBO J* 27:1231–1242.
- Lee-Six H, Olafsson S, Ellis P, Osborne RJ, Sanders MA, Moore L, Georgakopoulos N, Torrente F, Noorani A, Goddard M, Robinson P, Coorens THH, O'Neill L, Alder C, Wang J, Fitzgerald RC, Zilbauer M, Coleman N, Saeb-Parsy K, Martincorena I, Campbell PJ, and Stratton MR (2019) The landscape of somatic mutation in normal colorectal epithelial cells. *Nature* 574:532–537.
- Leone RD, Lo YC, and Powell JD (2015) A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. *Comput Struct Biotechnol J* 13:265–272.
- Lignitto L, Carlucci A, Sepe M, Stefan E, Cuomo O, Nisticò R, Scorziello A, Savoia C, Garbi C, Annunziato L, et al. (2011) Control of PKA stability and signalling by the RING ligase praja2. *Nat Cell Biol* 13:412–422.
- Linglart A, Menguy C, Couvineau A, Auzan C, Gunes Y, Cancel M, Motte E, Pinto G, Chanson P, Bougnères P, et al. (2011) Recurrent PRKARIA mutation in acrodyostosis with hormone resistance. *N Engl J Med* 364:2218–2226.
- Liu C, Ke P, Zhang J, Zhang X, and Chen X (2020) Protein kinase inhibitor peptide as a tool to specifically inhibit protein kinase A. *Front Physiol* 11:574030.
- Lochner A and Moolman JA (2006) The many faces of H89: a review. *Cardiovasc Drug Rev* 24:261–274.
- Lodish MB, Yuan B, Levy I, Braunstein GD, Lyssikatos C, Salpea P, Szarek E, Karageorgiadis AS, Belyavskaya E, Raygada M, et al. (2015) Germline PRKACA amplification causes variable phenotypes that may depend on the extent of the genomic defect: molecular mechanisms and clinical presentations. *Eur J Endocrinol* 172:803–811.
- Long DN, McGuire S, Levine MA, Weinstein LS, and Germain-Lee EL (2007) Body mass index differences in pseudohypoparathyroidism type Ia versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. *J Clin Endocrinol Metab* 92:1073–1079.
- Lu T-W, Aoto PC, Weng J-H, Nielsen C, Cash JN, Hall J, Zhang P, Simon SM, Cianfrocco MA, and Taylor SS (2020) Structural analyses of the PKA RII β holoenzyme containing the oncogenic DnaJB1-PKAC fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma. *PLoS Biol* 18:e3001018.
- Lu T-W, Wu J, Aoto PC, Weng J-H, Ahuja LG, Sun N, Cheng CY, Zhang P, and Taylor SS (2019) Two PKA RI α holoenzyme states define ATP as an isoform-specific orthosteric inhibitor that competes with the allosteric activator, cAMP. *Proc Natl Acad Sci USA* 116:16347–16356.
- Lubner JM, Dodge-Kafka KL, Carlson CR, Church GM, Chou MF, and Schwartz D (2017) Cushing's syndrome mutant PKA^{L205R} exhibits altered substrate specificity. *FEBS Lett* 591:459–467.
- Luzi NM, Lyons CE, Peterson DL, and Ellis KC (2018) Kinetics and inhibition studies of the L205R mutant of cAMP-dependent protein kinase involved in Cushing's syndrome. *FEBS Open Bio* 8:606–613.
- Ma S, Liu W, Zhang A, Pan L, Tang W, Jiang B, Wang F, Chen S, and Fu B (2019) Identification of a PRKAR1A mutation (c.491_492delTG) in familial cardiac myxoma: a case report. *Medicine (Baltimore)* 98:e14866.
- Ma Y and Taylor SS (2008) A molecular switch for targeting between endoplasmic reticulum (ER) and mitochondria: conversion of a mitochondria-targeting element into an ER-targeting signal in DAKAP1. *J Biol Chem* 283:11743–11751.
- Maass PG, Aydin A, Luft FC, Schächterle C, Weise A, Stricker S, Lindschau C, Vaegler M, Qadri F, Toka HR, et al. (2015) PDE3A mutations cause autosomal dominant hypertension with brachydactyly. *Nat Genet* 47:647–653.
- Maleszewski JJ, Larsen BT, Kip NS, Castonguay MC, Edwards WD, Carney JA, and Kipp BR (2014) PRKAR1A in the development of cardiac myxoma: a study of 110 cases including isolated and syndromic tumors. *Am J Surg Pathol* 38:1079–1087.
- Manna PR, Dyson MT, and Stocco DM (2009) Regulation of the steroidogenic acute regulatory protein gene expression: present and future perspectives. *Mol Hum Reprod* 15:321–333.
- Manschwetetus JT, Bendzunans GN, Limaye AJ, Knape MJ, Herberg FW, and Kennedy EJ (2019) A stapled peptide mimic of the pseudosubstrate inhibitor PKI inhibits protein kinase A. *Molecules* 24.
- Mantovani G and Elli FM (2018) Multiple hormone resistance and alterations of G-protein-coupled receptors signaling. *Best Pract Res Clin Endocrinol Metab* 32:141–154.
- Mantovani G and Elli FM (2019) Inactivating PTH/PTHrP signaling disorders. *Front Horm Res* 51:147–159.
- Mantovani G, Bondioni S, Locatelli M, Pedroni C, Lania AG, Ferrante E, Filipanti M, Beck-Peccoz P, and Spada A (2004) Biallelic expression of the Galpha gene in human bone and adipose tissue. *J Clin Endocrinol Metab* 89:6316–6319.
- Marbach F, Stoyanov G, Erger F, Stratakis CA, Settas N, London E, Rosenfeld JA, Torti E, Haldeman-Englert C, Sklirou E, et al.; Undiagnosed Diseases Network (2021) Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain. *Genet Med* [published ahead of print].
- Markowitz SD and Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. *N Engl J Med* 361:2449–2460.

- Martin AL, Steurer MA, and Aronstam RS (2015) Constitutive activity among orphan class-A G protein coupled receptors. *PLoS One* **10**:e0138463.
- Martinez A and Gil C (2014) cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. *Expert Opin Ther Pat* **24**:1311–1321.
- Marti-Solano M, Crilly SE, Malinverni D, Munk C, Harris M, Pearce A, Quon T, Mackenzie AE, Wang X, Peng J, Tobin AB, Ladds G, Milligan G, Gloriam DE, Puthenveedu MA, and Babu MM (2020) Combinatorial expression of GPCR isoforms affects signalling and drug responses. *Nature* **587**:650–656.
- Mavillard F, Hidalgo J, Megias D, Levitsky KL, and Velasco A (2010) PKA-Mediated Golgi remodeling during cAMP signal transmission. *Traffic* **11**:90–109.
- McKeage K (2013) Pasireotide: a review of its use in Cushing's disease. *Drugs* **73**:563–574.
- Meggio F, Donella Deana A, Ruzzene M, Brunati AM, Cesaro L, Guerra B, Meyer T, Mett H, Fabbro D, Furet P, et al. (1995) Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. *Eur J Biochem* **234**:317–322.
- Meoli E, Bossis I, Cazabat L, Mavrakis M, Horvath A, Stergiopoulos S, Shiferaw ML, Fumey G, Perlempo K, Muchow M, et al. (2008) Protein kinase A effects of an expressed PRKARIA mutation associated with aggressive tumors. *Cancer Res* **68**:3133–3141.
- Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, and Neefjes J (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. *Cancer Cell* **5**:597–605.
- Mika D, Leroy J, Vandecasteele G, and Fischmeister R (2012) PDEs create local domains of cAMP signaling. *J Mol Cell Cardiol* **52**:323–329.
- Miller LJ, Sexton PM, Dong M, and Hariikum KG (2014) The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus. *Int J Obes Suppl* **4** (Suppl 1):S9–S13.
- Milunsky J, Huang XL, Baldwin CT, Farah MG, and Milunsky A (1998) Evidence for genetic heterogeneity of the Carney complex (familial atrial myxoma syndromes). *Cancer Genet Cytogenet* **106**:173–176.
- Moen LV, Sener Z, Volchenkov R, Svarstad AC, Eriksen AM, Holen HL, and Skålhegg BS (2017) Ablation of the C/2 subunit of PKA in immune cells leads to increased susceptibility to systemic inflammation in mice. *Eur J Immunol* **47**:1880–1889.
- Molin MD, Matthaei H, Wu J, Blackford A, Debeljak M, Rezaee N, Wolfgang CL, Butturini G, Salvia R, Bassi C, et al. (2013) Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Ann Surg Oncol* **20**:3802–3808.
- Montminy MR, Sevarino KA, Wagner JA, Mandel G, and Goodman RH (1986) Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc Natl Acad Sci USA* **83**:6682–6686.
- Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo L, Thomas SR, Boehm JS, Kim SY, Wang ZC, and Hahn WC (2015) PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. *Oncogene* **34**:2061–2071.
- Moore MJ, Adams JA, and Taylor SS (2003) Structural basis for peptide binding in protein kinase A. Role of glutamic acid 203 and tyrosine 204 in the peptide-positioning loop. *J Biol Chem* **278**:10613–10618.
- Mouallef M, Shaharabany M, Weintrob N, Shalitin S, Nagelberg N, Shapira H, Zadik Z, and Farfel Z (2008) Cognitive impairment is prevalent in pseudohypoparathyroidism type Ia, but not in pseudopseudohypoparathyroidism: possible cerebral imprinting of Gsalpha. *Clin Endocrinol (Oxf)* **68**:233–239.
- Muda K, Bertinetti D, Gesellchen F, Hermann JS, von Zweydfel F, Geerlolf A, Jacob A, Ueffing M, Gloeckner CJ, and Herberg FW (2014) Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. *Proc Natl Acad Sci USA* **111**:E34–E43.
- Mukhopadhyay S and Rohatgi R (2014) G-protein-coupled receptors, Hedgehog signaling and primary cilia. *Semin Cell Dev Biol* **33**:63–72.
- Mullard A (2020) Targeted degraders clear first safety hurdles. *Nat Rev Drug Discov* **19**:435.
- Mullard A (2021) Targeted protein degraders crowd into the clinic. *Nat Rev Drug Discov* **20**:247–250.
- Muñiz M, Alonso M, Hidalgo J, and Velasco A (1996) A regulatory role for cAMP-dependent protein kinase in protein traffic along the exocytic route. *J Biol Chem* **271**:30935–30941.
- Murray AJ (2008) Pharmacological PKA inhibition: all may not be what it seems. *Sci Signal* **1**:re4.
- Mykityn K and Askwith C (2017) G-protein-coupled receptor signaling in cilia. *Cold Spring Harb Perspect Biol* **9**:a028183.
- Nagai Y, Nishimura A, Tago K, Mizuno N, and Itoh H (2010) Ric-8B stabilizes the alpha subunit of stimulatory G protein by inhibiting its ubiquitination. *J Biol Chem* **285**:11114–11120.
- Nagy G, Reim K, Matti U, Brose N, Binz T, Rettig J, Neher E, and Sørensen JB (2004) Regulation of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25. *Neuron* **41**:417–429.
- Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et al. (2015) Genomic spectra of biliary tract cancer. *Nat Genet* **47**:1003–1010.
- Natochin M and Artemyev NO (1998a) A single mutation Asp229 \rightarrow Ser confers upon Gs alpha the ability to interact with regulators of G protein signaling. *Biochemistry* **37**:13776–13780.
- Natochin M and Artemyev NO (1998b) Substitution of transducin ser202 by asp abolishes G-protein/RGS interaction. *J Biol Chem* **273**:4300–4303.
- Naviglio S, Pagano M, Romano M, Sorrentino A, Fusco A, Illiano F, Chiosi E, Spina A, and Illiano G (2004) Adenylate cyclase regulation via proteasome-mediated modulation of Galphas levels. *Cell Signal* **16**:1229–1237.
- Nelson KN, Peiris MN, Meyer AN, Siari A, and Donoghue DJ (2017) Receptor tyrosine kinases: translocation partners in hematopoietic disorders. *Trends Mol Med* **23**:59–79.
- Nesterova M, Noguchi K, Park YG, Lee YN, and Cho-Chung YS (2000) Compensatory stabilization of R11beta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A R1alpha protein. *Clin Cancer Res* **6**:3434–3441.
- Neves-Zaph SR (2017) Phosphodiesterase diversity and signal processing within cAMP signaling networks. *Adv Neurobiol* **17**:3–14.
- Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, and Albelda SM (2016) Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. *Cancer Immunol Res* **4**:541–551.
- Niewiadomski P, Zhujiang A, Youssef M, and Waschek JA (2013) Interaction of PACAP with Sonic hedgehog reveals complex regulation of the hedgehog pathway by PKA. *Cell Signal* **25**:2222–2230.
- Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE, and Gorelik J (2010) β 2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. *Science* **327**:1653–1657.
- Nishihara E, Amino N, Maekawa K, Yoshida H, Ito M, Kubota S, Fukata S, and Miyauchi A (2009) Prevalence of TSH receptor and Gsalpha mutations in 45 autonomously functioning thyroid nodules in Japan. *Endocr J* **56**:791–798.
- Nishikawa G, Sekine S, Ogawa R, Matsubara A, Mori T, Taniguchi H, Kushima R, Hiraoka N, Tsuta K, Tsuda H, et al. (2013) Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. *Br J Cancer* **108**:951–958.
- Niswender C, Willis B, Wallen A, Sweet I, Jetton T, Thompson B, Wu C, Lange A, and McKnight G (2005) Cre recombinase-dependent expression of a constitutively active mutant allele of the catalytic subunit of protein kinase A. *Genesis* **43**:109–119.
- Nonga OE, Enkvist E, Herberg FW, and Uri A (2020) Inhibitors and fluorescent probes for protein kinase PKAc β and its S54L mutant, identified in a patient with cortisol producing adenoma. *Biosci Biotechnol Biochem* **84**:1839–1845.
- Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, and Dikov MM (2008) Adenosine receptors in regulation of dendritic cell differentiation and function. *Blood* **112**:1822–1831.
- Novotny J and Svoboda P (1998) The long (Gs(alpha)-L) and short (Gs(alpha)-S) variants of the stimulatory guanine nucleotide-binding protein. Do they behave in an identical way? *J Mol Endocrinol* **20**:163–173.
- Nummela P, Saarinen L, Thiel A, Järvinen P, Lehtonen R, Lepistö A, Järvinen H, Aaltonen LA, Hautaniemi S, and Ristimäki A (2015) Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. *Int J Cancer* **136**:E282–E289.
- O'Connell JT, Hacker CM, and Barsky SH (2002) MUC2 is a molecular marker for pseudomyxoma peritonei. *Mod Pathol* **15**:958–972.
- Ogden SK, Fei DL, Schilling NS, Ahmed YF, Hwa J, and Robbins DJ (2008) G protein Galpha1 functions immediately downstream of Smoothed in Hedgehog signalling. *Nature* **456**:967–970.
- O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, and Gutkind JS (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. *Nat Rev Cancer* **13**:412–424.
- Ohoka N, Okuhira K, Ito M, Nagai K, Shibata N, Hattori T, Ujikawa O, Shimokawa K, Sano O, Koyama R, et al. (2017) *In vivo* knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). *J Biol Chem* **292**:4556–4570.
- Oldham WM and Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. *Nat Rev Mol Cell Biol* **9**:60–71.
- Olivieri C, Walker C, Karamafrooz A, Wang Y, Manu VS, Porcelli F, Blumenthal DK, Thomas DD, Bernlohr DA, Simon SM, et al. (2021) Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A. *Commun Biol* **4**:321.
- Omar F, Findlay JE, Carfray G, Alcock RW, Jiang Z, Moore C, Muir AL, Lannoy M, Fertig BA, Mai D, et al. (2019) Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. *Proc Natl Acad Sci USA* **116**:13320–13329.
- Omar MH and Scott JD (2020) AKAP signaling islands: venues for precision pharmacology. *Trends Pharmacol Sci* **41**:933–946.
- Omori K and Kotera J (2007) Overview of PDEs and their regulation. *Circ Res* **100**:309–327.
- Ostrem JM, Peters U, Sos ML, Wells JA, and Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature* **503**:548–551.
- Ould Amer Y and Hebert-Chatelain E (2018) Mitochondrial cAMP-PKA signaling: What do we really know? *Biochim Biophys Acta Bioenerg* **1859**:868–877.
- Palencia-Campos A, Aoto PC, Machal EMF, Rivera-Barahona A, Soto-Bielicka P, Bertinetti D, Baker B, Vu L, Piccini-Sparascio F, Torrente I, et al. (2020) Germline and mosaic variants in PRKACA and PRKACB cause a multiple congenital malformation syndrome. *Am J Hum Genet* **107**:977–988.
- Palorini R, De Rasmio D, Gaviraghi M, Danna LS, Signorile A, Cirulli C, Chiaradonna F, Alberghina L, and Papa S (2013) Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration. *Oncogene* **32**:352–362.
- Palorini R, Votta G, Pirola Y, De Vitto H, De Palma S, Airoldi C, Vasso M, Ricciardiello F, Lombardi PP, Cirulli C, et al. (2016) Protein kinase A activation promotes cancer cell resistance to glucose starvation and anoikis. *PLoS Genet* **12**:e1005931–e1005931.
- Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, Rueda-Chimeno C, Barreiro-Morandera F, Lado-Abeal J, Araujo Vilar D, Argüeso R, Barca O, Botana M, et al.; Galician Group for the Study of Toxic Multinodular Goitre (2008) Prevalence of mutations in TSHR, GNAS, PRKARIA and RAS genes in a large series of toxic

- thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. *Eur J Endocrinol* **159**:623–631.
- Paradis JS, Acosta M, Saddawi-Konefka R, Kishore A, Lubrano S, Gomes FG, Arang N, Tiago M, Coma S, Wu X, Ford K, Day C-P, Merlino G, Mali P, Pachter JA, Sato T, Aplin AE, and Gutkind JS (2021) Synthetic lethal screens reveal co-targeting FAK and MEK as a multimodal precision therapy for GNAQ-driven uveal melanoma. *Clin Cancer Res* **27**:3190–3200.
- Parker D, Ferreri K, Nakajima T, LaMorte VJ, Evans R, Koerber SC, Hoeger C, and Montminy MR (1996) Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. *Mol Cell Biol* **16**:694–703.
- Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, et al. (2018) Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. *Nat Cell Biol* **20**:811–822.
- Patronas Y, Horvath A, Greene E, Tsang K, Bimpaki E, Haran M, Nesterova M, and Stratakis CA (2012) In vitro studies of novel PRKARIA mutants that extend the predicted RLz protein sequence into the 3'-untranslated open reading frame: proteasomal degradation leads to RLz haploinsufficiency and Carney complex. *J Clin Endocrinol Metab* **97**:E496–E502.
- Pattabiraman DR, Bierie B, Kober KI, Thiru P, Krall JA, Zill C, Reinhardt F, Tam WL, and Weinberg RA (2016) Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. *Science* **351**:aad3680.
- Pelaseyed T and Hansson GC (2020) Membrane mucins of the intestine at a glance. *J Cell Sci* **133**:jcs240929.
- Pelly VS, Moeni A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, Blanco-Gomez A, Banyard A, Bromley CP, Flanagan E, Chiang S-C, Jorgensen C, Schumacher TN, Thommen DS, and Zelenay S (2021) Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy. *Cancer Discov* [published online ahead of print].
- Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, et al. (2016) GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. *J Transl Med* **14**:125.
- Pothuraju R, Krishn SR, Gautam SK, Pai P, Ganguly K, Chaudhary S, Rachagani S, Kaur S, and Batra SK (2020) Mechanistic and functional shades of mucins and associated glycans in colon cancer. *Cancers (Basel)* **12**:649.
- Raimondi F, Inoue A, Kadji FMN, Shuai N, Gonzalez JC, Singh G, de la Vega AA, Sotillo R, Fischer B, Aoki J, Gutkind JS, and Russell RB (2019) Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm. *Oncogene* **38**:6491–6506.
- Rao R, Salloum R, Xin M, and Lu QR (2016) The G protein *Gzs* acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis. *Cell Cycle* **15**:1325–1330.
- Regard JB, Malhotra D, Gvozdenovic-Jeremic J, Josey M, Chen M, Weinstein LS, Lu J, Shore EM, Kaplan FS, and Yang Y (2013) Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. *Nat Med* **19**:1505–1512.
- Reynen K (1995) Cardiac myxomas. *N Engl J Med* **333**:1610–1617.
- Rhayem Y, Le Stunff C, Abdel Khalek W, Auzan C, Bertherat J, Linglart A, Couvneau A, Silve C, and Clauser E (2015) Functional characterization of PRKARIA mutations reveals a unique molecular mechanism causing acrodysostosis but multiple mechanisms causing carney complex. *J Biol Chem* **290**:27816–27828.
- Ricouart A, Gesquiere JC, Tartar A, and Sergheraert C (1991) Design of potent protein kinase inhibitors using the substrate approach. *J Med Chem* **34**:73–78.
- Riggle KM, Riehle KJ, Kenerson HL, Turnham R, Homma MK, Kazami M, Samelson B, Bauer R, McKnight GS, Scott JD, et al. (2016) Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma. *Pediatr Res* **80**:110–118.
- Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, and Gehron Robey P (1997) Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. *Am J Pathol* **151**:1587–1600.
- Riminucci M, Robey PG, Saggio I, and Bianco P (2010) Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells. *J Mol Endocrinol* **45**:355–364.
- Riminucci M, Saggio I, Robey PG, and Bianco P (2006) Fibrous dysplasia as a stem cell disease. *J Bone Miner Res* **21** (Suppl 2):125–131.
- Rinaldi L, Delle Donne R, Catalanotti B, Torres-Quesada O, Enzler F, Moraca F, Nistico R, Chiuso F, Piccinin S, Bachmann V, et al. (2019) Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system. *Nat Commun* **10**:2572.
- Rinaldi L, Sepe M, Donne RD, and Feliciello A (2015) A dynamic interface between ubiquitylation and cAMP signaling. *Front Pharmacol* **6**:177.
- Rios RM, Celati C, Lohmann SM, Bornens M, and Keryer G (1992) Identification of a high affinity binding protein for the regulatory subunit RII beta of cAMP-dependent protein kinase in Golgi enriched membranes of human lymphoblasts. *EMBO J* **11**:1723–1731.
- Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, and Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. *Cancer Res* **62**:632–635.
- Robinson-Steiner AM and Corbin JD (1983) Probable involvement of both intrachain cAMP binding sites in activation of protein kinase. *J Biol Chem* **258**:1032–1040.
- Röck R, Mayrhofer J, Bachmann V, and Stefan E (2015) Impact of kinase activating and inactivating patient mutations on binary PKA interactions. *Front Pharmacol* **6**:170.
- Rogne M and Taskén K (2014) Compartmentalization of cAMP signaling in adipogenesis, lipogenesis, and lipolysis. *Horm Metab Res* **46**:833–840.
- Ronchi CL, Di Dalmazi G, Faillot S, Sbierra S, Assié G, Weigand I, Calebiro D, Schwarzmayr T, Appenzeller S, Rubin B, et al.; European Network for the Study of Adrenocortical Tumors (ENSAT) (2016) Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation. *J Clin Endocrinol Metab* **101**:3526–3538.
- Rosenberg D, Groussin L, Jullian E, Perlemoine K, Bertagna X, and Bertherat J (2002) Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. *Ann N Y Acad Sci* **968**:65–74.
- Rothermel JD and Parker Boteloh LH (1988) A mechanistic and kinetic analysis of the interactions of the diastereoisomers of adenosine 3',5'-(cyclic)phosphorothioate with purified cyclic AMP-dependent protein kinase. *Biochem J* **251**:757–762.
- Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, and Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet* **379**:1591–1601.
- Ruppelt A, Mosenden R, Grönholm M, Aandahl EM, Tobin D, Carlson CR, Abrahamsen H, Herberg FW, Carpén O, and Taskén K (2007) Inhibition of T cell activation by cyclic adenosine 5'-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. *J Immunol* **179**:5159–5168.
- Ryu H-S, Chang K-H, Yang H-W, Kim M-S, Kwon H-C, and Oh K-S (2000) High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. *Gynecol Oncol* **76**:320–325.
- Saldanha SA, Kaler G, Cottam HB, Abagyan R, and Taylor SS (2006) Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. *Anal Chem* **78**:8265–8272.
- Sanchez JN, Wang T, and Cohen MS (2018) BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. *Drugs* **78**:549–566.
- Sanchez-Collado J, Lopez JJ, Jardin I, Salido GM, and Rosado JA (2021) Cross-talk between the adenylyl cyclase/cAMP pathway and Ca²⁺ homeostasis. *Rev Physiol Biochem Pharmacol* **179**:73–116.
- Santoro M and Carlomagno F (2013) Central role of RET in thyroid cancer. *Cold Spring Harb Perspect Biol* **5**:a009233.
- Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, et al. (2017) A comprehensive map of molecular drug targets. *Nat Rev Drug Discov* **16**:19–34.
- Schächterle C, Christian F, Fernandes JM, and Klussmann E (2015) Screening for small molecule disruptors of AKAP-PKA interactions. *Methods Mol Biol* **1294**:151–166.
- Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, and Wright JD (2011) Natural history and outcome of mucinous carcinoma of the ovary. *Am J Obstet Gynecol* **205**:480.e1–480.e8.
- Schindler RFR and Brand T (2016) The Popeye domain containing protein family—A novel class of cAMP effectors with important functions in multiple tissues. *Prog Biophys Mol Biol* **120**:28–36.
- Schmid A, Meili D, and Salathe M (2014) Soluble adenylyl cyclase in health and disease. *Biochim Biophys Acta* **1842** (12 Pt B):2584–2592.
- Schou KB, Pedersen LB, and Christensen ST (2015) Ins and outs of GPCR signaling in primary cilia. *EMBO Rep* **16**:1099–1113.
- Schwede F, Chepurny OG, Kauffholz M, Bertinetti D, Leech CA, Cabrera O, Zhu Y, Mei F, Cheng X, Manning Fox JE, et al. (2015) Rp-cAMPS prodrugs reveal the cAMP dependence of first-phase glucose-stimulated insulin secretion. *Mol Endocrinol* **29**:988–1005.
- Schwede F, Christensen A, Liauw S, Hippe T, Kopperud R, Jastorff B, and Døskeland SO (2000) 8-Substituted cAMP analogues reveal marked differences in adaptability, hydrogen bonding, and charge accommodation between homologous binding sites (AI/AII and BI/BII) in cAMP kinase I and II. *Biochemistry* **39**:8803–8812.
- Seamon KB, Padgett W, and Daly JW (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. *Proc Natl Acad Sci USA* **78**:3363–3367.
- Seifert R, Wenzel-Seifert K, Lee TW, Gether U, Sanders-Bush E, and Kobilka BK (1998) Different effects of G α splice variants on beta₂-adrenoreceptor-mediated signaling. The Beta₂-adrenoreceptor coupled to the long splice variant of G α has properties of a constitutively active receptor. *J Biol Chem* **273**:5109–5116.
- Seino S and Shibasaki T (2005) PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. *Physiol Rev* **85**:1303–1342.
- Sengupta R, Dubuc A, Ward S, Yang L, Northcott P, Woerner BM, Kroll K, Luo J, Taylor MD, Wechsler-Reya RJ, et al. (2012) CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. *Cancer Res* **72**:122–132.
- Sharma ST, Nieman LK, and Feelders RA (2015) Cushing's syndrome: epidemiology and developments in disease management. *Clin Epidemiol* **7**:281–293.
- Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, Kishimoto Y, and Kawasaki H (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. *Hepatogastroenterology* **46**:407–412.
- Shirley MD, Tang H, Gallione CJ, Baugher JD, Frelin LP, Cohen B, North PE, Marchuk DA, Comi AM, and Pevsner J (2013) Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. *N Engl J Med* **368**:1971–1979.
- Singhi AD, Wood LD, Parks E, Torbenson MS, Felsenstein M, Hruban RH, Nikiforova MN, Wald AI, Kaya C, Nikiforov YE, Favazza L, He J, McGrath K, Fasanella KE, Brand RE, Lennon AM, Furlan A, Dasyam AK, Zureikat AH, Zeh HJ, Lee K, Bartlett DL, and Slivka A (2020) Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct. *Gastroenterology* **158**:573–582.e572.
- Skälhegg BS, Huang Y, Su T, Idzerda RL, McKnight GS, and Burton KA (2002) Mutation of the Calpha subunit of PKA leads to growth retardation and sperm dysfunction. *Mol Endocrinol* **16**:630–639.

- Skieterska K, Rondou P, and Van Craenenbroeck K (2017) Regulation of G Protein-Coupled Receptors by Ubiquitination. *Int J Mol Sci* **18**:923.
- Skroblin P, Grossmann S, Schäfer G, Rosenthal W, and Klusmann E (2010) Mechanisms of protein kinase A anchoring. *Int Rev Cell Mol Biol* **283**:235–330.
- Smith FD, Esseltine JL, Nygren PJ, Veessler D, Byrne DP, Vonderach M, Strashnov I, Eyers CE, Eyers PA, Langeberg LK, and Scott JD (2017) Local protein kinase A action proceeds through intact holoenzymes. *Science* **356**:1288–1293.
- Søberg K and Skälhøgg BS (2018) The molecular basis for specificity at the level of the protein kinase a catalytic subunit. *Front Endocrinol (Lausanne)* **9**:538.
- Søberg K, Moen LV, Skälhøgg BS, and Laerdahl JK (2017) Evolution of the cAMP-dependent protein kinase (PKA) catalytic subunit isoforms. *PLoS One* **12**:e0181091.
- Sonntag T, Ostojić J, Vaughan JM, Moresco JJ, Yoon Y-S, Yates JR, and Montminy M (2019) Mitogenic signals stimulate the CREB coactivator CRTC3 through PP2A recruitment. *iScience* **11**:134–145.
- Sprang SR (2016) Invited review: activation of G proteins by GTP and the mechanism of G α -catalyzed GTP hydrolysis. *Biopolymers* **105**:449–462.
- Steffensen C, Bak AM, Zøjberg Rubeck K, and Jørgensen JOL (2010) Epidemiology of Cushing's syndrome. *Neuroendocrinology* **92**(Suppl 1):1–5.
- Stephenson A, Eszlinger M, Stewardson P, McIntyre JB, Boesenberg E, Bircan R, Sancak S, Gozu HI, Ghaznavi S, Krohn K, and Paschke R (2020) Sensitive sequencing analysis suggests TSHR and GNAS as sole driver mutations in hot thyroid nodules. *Thyroid* **30**:1482–1489.
- Stratakis CA, Kirschner LS, and Carney JA (2001) Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. *J Clin Endocrinol Metab* **86**:4041–4046.
- Sunahara RK, Tesmer JGG, Gilman AG, and Sprang SR (1997) Crystal structure of the adenylyl cyclase activator Gs α . *Science* **278**:1943–1947.
- Sunitsch S, Gilg MM, Kashofer K, Gollwitsch F, Leithner A, and Liegl-Atzwanger B (2018) Detection of GNAS mutations in intramuscular / cellular myxomas as diagnostic tool in the classification of myxoid soft tissue tumors. *Diagn Pathol* **13**:52.
- Swords FM, Noon LA, King PJ, and Clark AJ (2004) Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. *Mol Cell Endocrinol* **213**:149–154.
- Take Y, Koizumi S, and Nagahisa A (2020) Prostaglandin E receptor 4 antagonist in cancer immunotherapy: mechanisms of action. *Front Immunol* **11**:324.
- Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, et al. (2019) COSMIC: the catalogue of somatic mutations in cancer. *Nucleic Acids Res* **47** (D1):D941–D947.
- Taylor SS, Ilouz R, Zhang P, and Kornev AP (2012) Assembly of allosteric macromolecular switches: lessons from PKA. *Nat Rev Mol Cell Biol* **13**:646–658.
- Taylor SS, Wallbott M, Machal EMF, Søberg K, Ahmed F, Bruystens J, Vu L, Baker B, Wu J, Raimondi F, et al. (2021) PKA C β : a forgotten catalytic subunit of cAMP-dependent protein kinase opens new windows for PKA signaling and disease pathologies. *Biochem J* **478**:2101–2119.
- Tengholm A and Gylfe E (2017) cAMP signalling in insulin and glucagon secretion. *Diabetes Obes Metab* **19** (Suppl 1):42–53.
- Tidymam WE and Rauken KA (2009) The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. *Curr Opin Genet Dev* **19**:230–236.
- Tilley SK and Fry RC (2015) Hormone response pathways as responders to environmental contaminants and their roles in disease, in *Systems Biology in Toxicology and Environmental Health*, chap 10. Fry RC, ed) pp 225–238, Academic Press, Boston.
- Tong D, Liu Q, Wang LA, Xie Q, Pang J, Huang Y, Wang L, Liu G, Zhang D, Lan W, et al. (2018) The roles of the COX2/PGE2/EP axis in therapeutic resistance. *Cancer Metastasis Rev* **37**:355–368.
- Torres-Quesada O, Mayrhofer JE, and Stefan E (2017) The many faces of compartmentalized PKA signalosomes. *Cell Signal* **37**:1–11.
- Tresguerres M, Levin LR, and Buck J (2011) Intracellular cAMP signaling by soluble adenylyl cyclase. *Kidney Int* **79**:1277–1288.
- Tschaikner P, Enzler F, Torres-Quesada O, Aanstad P, and Stefan E (2020) Hedgehog and Gpr161: Regulating cAMP signaling in the primary cilium. *Cells* **9**:118.
- Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, et al. (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. *Cancer Res* **59**:987–990.
- Turan S and Bastepe M (2015) GNAS spectrum of disorders. *Curr Osteoporos Rep* **13**:146–158.
- Turnham RE and Scott JD (2016) Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology. *Gene* **577**:101–108.
- Turnham RE, Smith FD, Kenerson HL, Omar MH, Golkowski M, Garcia I, Bauer R, Lau H-T, Sullivan KM, Langeberg LK, Ong S-E, Riehle KJ, Yeung RS, and Scott JD (2019) An acquired scaffolding function of the DNAJ-PKA fusion contributes to oncogenic signaling in fibrolamellar carcinoma. *eLife* **8**:e44187.
- Unson CG, Wu C-R, Sakmar TP, and Merrifield RB (2000) Selective stabilization of the high affinity binding conformation of glucagon receptor by the long splice variant of Galpha(s). *J Biol Chem* **275**:21631–21638.
- Valenta T, Hausmann G, and Basler K (2012) The many faces and functions of β -catenin. *EMBO J* **31**:2714–2736.
- Vander Heiden MG, Cantley LC, and Thompson CB (2009) Understanding the Warburg Effect: the metabolic requirements of cell proliferation. *Science* **324**:1029–1033.
- Vannam R, Sayilgan J, Ojeda S, Karakyriakou B, Hu E, Kreuzer J, Morris R, Herrera Lopez XI, Rai S, Haas W, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell Chem Biol* **28**:503–514.e12.
- Velich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, and Augenlicht L (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. *Science* **295**:1726–1729.
- VerPlank JJS, Lokireddy S, Zhao J, and Goldberg AL (2019) 26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. *Proc Natl Acad Sci USA* **116**:4228–4237.
- Veuglers M, Wilkes D, Burton K, McDermott DA, Song Y, Goldstein MM, La Perle K, Vaughan CJ, O'Hagan A, Bennett KR, et al. (2004) Comparative PRKARIA genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. *Proc Natl Acad Sci USA* **101**:14222–14227.
- Visscher M, Arkin MR, and Dansen TB (2016) Covalent targeting of acquired cysteines in cancer. *Curr Opin Chem Biol* **30**:61–67.
- Visser SS, Theron AJ, Ramafi G, Ker JA, and Anderson R (2000) Apparent involvement of the A(2A) subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils. *Biochem Pharmacol* **60**:993–999.
- Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, and Kinzler KW (2013) Cancer genome landscapes. *Science* **339**:1546–1558.
- Vyas M, Hechtman JF, Zhang Y, Benayed R, Yavas A, Askan G, Shia J, Klimstra DS, and Basturk O (2020) DNAJB1-PRKACA fusions occur in oncogenic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. *Mod Pathol* **33**:648–656.
- Wainger BJ, DeGennaro M, Santoro B, Siegelbaum SA, and Tibbs GR (2001) Molecular mechanism of cAMP modulation of HCN pacemaker channels. *Nature* **411**:805–810.
- Walczak EM and Hammer GD (2015) Regulation of the adrenocortical stem cell niche: implications for disease. *Nat Rev Endocrinol* **11**:14–28.
- Walker C, Wang Y, Olivieri C, Karamafrooz A, Casby J, Bathon K, Calebiro D, Gao J, Bernlohr DA, Taylor SS, and Veglia G (2019) Cushing's syndrome driver mutation disrupts protein kinase A allosteric network, altering both regulation and substrate specificity. *Sci Adv* **5**:eaaw9298.
- Walker C, Wang Y, Olivieri C, v S M, Gao J, Bernlohr DA, Calebiro D, Taylor SS, and Veglia G (2021) Is disrupted nucleotide-substrate cooperativity a common trait for Cushing's syndrome driving mutations of protein kinase A? *J Mol Biol* [published online ahead of print].
- Wang D and DuBois RN (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. *Oncogene* **29**:781–788.
- Wang J, Gareri C, and Rockman HA (2018a) G-protein-coupled receptors in heart disease. *Circ Res* **123**:716–735.
- Wang L, Wang Q, Zhou Y, Xue Q, Sun X, Wang Z, and Ji G (2018b) Recurrent left atrial myxoma in Carney complex: a case report of a familial pedigree. *Medicine (Baltimore)* **97**:e0247.
- Wang S, Li Z, Shen H, Zhang Z, Yin Y, Wang Q, Zhao X, and Ji J (2016) Quantitative phosphoproteomic study reveals that protein kinase A regulates neural stem cell differentiation through phosphorylation of catenin beta-1 and glycogen synthase kinase 3 β . *Stem Cells* **34**:2090–2101.
- Wang Y, Ho TG, Bertinetti D, Neddermann M, Franz E, Mo GCH, Schendowich LP, Sukhu A, Spelts RC, Zhang J, et al. (2014) Isoform-selective disruption of AKAP-localized PKA using hydrocarbon stapled peptides. *ACS Chem Biol* **9**:635–642.
- Wang Y, Ho TG, Franz E, Hermann JS, Smith FD, Hehnly H, Esseltine JL, Harold LE, Murph MM, Bertinetti D, et al. (2015) PKA-type I selective constrained peptide disruptors of AKAP complexes. *ACS Chem Biol* **10**:1502–1510.
- Wehbi VL and Taskén K (2016) Molecular mechanisms for cAMP-mediated immunoregulation in T cells - role of anchored protein kinase A signaling units. *Front Immunol* **7**:222.
- Weinstein LS, Liu J, Sakamoto A, Xie T, and Chen M (2004) Minireview: GNAS: normal and abnormal functions. *Endocrinology* **145**:5459–5464.
- Welch EJ, Jones BW, and Scott JD (2010) Networking with AKAPs: context-dependent regulation of anchored enzymes. *Mol Interv* **10**:86–97.
- Wendell SG, Fan H, and Zhang C (2020) G protein-coupled receptors in asthma therapy: pharmacology and drug action. *Pharmacol Rev* **72**:1–49.
- Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, Sicklick J, Nishihara H, Lowy AM, and Insel PA (2018) GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. *FASEB J* **32**:1170–1183.
- Willis BS, Niswender CM, Su T, Amieux PS, and McKnight GS (2011) Cell-type specific expression of a dominant negative PKA mutation in mice. *PLoS One* **6**:e18772.
- Wilson CH, McIntyre RE, Arends MJ, and Adams DJ (2010) The activating mutation R201C in GNAS promotes intestinal tumorigenesis in Ap(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. *Oncogene* **29**:4567–4575.
- Wong TH, Chiu WZ, Breedveld GJ, Li KW, Verkerk AJMH, Hondius D, Hukema RK, Seelaar H, Frick P, Severijnen L-A, et al.; Netherlands Brain Bank; International Parkinsonism Genetics Network (2014) PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. *Brain* **137**:1361–1373.
- Wong W and Scott JD (2004) AKAP signalling complexes: focal points in space and time. *Nat Rev Mol Cell Biol* **5**:959–970.
- Wu J, Brown SH, von Daake S, and Taylor SS (2007) PKA type IIalpha holoenzyme reveals a combinatorial strategy for isoform diversity. *Science* **318**:274–279.
- Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, Inoue A, Russell RB, Tamayo P, and Gutkind JS (2019) Illuminating the Onco-GPCRome: novel G protein-coupled receptor-driven oncogene networks and targets for cancer immunotherapy. *J Biol Chem* **294**:11062–11086.
- Xie G-D, Liu Y-R, Jiang Y-Z, and Shao Z-M (2018) Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study. *Sci Rep* **8**:6117.
- Yamada M, Sekine S, Ogawa R, Taniguchi H, Kushima R, Tsuda H, and Kanai Y (2012) Frequent activating GNAS mutations in villous adenoma of the colorectum. *J Pathol* **228**:113–118.

- Yang H and Yang L (2016) Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy. *J Mol Endocrinol* **57**:R93–R108.
- Ye Q, Qi F, Bian L, Zhang SH, Wang T, and Jiang ZF (2017) Circulating-free DNA mutation associated with response of targeted therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer. *Chin Med J (Engl)* **130**:522–529.
- Yonemoto W, McGlone ML, Grant B, and Taylor SS (1997) Autophosphorylation of the catalytic subunit of cAMP-dependent protein kinase in *Escherichia coli*. *Protein Eng* **10**:915–925.
- Young A, Mittal D, Stagg J, and Smyth MJ (2014) Targeting cancer-derived adenosine: new therapeutic approaches. *Cancer Discov* **4**:879–888.
- Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, et al. (2018) A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. *Cancer Res* **78**:1003–1016.
- Yu FX, Zhang Y, Park HW, Jewell JL, Chen Q, Deng Y, Pan D, Taylor SS, Lai ZC, and Guan KL (2013) Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. *Genes Dev* **27**:1223–1232.
- Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mills GB, and Guan KL (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell* **150**:780–791.
- Yu S, Yu D, Lee E, Eckhaus M, Lee R, Corria Z, Accili D, Westphal H, and Weinstein LS (1998) Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (*Gsalpha*) knockout mice is due to tissue-specific imprinting of the *gsalpha* gene. *Proc Natl Acad Sci USA* **95**:8715–8720.
- Zagotta WN and Siegelbaum SA (1996) Structure and function of cyclic nucleotide-gated channels. *Annu Rev Neurosci* **19**:235–263.
- Zauber P, Marotta SP, and Sabbath-Solitare M (2016) GNAS gene mutation may be present only transiently during colorectal tumorigenesis. *Int J Mol Epidemiol Genet* **7**:24–31.
- Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, and Reis e Sousa C (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. *Cell* **162**:1257–1270.
- Zhang JZ, Lu T-W, Stolerman LM, Tenner B, Yang JR, Zhang J-F, Falcke M, Rangamani P, Taylor SS, Mehta S, and Zhang J (2020) Phase separation of a PKA Regulatory subunit controls cAMP compartmentation and oncogenic signaling. *Cell* **182**:1531–1544.e1515.
- Zhang X, Odom DT, Koo SH, Konkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolzheimer E, Jacobsen E, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. *Proc Natl Acad Sci USA* **102**:4459–4464.
- Zhao X, Deng P, Iglesias-Bartolome R, Amornphimoltham P, Steffen DJ, Jin Y, Molinolo AA, de Castro LF, Ovejero D, Yuan Q, et al. (2018) Expression of an active *G α_s* mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. *Proc Natl Acad Sci USA* **115**:E428–E437.
- Zhou XY, Shibusawa N, Naik K, Porras D, Temple K, Ou H, Kaihara K, Roe MW, Brady MJ, and Wondisford FE (2004) Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. *Nat Med* **10**:633–637.
- Zimmermann KC, Sarbia M, Weber A-A, Borchard F, Gabbert HE, and Schrör K (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. *Cancer Res* **59**:198–204.
- Zimmermannova O, Doktorova E, Stuchly J, Kanderova V, Kuzilkova D, Strnad H, Starkova J, Alberich-Jorda M, Falkenburg JHF, Trka J, Petrak J, Zuna J, and Zaliava M (2017) An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia. *Oncogene* **36**:5985–5994.